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ProxiMAX randomisation is a nondegenerate saturation mutagenesis technology 
that offers control over identity, location and relative ratio of amino acids within a 
protein library. It employs a maximum of 20 codons in saturated positions to encode 
20 amino acids. This eliminates bias, degeneracy and provides maximal diversity. 
Since a maximum of 20 codons are used, many codons remain available to encode 
unnatural amino acids (UAAs). Incorporation of UAAs is essential tool in protein 
engineering to expand protein repertoires. The aim of this project is to establish 
fundamentals for the development of an in vitro transcription/translation system that 
will ultimately be coupled with ProxiMAX randomisation to produce synthetic gene 
libraries simultaneously encoding multiple UAAs.  
The focus of the current project was E. coli Alanyl-tRNA synthetase (AlaRS), an 
enzyme that aminoacylates tRNAAla with L-Alanine. The aim was to engineer the 
active site of the synthetase to incorporate UAAs and to develop an assay by which 
the resulting AlaRS protein library might be screened. ProxiMAX randomisation was 
employed to produce two variant libraries of AlaRS, each had removed native amino 
acid editing function. Six positions from amino acid binding pocket were selected for 
randomisation to encode 18 natural amino acids. Each resulting library encoded 
>107 novel variant proteins. 
The initial development of screening assay for synthetase libraries involved using 
eGFP with stop codon as a reporter gene to assess aminoacylation of tRNA 
suppressor by AlaRS enzyme. The assay was designed in S. cerevisiae to prevent 
exogenous E. coli AlaRS and tRNA from working with endogenous system. The 
controls designed for the assay revealed that yeast read through the stop codon in 
eGFP and therefore, aminoacylation of tRNA suppressor by AlaRS proved to be 
difficult to assess. Alternative stratagems for future screens are considered in light 
of the results contained within the current study. 
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Chapter 1: Introduction 
1.1. The importance of translation 
During the early studies on protein translation, Francis Crick in his paper “On protein synthesis” 
(Crick, 1958) gathered all up-to-date research and developments towards understanding the process 
of protein generation. He outlines the early experimental evidence proving former theoretical 
speculations surrounding the subject and considers the universal formation of proteins from amino 
acids across all living organisms and the control of the process. At this time in the past, little was 
also known about the site of protein synthesis with possibilities including the nucleus, cytoplasm or 
both locations. Nevertheless, the vague idea of the process was forming into what is known today as 
the basic principles of translation. Crick writes about microsomal particles, their association with 
amino acids and abundance in cells, they are later to be named as ribosomes. At this stage, the family 
of “activating enzymes” and their role in binding and activating its cognate amino acids for protein 






Figure 1.1. The reaction of amino acid activation. 
The reaction is catalysed by aminoacyl-tRNA synthetase, here called “activating enzyme”.  
 
 
Crick also accurately reports that the activated amino acid has phosphorylated carboxyl group and in 
this form is only found when bound with its enzyme. The discovery of aminoacyl-tRNA synthetases 
(aaRSs) in the cell-sap fraction of rat liver cells was published as early as 1955 by Hoagland (1955) 
and colleagues, and by Berg in 1956 in yeast cells (1956). Subsequently, more publications reported 
the discovery of the same enzymes in bacterial cells and finally in animals. 
amino acid  +  ATP                                        amino acid-AMP  +  pyrosphosphate 
“activating enzyme” 
18 
Translation is the process of protein synthesis which takes place in the cytoplasm and uses amino 
acids as monomers for building a polypeptide chain. The generation of new polymer is very complex 
with many different components and careful control by various translation-associated factors. The 
fundamental role in protein generation belongs to different types of ribonucleic acids (RNA): 
messenger RNA (mRNA) – a carrier of genetic information for the sequence of protein, transfer RNA 
(tRNA) – a carrier of amino acid to the site of protein synthesis, and ribosomal RNA (rRNA) which 
makes up ribosome, an organelle which coordinates addition of amino acids (Figure 1.2.). Translation 
process is precisely controlled and regulated by different factors such as initiation or elongation 
factors. A very important molecule that also facilitates the process is enzyme aminoacyl-tRNA 




Figure 1.2. The process of protein synthesis. 
Aminoacyl-tRNA synthetase (in yellow) activates amino acids to aminoacyl adenylate intermediates that are 
then attached to tRNAs (in blue). Aminoacylated tRNAs transport attached amino acids to the ribosome (in 
grey) which reads the sequence of mRNA and translates it into protein. Charged tRNA occupies A site in the 
ribosome, followed by P site and E site. Translation takes place in the cytoplasm. 
19 
The cellular translational machinery uses only natural amino acids (AAs) in their L-forms or achiral 
amino acid (Glycine only) to build polypeptide chain. It would be very valuable to use unnatural 
amino acids (UAAs) in their D-forms (mirror images to AAs as seen in Figure 1.3.) to expand the 
protein repertoire during synthetic protein synthesis for different applications in life sciences. D-AAs 
are not naturally recognised by aaRSs since evolution favoured L-AAs. This means that proteases 
might not be able to recognise D-AAs, so potentially preventing cleavage of proteins where the 
unnatural D-form is found. This gives the potential for new drug candidates with the possibility of 
longer half-life and better fit to the target receptors. Using D-AAs in proteins would also be useful 






Figure 1.3. Enantiomers of amino acids. 
Enantiomers are amino acids that are mirror images of each other such as naturally occurring L-amino acid 





1.2.1. History of discovery 
The initial speculations about a single-stranded RNA molecule that carries attached amino acids to a 
complementary template strand for protein synthesis were proposed in 1955 in the letter by Francis 
Crick “On Degenerate Templates and the Adaptor Hypothesis” (Berg, 1956; Barciszewska, Perrigue, 
and Barciszewski, 2016). More work towards the discovery of tRNA was later done by Paul 
Zamecnik in 1958 (Hoagland, Stephenson, Scott, Hecht, and Zamecnik, 1958). The very first 
experimental studies proving that monomers of proteins, amino acids, were activated to aminoacyl 
adenylates involved in catalytic reactions by enzymes (later discovered as aaRSs), were conducted 
as early as 1955 by different research groups. These experiments involved charging single-stranded 
small RNAs with radioactive amino acids, what ultimately, lead to the discovery that enzymes 
associated required ATP-AMP exchange during catalysis and that there are many specific enzyme 
species needed for activation of different amino acids and binding to again specific tRNAs. The 
discovery of the family of aaRSs was published in 1956 by Paul Berg and his co-workers (Berg, 
1956; Barciszewska et al., 2016). 
 
1.2.2. The primary, secondary and tertiary structure of tRNA 
The studies on tRNA structure commenced in 1956 by Robert Holley (Holley, 1963, 1968; 
Barciszewska et al., 2016). The very first tRNA that he was working with was tRNAAla from 
Saccharomyces cerevisiae and the research was focused on resolving its sequence and relationship 
between nucleotides in terms of Watson-Crick base pairing. It took nine years to identify the 
sequence of tRNAAla yet it still had to be corrected a few years later. Robert Holley was awarded the 
Nobel Prize in 1968 for his findings (Holley, 1968). Based on the first sequence of tRNAAla, the 
secondary structure of the cloverleaf model was suggested by Elisabeth Keller. The model was later 
confirmed by others including Tom RajBhandary for tRNAPhe from S. cerevisiae (Figure 1.4.) 
(RajBhandary, Stuart, Faulkner, Chang, and Khorana, 1966). After many years of research, it was 
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established that all tRNA molecules share the same cloverleaf model of secondary structure based 
on common Watson-Crick base pairing. Moreover, all tRNAs have conserved CCA-3’ sequence at 
the end of the acceptor arm, an extension of double-stranded acceptor stem, as well as four hairpin 
helices including three major loops and one variable loop (Figure 1.4.). One of the major loops is 
called the anticodon loop responsible for interaction with mRNA that determines next amino acid in 






Figure 1.4. The secondary and tertiary structure of tRNA. 
The illustrated tRNA is the first-ever sequenced tRNAPhe from S. cerevisiae showing the colour-coded details 
of its structure. A. The cloverleaf model of secondary structure tRNAPhe. The discriminator base for this tRNA 
is highlighted in orange, anticodon in grey and post-transcriptional modification are in red. The grey dashed 
lines show interactions within tRNA in the tertiary structure. B. The L-shaped tertiary structure of tRNAPhe with 





The first tertiary structure of tRNA, specifically tRNAPhe, was resolved in 1973 by Alexander Rich 
and his group at a resolution of 4 Å (Kim et al., 1973). The work continued and allowed to obtain a 
better resolution in later years. The structural research confirmed that all tRNAs have two helices in 
the tertiary structure with L-shape folding (Figure 1.4.). The three-dimensional structure is stabilised 
by base triplets and non-Watson-Crick base pairing. In this L-shaped form, the distance between the 
anticodon loop and 3’ attachment site of amino acid is of over 70 Å, providing a binding domain for 
aaRSs. The tRNA generally remains in this form upon binding with aaRSs and other proteins with 
some tRNAs undergoing slight bending (Barciszewska et al., 2016). 
 
1.2.2.1. Watson-Crick and wobble base pairing 
Crick and Watson first described the molecular shape of DNA as double helix which is two strands 
of DNA running opposite to each other and forming a double-stranded molecule (Watson and Crick, 
1953). DNA strands are antiparallel and while one runs in 5’  3’ direction, the opposite one runs 
in 3’  5’. DNA comprises long stretches made of a combination of four nucleotides: two purines – 
guanine (G) and adenine (A) and two pyrimidines – cytosine (C) and thymine (T). They bind together 
via sugar-phosphate backbones forming hydrogen bonds in a complementary interaction between 
nucleotides to form base pairs. So-called Watson-Crick base pairing includes G binding to C and A 
to T. There are three hydrogen bonds between G and C, and two between A and T. In RNA strand, 
uracil (U) is substituted for thymine. Exceptions to the above rules are defined by wobble pairing 
(non-Watson-Crick pairing) (Eun, 1996). 
 
Complementary base pairing occurs during DNA replication, transcription and translation. During 
protein synthesis, nucleotides form Watson-Crick base pairs during anticodon-codon recognition 
between tRNA and mRNA. As seen in Figure 1.5., complementary base pairing rules are strictly 
followed in the first and second position of a codon with the third and second position of an anticodon 
interaction. The third and the last position of the codon can also form a normal pair with the first 
position of the anticodon. However, it often does not follow this rule and instead forms a wobble pair 
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(Topal and Fresco, 1976). The most common non-Watson-Crick pair is G•U, a consequence of 
amino-imino tautomerism (Eun, 1996). It is a type of tautomerism in which the amino and the imino 
forms are in equilibrium and the migration of a hydrogen atom takes place. Other common wobble 






Figure 1.5. Wobble base pairing during an interaction between anticodon of tRNA and codon of mRNA. 
Normal pairing refers to Watson-Crick base pairs: G with C and A with T. Wobble pairing is allowed at the 
third codon position and the first anticodon position. 
 
 
Wobble pairs are important in the codon-anticodon interaction. They allow for fewer tRNA 
molecules to recognise multiple codons in the mRNA. However, this process is carefully controlled. 
During translation, elongation factor Tu (EF-Tu) first selects for cognate tRNA to bind at the A site 
of the ribosome during initial binding. At this stage, the wobble pairing may occur in the first or 
second position of the codon. However, later on, the ribosome proofreads the attached tRNA at the 
A site and if the base paring does not follow Watson-Crick rules at these positions, the ribosome 
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discards the tRNA. The conserved nucleotides of 16S rRNA G530, A1492 and A1493 are known to 
participate in this checkpoint. Once the cognate tRNA is accepted, the ribosome undergoes a 
conformational change. This change closes the ribosomal domain that discriminates against wobble 
pairs in the first or second codon positions but still accepts wobble in the third position. (Demeshkina, 
Jenner, Westhof, Yusupov, and Yusupova, 2012)  
 
1.2.2.2. G•U wobble base pair  
A G•U wobble base pair is also found in the tRNAAla acceptor stem where it plays a critical role as a 
major determinant in recognition by alanyl-tRNA synthetase – a relationship that is going to be 
discussed in more details in Section 1.5.2. This base pair was initially discovered upon first 
sequencing of tRNA – yeast tRNAAla (Holley et al., 1965; Varani and McClain, 2000). During this 
discovery, it was shown that the primary sequence of tRNAAla was folding into the secondary 
structure including the G•U base pair. The role of the same base pair was later discovered as the 
major discriminator in the recognition of tRNAAla by the synthetase (Hou and Schimmel, 1988, 1989) 
and that the occurrence of this base pair is widely found in all tRNA species (Varani and McClain, 
2000). In Figure 1.4., the G•U base pair is present in the acceptor stem of tRNAPhe as G4•U69, while 
in Figure 1.11. of tRNAAla as G3•U70. 
 
1.2.3. Generation of tRNAs 
In eukaryotes, RNA Polymerase III (PolIII) is responsible for the transcription of tRNAs genes. 
PolIII also synthesises 5S rRNA and other small cytoplasmic and nuclear RNAs species. In short, 
this transcription is controlled by internal control regions which comprise different types of 
discontinued structures with essential sequences (including box A and box B) separated by 
nonessential ones. Alternative gene organisations can include an upstream promoter where box A 
and box B are found either within tRNA itself or are located in various places nearby (Guffanti et 
al., 2006). The location of box A and B depends on the type of RNA transcribed by PolIII and what 
genes are involved in transcription. After tRNA transcription, the maturation process involves cutting 
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3’-trailer sequence with endo- and exonucleases and adding CCA-3’ conserved sequence. Moreover, 
the maturation includes trimming 5’-end nonessential sequence with RNase P, intron splicing, 
ligation and finally, post-transcriptional modifications of nucleosides within tRNA (Barciszewska et 
al., 2016).  
 
In bacteria, tRNA genes are often localised in clusters on the chromosomes. The transcription units 
for tRNA can be divided into tRNA genes only, tRNA genes within rRNA operons (specifically in 
the spacer sequence) and last but not the least, tRNA operons – with some of these also carrying 
genes like EF-Tu (Toh, Hori, Tomita, Ueda, and Watanabe, 2009). RNA polymerase recognises these 
different gene organisations and allows for transcription of tRNA with a single promoter. The first 
transcript of tRNA is called precursor and it has extra sequences that need to be trimmed to achieve 
fully mature tRNA that is ready to participate in translation (Altman, 1975). In Escherichia coli (E. 
coli), initially the 3’-end additional sequence is cut with several nucleases and after that, the 5’-end 
is processed by RNase P. Also, CCA-3’ is already present in the acceptor’s arm, unlike in eukaryotes. 
Due to a different copy number of tRNA genes, the number of transcripts respectively varies and can 
be influenced by promoter activity, abundant or deprived amino acid level, the growth rate of 
organism etc. (Toh et al., 2009). Just like eukaryotic tRNAs, prokaryotic tRNAs undergo post-
transcriptional modifications.  
 
1.2.4. Function of tRNAs 
The main and the most important function of tRNA is its participation and key role in protein 
synthesis. Up to 10% of the total RNA in the cell corresponds to tRNAs, making it the most abundant 
RNA. As mentioned, its key role is to transport amino acids from the cell to the site of protein 
translation in the ribosome. The anticodon of tRNA determines binding of the molecule with the 
attached amino acid to the complementary sequence within mRNA. In regards to nontranslational 
functions, tRNA participates in the regulation of gene expression during deficiency of amino acids. 
It also has a role in amino acid biosynthesis and energy metabolism. Moreover, mutations to tRNA 
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sequence can lead to disease and dysfunctions in protein synthesis as well as other cellular processes 
(Barciszewska et al., 2016). The examples include encephalopathies such as MELAS (mitochon-
drial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) or MERRF (myoclonus 
epilepsy associated with ragged-red fibres). While other diseases reduce respiratory capacity, leading 
to increases in the level of reactive oxygen species and consequently, leading to hypertension 
(Kirchner and Ignatova, 2014). 
 
1.3. The family of aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetase (aaRS) is a key enzyme in protein synthesis. It catalyses the addition 
of a cognate amino acid to a corresponding tRNA (Maršavelski, Lesjak, Močibob, Weygand-
Đurašević, and Tomić, 2014). This process is called aminoacylation and it occurs in a two-step 
reaction. Its initial phase involves binding the amino acid and ATP, followed by activating the amino 
acid with ATP to form an intermediate aminoacyl-AMP (Figure 1.1.). Subsequently, the enzyme 
recognises its cognate tRNA, and the aminoacyl moiety is attached by the covalent bond to adenosine 
of the 5’-CCA-3’ in the tRNA acceptor arm. Once tRNA is charged with the amino acid, it leaves 




















Figure 1.6. Aminoacylation reaction catalysed by aminoacyl-tRNA synthetase. 
Firstly, an amino acid is activated to form aminoacyl adenylate. Secondly, the amino acid is attached to tRNA what is catalysed by aminoacyl-tRNA synthetase. 
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In E. coli, the full set of enzymes includes twenty different aaRSs, with one enzyme per amino acid. 
Over a number of decades, the research on these catalysts from various organisms was focused on 
understanding the structure-function correlation, nontranslational functions and other related 
questions. The research on these enzymes proved to be more challenging than first anticipated. 
Although all enzymes are involved in aminoacylation and share common domains and motifs, overall 
their structure varies between enzymes activating different amino acids but also between enzymes 
activating the same amino acids found in different organisms. This phenomenon is illustrated in 
Figure 1.7. Besides, eukaryotic aaRSs differ from bacterial and often are made of more subunits since 
they may interact with larger complexes such as multi-tRNA synthetase complex (MARS) (Perona 
and Hadd, 2012). The family of enzymes is divided into class I and II, based on the two distinct types 
of the aminoacylation domain related to the attachment of amino acid. In class I, the amino acid is 
attached by its carbonyl group to the 2’-OH of the ribose of the terminal adenosine A76 of tRNA. 
While in class II enzymes, the site of amino acid’s attachment is 3’-OH. The two different sites of 
attachments are caused by various amino acids’ features such as hydrophobicity of large amino acids 
catalysed by class I aaRSs (Tamura and Hasegawa, 1999). 
 
The enzymes from class I are more structurally related to each other than enzymes from class II. 
They are mostly monomers. The general structure of class II enzymes (the interest of this study) 
includes seven-stranded β-sheet flanked by α-helices and they can be homodimers (class IIA and B) 
or the mixture of homo- and heterodimers (class IIC) (Perona and Hadd, 2012). Enzymes from class 
II have three conserved motifs in the active site domain. Motif 1 is made of long α-helix with a 
conserved proline at its end and is involved in dimer formation in most enzymes. The other two 
conserved motifs are involved in the reactions of the active site and are arranged as antiparallel β-
strands connected by a loop. While motif 3 binds ATP required for activation of amino acid, motif 2 
is responsible for coupling this ATP with the amino acid, and binding the resulting aminoacyl 
adenylate to the 3’-end of tRNA. In class II enzymes, the major groove of the tRNA acceptor stem 
is positioned facing the aminoacylation domain. While the process of tRNA binding is complex in 
terms of structural changes, understanding what is happening during aminoacylation is even more 
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challenging, with incomplete information for most of the enzymes or little information at all for 
others. As such, the process of aminoacylation varies between different enzymes. During 
aminoacylation, with class II enzymes, the tRNA is first recognised and bound with the enzyme via 
its major groove. Conversely, class I enzymes bind their cognate tRNA via the minor groove of the 
acceptor stem (Ruff et al., 1991; Penny J. Beuning, Gulotta, and Musier-Forsyth, 1997). The 
differences between the organisation of protein domains between two classes but also within class II 
enzymes are shown in Figure 1.7a. As this was not complicated enough the same type of enzyme, 
for example, Phenylalanyl-RS (PheRS), in different organisms also show major differences in the 
crystal structures (Figure 1.7b.).  
 
Difficulties in understanding the aminoacylation process are restricting the progress of synthetases 
in research areas including protein engineering and synthetic biology. Through extensive studies on 
this family of enzymes, it was discovered that apart from the role in translation, aaRSs have many 



















Figure 1.7. The family of aminoacyl-tRNA synthetases: division into classes. 
a. The schematic image of the family of aaRSs show differences between a set of enzymes in terms of 
organisation of the same domains in the protein, extra domains in some enzymes probably associated with an 
extra function of this enzyme The family is divided into class I and II, and subclasses within class II. b. The 
variety of structures from aaRS family across different species bound with tRNA (in orange) and ATP (in pink). 
The colour coding is connected to the same domains (Perona and Hadd, 2012). 
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1.4. E. coli Alanyl-tRNA synthetase  
1.4.1. Structure and function 
The focus of this project is an enzyme alanyl-tRNA synthetase (AlaRS) from the bacterium E. coli. 
AlaRS belongs to the class IIC family of aaRSs. In E. coli, it is composed of 875 amino acids (Beebe, 
Mock, Merriman, and Schimmel, 2008) and its molecular weight is 96 000 DA (Sood, Slattery, 
Filley, Wu, and Hill, 1996; Sood, Hill, and Slattery, 1997).  
 
1.4.1.1. Domains of E. coli AlaRS 
E. coli AlaRS has three domains: the N-terminal catalytic domain, the editing domain and the C-
terminal domain (Figure 1.8.). The catalytic domain is 461 amino acids long and is responsible for 
aminoacylation and tRNA recognition via G3:U70 base pair recognition in the acceptor stem of 
tRNA. Sometimes this domain is additionally divided based on its aminoacylation function and 
tRNA recognition as shown in Figure 1.8. (Beebe et al., 2008). The editing domain is responsible for 
the removal of mischarged amino acids by hydrolytic editing. The core editing centre is found in the 
region of residues 553-705. AlaRS can incorrectly activate serine (Ser) and glycine (Gly) because of 
their structural similarity to cognate alanine (Ala) as shown in Figure 1.9. (Guo et al., 2009). Once 
Ser or Gly is activated, the enzyme can even charge them onto tRNAAla. The last domain of AlaRS 
is the C-terminal domain. One of its functions is oligomerisation but others are not well described 
because it is a poorly-defined region of the enzyme. However, in mutated AlaRS without the C-
terminal domain, both aminoacylation and the editing activity are reduced. Unfortunately, the exact 
mechanism of that reduction is still unknown (Dignam et al., 2011). 
 
Unlike eukaryotic AlaRSs which are monomers, in archaea and bacteria including E. coli, the enzyme 
forms a dimer of identical subunits in solution. Sedimentation experiments (Dignam et al., 2011) and 
results from other studies using dynamic light scattering (Sood et al., 1996) and analytical 








Figure 1.8. Three domains of full-length E. coli AlaRS. 
Full-length E. coli AlaRS includes three domains: catalytic domain, 1-442, compromising aminoacylation 
domain and tRNA-recognition motif; editing domain, 468-701; C-terminal domain, 766-875. Adapted from 







Figure 1.9. Recognition of Ala, Ser and Gly by E. coli AlaRS catalytic domain.  
The figure shows the amino acid binding pocket of E. coli AlaRS catalytic domain with mutation G237A. The 
mutated catalytic domain still maintains binding and activation of three amino acids: Ala, Ser and Gly. White 
schematics represent the wild type catalytic domain of AlaRS, while coloured (gold, teal, peach) mutated 
enzyme. The grey active site cavity belongs to the wild type enzyme for simplicity of understanding the diagrams 





The full crystal structure of AlaRS in E. coli has not yet been resolved. This is common for all 
enzymes from this family and one of the reasons is that the enzyme undergoes structural changes 
when it binds Ala, ATP and tRNAAla (Swairjo et al., 2004). These are very dynamic changes taking 
place in a short time, and consequently, are difficult to characterise. For instance, complex 
interactions between editing and aminoacylation domains lead to a variety of geometrical changes 
that cannot be captured in the crystal structure of AlaRS (Dignam et al., 2011). However, the crystal 
structure of the catalytic domain AlaRS of E. coli is available, both in free form and bound with 
activated Ala (Guo et al., 2009). 
 
Figure 1.10. demonstrates the crystal structure of the catalytic domain with Ala-SA (5’-O-[N-(L-
alanyl)-sulfamoyl]adenosine), an adenylate analogue. The Ala-SA is bound in the middle of the 
active site of the aminoacylation domain (darker shade of blue) with tRNA recognition motif on the 






Figure 1.10. The crystal structure of the catalytic domain of E. coli AlaRS441-LZ with attached Ala-SA (an 
adenylate analogue). 
The aminoacylation domain is in blue and the tRNA recognition domain in light blue. The Ala-SA is bound by 
the aminoacylation domain in the amino acid binding site. The green helix represents three leucine 
substitutions that were crucial for crystallisation (Guo et al., 2010).  
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1.5. The system of E. coli AlaRS and tRNAAla  
1.5.1. The relationship between AlaRS and tRNAAla 
The cognate aaRS and tRNA pairs have sophisticated and precise recognition mechanisms that are 
unique for individual pairs to select correct molecules from the pool of enzymes, tRNAs and amino 
acids. The structure of tRNA contains identity determinants that are responsible for the recognition 
by cognate aaRS. Similarly, enzymes have conserved residues that are of higher or lower importance 
in the recognition of tRNAs. Both determinants cannot be changed because this would have adversely 
affected the tRNA recognition and the aminoacylation process (Cavarelli and Moras, 1993).  
 
The orientation of tRNAAla on the enzyme surface is influenced by the attachment of Ala and ATP 
to the binding sites (Dignam et al., 2011). This is caused by the changes in the conformational shape 
of AlaRS which depend on the type of ligand bound. The 3’-end of tRNAAla interacts with Lys74 
found in the aminoacylation domain of AlaRS (Dignam et al., 2011). From mutation studies, it was 
confirmed that this amino acid is not responsible for catalysing aminoacylation but it is important for 
alignment of tRNA with AlaRS (Hill and Schimmel, 1989). Therefore, even if Lys74 does not 
participate in aminoacylation directly, its substitution led to a 98% decrease in the enzyme catalytic 
efficiency (Hill and Schimmel, 1989).  
 
1.5.2. The importance of the G3:U70 base pair and other determinants 
in tRNAAla 
It has been long established that AlaRS recognises only the tRNAAla acceptor arm and that there is 
no interaction with the tRNAAla anticodon. The same recognition pattern is also known for a few 
other aaRSs, including LeuRS and SerRS (P. J. Beuning and Musier-Forsyth, 1999). Naganuma et 
al. (2014) confirmed that AlaRS recognises G3:U70 wobble base pair found in the acceptor stem of 
tRNAAla. Although the experiments are on the AlaRS-tRNAAla system from Archaeoglobus fulgidus 
and not from E. coli, the regions of interests are conserved between these species (Figure 1.11.). 
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There are several base pairs from the acceptor stem which get involved in the interaction with the 
aminoacylation domain of AlaRS. The study found that the nucleotide G3 most likely forms 
hydrogen bonds with Asp450, while U70 with Asp450, Tyr449 and Gly453 in AlaRS from A. 
fulgidus. Generally, the region of residues 449-453 (Tyr-Asp-Ser-His-Gly) at the α14 tip fits tightly 
with the nucleotides in the acceptor stem of tRNAAla (Figure 1.12.). This region is conserved within 





a.              b.        . 
 
 
Figure 1.11. The cloverleaf model of tRNAAla from A. fulgidus and acceptor arm of tRNAAla from E. coli. 
a. The structure has a distinguished anticodon loop, major discriminator G3:U70 and A73 discriminator 





For several years, many studies confirmed that the wobble pair G3:U70 in tRNAAla is a major 
determinant in AlaRS binding (Figure 1.11b.) (Hou and Schimmel, 1989). Moreover, the recognition 
of this base pair is so specific that the enzyme can recognise and aminoacylate different isolated 
tRNA fragments, for instance, a “minihelix” or a “microhelix”, as long as they have the wobble pair 
in their sequence (Musier-Forsyth and Schimmel, 1999; Naganuma, Sekine, Fukunaga, and 
Yokoyama, 2009). Concerning tRNAAla, the microhelix and minihelix are synthetic, truncated 
species of tRNA molecule comprising either the acceptor arm only (microhelix) or the acceptor arm 
plus the TΨC arm and loop (minihelix). Importantly, both can be aminoacylated although neither has 
an anticodon loop. They are used in the studies with aaRSs, for example, to prove the importance of 
determinants found in the acceptor stem of microhelixAla (Francklyn and Schimmel, 1989; Francklyn, 
Shi, and Schimmel, 1992). Mutations within microhelixAla were also tested for aminoacylation by 
AlaRS. The first substitution of U2:A71 reduced but did not stop aminoacylation, while C2:G71 
prevented it. Whereas the introduction of U1:A73 resulted in a very low but reproducible 
aminoacylation, the substitution G1:C73 blocked it (Francklyn et al., 1992). Determinants specific 
for recognition of G3:U70 of tRNAAla are found within the N-terminal domain of AlaRS, AlaRS(1-
461) and include: Asp235, Asp285, Arg314, Ala409 (Beebe et al., 2008). Moreover, it was found 
that for in vitro translation, the fragment AlaRS(1-461) consisting of the catalytic domain is 
satisfactory for the aminoacylation of tRNAAla because it contains one of the tRNA recognition motif 
(Swairjo et al., 2004). Also, the fragments of 76 or 93 fewer amino acids, 385N and 368N, 
respectively, can activate Ala to its aminoacyl adenylate intermediate but they do not have the power 
to aminoacylate tRNAAla. Therefore, a motif responsible for the tRNA recognition and 








Figure 1.12. The interaction between the A. fulgidus AlaRS and tRNAAla.  
The G3:U70 base pair hydrogen bonds with the residues in the α14 tip in the tRNA recognition domain 
(Naganuma et al., 2014). 
 
 
Thermodynamic studies (Strazewski, Biala, Gabriel, and McClain, 1999) confirmed that the mutated 
tRNAs in which the wobble pair G3:U70 was substituted for Watson-Crick base pairs have higher 
stability but lower acceptor activity for Ala. Moreover, these mutated tRNAs have different 
geometric conformations from a wild type (wt) tRNA that prevent them from forming 
alanine:enzyme complex and so from charging tRNA with Ala (Strazewski et al., 1999). It transpires 
that particular base pair (G3:U70) generates a deformation point in tRNAAla so it can fit within the 
enzyme. The mutated tRNAs do not have this property (Chang, Varani, Bhattacharya, Choi, and 
McClain, 1999). In E. coli, an additional determinant is the nucleotide A73, of which mutation does 
not stop aminoacylation as long as the wobble pair is present, but it decreases the efficiency of 
reaction considerably (Fischer, Beuning, and Musier-Forsyth, 1999). This nucleotide is also 
responsible for the stabilisation of the G1:C72 base pair (Fischer et al., 1999). The above nucleotide 
and base pairs are illustrated in Figure 1.11.  
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1.5.3. tRNAAla recognition elements within E. coli AlaRS 
There are several independent tRNAAla recognition sites found across different domains of E. coli 
AlaRS (Beebe et al., 2008). In the studies using AlaRS enzymes without the catalytic domain, 
AlaRS(438-730) and AlaRS(438-875), both mutants were able to recognise tRNAAla even when they 
lacked identified specific determinants supposedly responsible for binding to the G3:U70 base pair: 
Asp235, Asp285, Arg314 and Ala409. This leads to the conclusion that the specificity of mutated 
AlaRS was overseen by the acceptor stem of tRNAAla, and in fact, the specific determinants that are 
involved in the editing role are found in residues 438-730. Taking this further, the substitution of a 
conserved Arg693 for Lys693 found in the strand-loop-strand motif, increased specificity for 
tRNAThr and loss of selectivity for tRNAAla with about 20% lower rate of editing activity. This 
indicates that Arg693 is a critical determinant in the tRNA recognition for editing function of the 
enzyme, and it is highly conserved in AlaRS. 
 
The recognition of tRNA by domains other than the aminoacylation domain is important, for 
example, for the editing function of the enzyme. In E. coli, the AlaRS editing centre is in the region 
of residues 553-705 and this is conserved through evolution. Those recognition sites located within 
the editing and C-terminal domains recognise misacylated Gly-tRNAAla and Ser-tRNAAla. Since 
AlaRS readily misacylates Ser and Gly, the editing mechanism for the hydrolysis of mischarged 
amino acids from tRNAAla has to be reliable. The problem of a relatively significant rate of 
misacylation by AlaRS was solved by adding free-standing AlaXps during evolution (Guo et al., 
2009). Thus, the recognition elements for tRNAAla found within both the editing domain and AlaXps 
function as checkpoints for aminoacylation of correct amino acid in order to prevent mutations in 
proteins and their consequences. These checkpoints complement each other so if the editing 
mechanism of AlaRS does not clear Ser-tRNAAla, AlaXps will act instead. The selection pressure of 
AlaXps is really focused on deacylation of Ser as they do not always pick up misacylation of Gly-
tRNAAla during editing (Guo et al., 2009).  
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AlaXps are free-standing fragments found in the cells alongside AlaRS. Thus, Type I AlaXp is 
homologous to E. coli AlaRS(438-730) including the core editing domain and extra flanking 
sequence. When used in the studies for clearance of Ser-tRNAAla, Type I AlaXp was inactive. Its 
inactivity was associated with the lack of tRNAAla binding and reduction in editing activity resulted 
from a loss of affinity for tRNAAla. However, at much higher concentration of Ser-tRNAAla (2000 x), 
the free-standing editing domain was capable of deacylating misacylated tRNAAla. Type II AlaXp 
consists of Type I AlaXp and an extended carboxy domain like in E. coli AlaRS, making it 
homologous to E. coli AlaRS(438-875). This protein is fully active during the clearance of Ser-
tRNAAla. Even though AlaRS(438-875) lacks G:U specific determinants that are found within the 
aminoacylation domain, it still manages to clear mischarged tRNAAla with strong activity. As an 
example, this portion of the enzyme fails to deacylate Ser-tRNAThr but upon insertion of G3:U70 into 
tRNAThr it clears serine from Ser-tRNAThrG3:U70. Additionally, R693K mutation of AlaRS(438-875) 
results in loss of selectivity for tRNAAla and about 20% lower rate of editing activity.  
 
Summing up, the tRNAAla recognition elements are found across different motifs in AlaRS such as: 
1) the aminoacylation domain: Asp235, Asp285, Arg314, Ala409, 
2) the editing domain between 680-699 with key residue Arg693, 
3) the C-terminal domain with nonspecific binding between 808-875. 
Recognition in 1) and 2) are independent of each other because these domains can fulfil their 
functions when isolated from AlaRS enzyme. 
 
For the purpose of the current study, the only required function of AlaRS is the aminoacylation of 
tRNAAla. The editing domain function is undesirable, since the aim of the project is precisely to 
engineer AlaRS to misacylate tRNAAla with UAAs. Fortunately, it has been reported previously that 
the catalytic domain is sufficient for tRNA charging (Swairjo et al., 2004; Guo et al., 2010). 
Therefore, the catalytic domain fragment of AlaRS(1-461) alone may be sufficient for the current 
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study. Alternatively, the editing function of AlaRS can be inactivated by mutating residue 666 from 
Cys to Ala (Guo et al., 2009). 
 
1.6. Engineering novel aaRSs via saturation mutagenesis 
The key to engineering novel enzymes (here aaRSs) is to change key residues in the active site of the 
enzymes such that different substrates may be accepted. Where structural information concerning the 
enzyme is available, those key residues have already been identified. In that case, the next stage is to 
make as many changes as possible to those key residues. The resulting DNA library encodes a 
mixture of proteins (a protein library) which ideally contains every possible combination of amino 
acids in those key locations. The library is then screened against a substrate of interest with the hope 
that one or more of the variant enzymes will have specificity for the required, novel substrate. 
 
Traditionally, mutations were made one at a time by a variety of techniques, but a change in substrate 
specificity normally requires mutations at several positions and multitudes of individual genes each 
containing multiple, single changes would be prohibitive in terms of time. Therefore, many years 
ago, the concept of saturation mutagenesis was introduced. Here, key codons are each replaced with 
a degenerate codon (typically NNN or NNK/NNS), to encode all 20 amino acids at each of the key 
locations. Within the resulting mixture, any one gene will be unique, but collectively, the library 
should include all possible combinations of codons and thus encode all possible combinations of 
amino acids at these key locations. 
 
Unfortunately for the subsequent screening, the genetic code is degenerate. For NNN, each codon or 
nucleotide triplet results from a different combination of four bases: adenine (A), guanine (G), 
cytosine (C), and thymine (T). Altogether, there are 64 possible combinations of codons divided into 
61 codons for 20 amino acids and 3 codons for termination codons. This means that one amino acid 
can be encoded by two codons (Cys, Asp, Glu, Phe, His, Lys, Asn, Gln, Tyr), three codons (Ile), four 
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codons (Ala, Gly, Pro, Thr, Val), or even six codons (Leu, Ser, Arg). Only two amino acids, Trp and 
Met are encoded by one codon. The degeneracy of the codon, when considered in making a gene 
library, can limit its diversity and consequently introduce bias. As such, a disproportionate content 
of codons has a direct influence on the library size (higher degeneracy increases the number of 
variants), which is a very important factor when choosing the method of the library screening in the 
subsequent steps because each method has its own limitation in terms of the number of variants. 
Additionally, the bias that is carried when using saturated codons will have an impact during the 
screening process, especially with ligand-based methods that assume an equal concentration of 
proteins in order to function properly.  
 
1.6.1. Reducing degeneracy in saturated libraries 
Several different approaches have been introduced in order to overcome the consequences of using 
degenerate codons and among these are NNK and NNS saturation codons (K=T/G, S=G/C). They 
aim to reduce redundancy by limiting the third base in the codon which decreases the number of 
combinations from 64 to 32 codons for 20 amino acids and one termination codon. This not only 
decreases redundancy but also reduces the numbers that are so important both in the library 
construction and screening processes. The next approach was the development of the 22c-Trick that 
uses only 22 codons for 20 amino acids (Kille et al., 2013), greatly decreasing the redundancy and 
library size. The 22c-Trick relies on the subsets of oligonucleotides with limited degeneracy at 
specified codons (Kille et al., 2013). There are three primers that aid generation of saturated codons 
in PCR: first contains NDT (A/C/G/T; A/G/T; T), second VHG (A/C/G; A/C/T; G), third codon 
TGG. If a combination of these primers is used, valine and leucine appear twice what gives the name 
to this methodology as 22c stands for 22 codons. In particular, it is important to optimise the 
annealing temperature of the primers to accomplish a good codon saturation (Kille et al., 2013). 
Otherwise, the diversity of the library will be compromised. The consequences of these methods in 
comparison with fully nondegenerate saturation (exactly 20 codons encoding 20 amino acids) are 





Figure 1.13. Comparison of performance of common saturation mutagenesis techniques. 
Green colour shadowing indicates ideal performance, pale pink colouration indicates tolerable performance, 
and dark pink indicates unacceptable performance, where nondegenerate methodsa may be created via various 
methodologies as described in Section 1.6.2. (A) Diversity was calculated using the formula d = 1/(N∑kpk2) 
(Makowski & Soares, 2003) and is in agreement for a 12-mer peptide saturated with codon NNN (Krumpe, 
Schumacher, McMahon, Makowski, & Mori, 2007). (B) Ratiosb represent the theoretical relative 
concentrations of each individual gene combining any of the most common codons (Leu/Arg/Ser, NNN/NNK; 
or Leu/Val, 22c-trick) vs each individual gene containing any combination of the rarest codons (Met/Trp, NNN; 
Cys/Asp/Glu/Phe/His/Ile/Lys/Met/Asn/Gln/Trp/Tyr, NNK; or 18 codons (omitting Leu/Val), 22c-trick). (C) 
Truncation is calculated as the percentage of sequences that contain one or more termination codons within 
the saturated region (Ferreira Amaral, Frigotto, and Hine, 2017). 
 
When both constructing and screening a DNA library, its diversity, which is defined as the percentage 
of unique species, is imperative. However, when mutating only a single codon using a degenerate 
(NNN or NNK/NNS) method, the diversity is immediately decreased to 60-70%. With every one 
codon targeted, diversity drops drastically, resulting in only up to 10 % diversity when 12 codons are 
mutated. Even with near-nondegenerate saturation, the 22c-Trick, the diversity decreasing pattern 
follows degenerate methods with the number of targeted codons, resulting in 40 % diversity only for 
12 targeted codons. Nevertheless, the diversity remains unchanged and equals 100 %, at least at a 
theoretical level, regardless number of targeted codons in nondegenerate mutagenesis (Figure 




Bias is introduced to the protein library by encoding some amino acids with multiple codons and 
others with just one or two codons, according to the nature of the genetic code. However, in 
preparation for a gene library, there is a need for equal representation of amino acids and this can 
only be delivered by using nondegenerate saturation methods. The bias is also being enriched with 
the number of amino acids introduced. The ratios in the bias table (Figure 1.13B.) give the theoretical 
proportion for mutated codons found in a gene between combinations of the most abundant codons 
(such as six codons for Ser), and combination of the least abundant codons (such as Trp). Although 
Figure 1.13B. gives results of a bias with the maximum codon per amino acid, pointing out the worst 
possible consequence, it is apparent that major bias is introduced while using NNN/NNK/NNS or 
the 22c-Trick. Such bias is totally removed in nondegenerate methods because there is only one 
codon assigned for one amino acid during randomisation for example in MAX, ProxiMAX or 
Slonomics®. Because amino acids are not equally represented by the genetic code, if using all codons 
in the mutagenesis, gene sequences are unevenly represented. The last but not least, there is the risk 
of protein truncation while opting for degenerate methods of mutagenesis because they do not 
exclude the termination codons (Figure 1.13C.). This is especially important as nonfunctional 
truncated protein may aggregate inside the cells (Ferreira Amaral et al., 2017).  
 
In summary, nondegenerate saturation mutagenesis gives the possibility to include all twenty codons 
in theoretically equal ratio and some methods like ProxiMAX allow the user to select specific 
combinations of codons for targeted positions. At the same time, they exclude termination codons 
eliminating the risk of introducing gene sequences that can potentially give rise to truncated proteins. 
Moreover, the library size is kept to the minimum as it removes degenerate codons and instead of 64 
uses only 20. This also means that the diversity or the value of unique DNA sequences is maximised 
to 100 %. All of these characteristics of nondegenerate methods allow for generation of diverse, high-
quality libraries with a reduced pool of variants (all unique) which in turn results in improved 
efficiency of screening techniques (Tang et al., 2012).  
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1.6.2. Nondegenerate saturation mutagenesis methodologies 
1.6.2.1. TRIM Technology: Trinucleotide Phosphoramidites 
The first-ever found method of nondegenerate mutagenesis was TRIM technology which uses 
trinucleotide phosphoramidites (Virnekas et al., 1994). TRIM adds a triplet onto a growing 
nucleotide in a single reaction that is more efficient than adding one base. Ahead of reaction, a 
mixture of trinucleotide phosphoramidites is produced and used later during mutagenesis. Although 
the method is, at least in theory, controlled, in practice it has risks of introducing a biased mixture of 
phosphoramidites because single bases are known to have various coupling efficiency during oligo 
synthesis (Ho et al., 1996). Later this bias can be further enriched during the mutagenesis step. To 
prevent this from happening, commercial kits with TRIM technology are available such as GeneArt 
Combinatorial DNA Libraries (Thermo Fisher Scientific). (Ferreira Amaral et al., 2017) 
 
1.6.2.2. MAX randomisation 
One of the first published nondegenerate saturation mutagenesis that did not require specialised 
equipment or reagents but could be replicated in any lab was developed in Hine lab and called MAX 
randomisation (Hughes, Nagel, Santos, Sutherland, and Hine, 2003). This technology relies on 
delivery of selection oligos that hybridise to complementary DNA template while at the same time 
delivering saturation mutagenesis at the selected codons (Figure 1.14.). After hybridisation of 
selection oligos, they are ligated to seal the gaps between individual ones, followed by amplification 
in PCR to generate a randomisation cassette. Selection oligonucleotides are short, usually made of 
nine nucleotides (six nucleotides are conserved with the template while three correspond to one MAX 
codon) and can form a mixture of twenty in order to saturate defined position. Besides selection 
oligos, there are also two-terminal oligos that serve as primer sites for the last step of MAX 







Figure 1.14. Overview of the MAX randomisation technique.  
In MAX randomisation (Hughes et al., 2003) a single template oligonucleotide is synthesised that is fully 
degenerate at the designated, saturated codons. Meanwhile, a set of up to 20 small selection oligonucleotides 
are synthesised individually, for each saturated position. Each selection oligonucleotide consists of a short 
(typically in the order of 6 bp) addressing region that is fully complementary to the template and one MAX 
codon, where a MAX codon is the favoured codon for a single amino acid in the organism of interest. The 
selection oligonucleotides are mixed as required and, alongside two terminal oligonucleotides, are hybridised 
with the template and ligated together. The ligated strand is then selectively amplified with primers 




The randomisation cassette generated in the process can later be used in the production of gene 
libraries via overlap PCR or be employed for site-directed mutagenesis as a double-stranded primer 
in QuikChange® mutagenesis (Agilent) or Q5® Site-Directed Mutagenesis Kit (NEB). Even though 
MAX randomisation offers saturation mutagenesis of multiple codons, only two contiguous codons 
can be targeted at the same time what is a limiting factor while using this technology for example for 
antibody libraries.  
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1.6.2.3. ProxiMAX randomisation 
To permit nondegenerate saturation of multiple contiguous codons, the Hine lab next invented 
ProxiMAX randomisation. ProxiMAX is a nondegenerate saturation technology that like MAX 
randomisation, uses one codon only per amino acid (Ashraf et al., 2013). The technology itself can 
be replicated and adapted for a small scale library production in any lab because it relies on common 
molecular techniques such as restriction digest with Type IIS enzymes, amplification and blunt-
ended ligation (Figure 1.15.). The fundamental components of ProxiMAX are oligonucleotides that 
play a key role in delivering MAX codon at the site of randomisation. The process of randomisation 
consists of ligation, amplification and restriction digestion that form one cycle if more contiguous 
codons are to be changed. In ProxiMAX, one codon, called MAX, is added per cycle onto a 
conserved DNA section. This codon is a combination of a number of amino acids that are introduced 
at the mutation site and the ratio of amino acids as well as codon optimisation is fully controlled and 
decided on beforehand. As this is nondegenerate mutagenesis, one amino acid can only be expressed 
by one codon to eliminate degeneracy. MAX codons are delivered at 3’-end of double-stranded 
oligonucleotides which sequence is largely-conserved and can even be only partially double-
stranded, or be self-complementary hairpins. The positions of randomisation, scattered or contiguous 
within a gene are controlled and can achieve full saturation. The technology was until recently 
available under commercial platform Colibra™ at Isogenica Ltd, which was partially automated 
giving outstanding results in gene libraries and advantage of adding two codons at the time (Frigotto 
et al., 2015) instead of one in a manual setting. Nevertheless, fully manual ProxiMAX can be 
achieved in any lab as it does not require specialised reagents and it also offers a good result for the 
library (Poole, 2015). The advantage of using hexamer nucleotides as two MAX codons per cycle 












Figure 1.15. A schematic of ProxiMAX randomisation.  
Double-stranded DNA donors, carrying the required “MAX” codons at their termini, are ligated onto a 
double-stranded DNA acceptor sequence (phosphorylated at the required 5’-end only). The donors can take 
the form of partially double-stranded DNA, fully double-stranded DNA, or hairpin oligonucleotides (as 
shown). After ligation, the products are amplified by PCR. Depending on whether the process is performed 
with automation or manually, the donor oligonucleotides can either be combined before or after ligation, with 
the automated process substantially reducing the number of steps involved and permitting the use of 
hexanucleotide donors as required (Frigotto et al., 2015). The amplified, purified product is then digested with 
MlyI and the process repeated, using the digestion product from round 1 as the acceptor for the next round of 
ligation. Different sets of donor oligonucleotides (up to 20 independently synthesised, double-stranded 
oligonucleotides) are cycled to prevent potential carryover from one round of addition to the next (Ferreira 






This method was first published as an automated gene synthesis technology (Van den Brulle et al., 
2008; Schatz, Delcher, and Salzberg, 2010). Slonomics® relies on cycles of reactions including in 
the first instance sticky-end ligation between two hairpin oligonucleotides, a splinker and an anchor 
(Figure 1.16.). These hairpins have overhangs of usually three bases and once ligated, they are 
immobilised via a biotin moiety of the anchor. To ensure only immobilised product is taken into the 
next step, subsequent washes remove any unligated splinker. The next step, digestion with a Type 
IIS endonuclease enzyme of the immobilised product leaves a three-base, single-stranded overhang 
anchor which is then discarded, while supernatant contains splinker with a new codon. The elongated 
splinker can enter the next cycle if required, for up to six codons (18 bp). An extended fragment is 
called ‘elongation fragment’ and individual fragments when digested with Type IIS restriction 
enzymes can be later combined by ligations (Waldmann, 2006, 2013). This technology does not 
involve PCR amplification step seen with MAX and ProxiMAX randomisations or TRIM 
technology. Slonomics® was commercialised as SlonoMAX™ and it can be used to make 
combinatorial libraries. The advantage of Slonomics® to other traditional gene synthesis 
methodologies is relying on a universal set of building blocks, a total of 64 splinkers and 4096 
anchors, rather than single-stranded oligos that require to be generated separately (Waldmann and 












Figure 1.16. Overview of the Slonomics® process.  
Slonomics®  (Waldmann, 2006; Van den Brulle et al., 2008; Waldmann, 2013) begins with joining hairpin 
splinker oligonucleotides via sticky-ended ligation, to a mixture of hairpin anchor oligonucleotides. The ligated 
product is then immobilised via a biotin moiety contained within the anchors, washed and digested with Type 
IIS restriction enzyme Eam1104I, which generates a three-base sticky-ended overhang. The resulting extended 
splinker, which is now free in solution, enters the next round of addition. Up to six rounds of addition are 
performed to generate an “elongation block” and several elongation blocks may be joined together via further 
Type IIS digestion and subsequent ligation (Van den Brulle et al., 2008). No PCR amplification is involved in 




1.7. Methods for screening enzyme libraries 
Once the library of variants is produced, the next step is to subject this library to a reliable screening 
or selection method. The difference between those two is that screening considers every protein in 
terms of anticipated function, while selection excludes nonfunctional protein variants in the first 
instance (Xiao, Bao, and Zhao, 2015). Since some of the libraries have a high number of variants, 
once expressed, they cannot be examined one by one. Rather, a high-throughput method has to be 
employed. The choice of library screening technique depends on the nature of the library, properties 
of the engineered protein, the number of variants and others. Those libraries with variants higher than 
1010 have to be screened in in vitro methods because the transformation efficiency of in vivo methods 
would limit the number of clones. Anything of a smaller size can be fitted in in vivo techniques. For 
those protein libraries which express ligand-binding activities, suitable methods involve ligand 
immobilisation followed by exposure of the library variants found in solution. Those proteins that do 
not bind with the ligand are washed away and those bound are later eluted and amplified. This cycle 
is often repeated 3-5 times and is called enrichment. Due to the binding activity of the proteins, 
screening methods such as ribosome display (Hanes and Plückthun, 1997) or CIS display (Odegrip 
et al., 2004) can be employed because when the successful protein is immobilised, it can be isolated 
and its DNA sequenced.  
 
There is a different challenge with enzyme libraries because they often catalyse the reaction between 
components via binding but release them shortly after the catalysis is completed. Because of the rapid 
action of the catalysis and often short binding of the substrate, enzymes cannot be immobilised and 
their encoding sequences resolved. For this reason, any of the above display methods cannot be used 
for screening enzyme libraries, unless the activity of the enzyme is a permanent inhibition through 
binding. Instead of a display technique, the enzyme activity is often tested in a positive and negative 
selection based on various selection pressures such as life and death of cells through antibiotic 
resistance, production of the gene and others.  
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1.7.1. Double selection: positive and negative 
Double selection relies on positive and negative selection markers, to analyse and screen the library 
that expresses enzyme variants (Liu and Schultz, 1999; M. Pastrnak and Schultz, 2001). The aim of 
selection is to lead to a discovery of novel enzymes, with a new or enhanced, desired function. The 
positive and negative steps are designed to select for functional enzymes that exhibit a desired 
feature. They are often based on a reporter-based selection such as the activity of the enzyme variant 
that will regulate reporter activity. For example, the reporter can be a gene of which expression 
ensures the survival of the cells when exposed to the antibiotic. Production of this antibiotic-resistant 
protein is, therefore, controlled by the desired enzyme variants (Xiao et al., 2015). This type of 
reporter based selection can be either riboswitch/ribozyme-based or transcriptional-regulator-based 
strategies. An example of a reporter based selection as a positive marker in double selection is β-
lactamase gene. This popular antibiotic resistance gene is often substituted for one with stronger 
selection pressure, chloramphenicol acetyltransferase (Miro Pastrnak, Magliery, and Schultz, 2000). 
Negative selection marker may be a toxic gene, for example, barnase or uracil 
phosphoribosyltransferase.  
 
Schultz and co-workers regularly employ their well-established double selection assays for screening 
aaRS variants coupled with a tRNA suppressor, to introduce UAAs into proteins and thus expand the 
genetic code with a variety of UAAs. In the first step, positive selection relies on the production of 
antibiotic-resistant proteins to identify clones that encode any functional protein. The enzyme 
variants are expressed in the presence of tRNA suppressor, UAAs and AA and antibiotic-resistant 
protein gene with an amber stop codon in a permissive position. When the variant aminoacylates the 
tRNA suppressor with any of the amino acids present (UAA or AA), it reads through a stop codon, 
successfully expressing an antibiotic-resistant protein that results in cell survival – a cell with a 
functional aaRS variant. The second step subjects all of the survivors to a negative selection. This 
time the expression is carried out in the absence of the chosen UAA (i.e. natural AAs only) to express 
a toxic gene such as barnase, again containing an amber stop codon. Cells with aaRS variants that 
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are capable of aminoacylating the suppressor tRNA with natural AAs successfully read through the 
stop codon, whereas those that can only incorporate the UAA do not. This expression (i.e. successful 
read-through) results in the production of a toxic gene that ultimately, kills the clones encoding those 
enzyme variants that recognise both natural AAs. The surviving cells carry the desired functional 
enzyme variants that have passed double selection process and are able to recognise only the UAA 
of choice (Melancon and Schultz, 2009). 
 
1.7.2. GFP-reporter and FACS screening 
Another reporter-based selection system widely used is GFP-reporter that is coupled with 
Fluorescence-Activated Cell Sorting (FACS) (G. Yang and Withers, 2009). FACS, a type of flow 
cytometry is able to sort cells based on their fluorescence signals, single or multiple as required. The 
method itself is highly sensitive and also considered as ultrahigh-throughput screening suitable for 
directed enzyme evolution. Although FACS can be also used during in vitro compartmentalisation, 
product entrapment in the cells, or active enzymes displayed on the cell surface, for the purpose of 
this project, only GFP-reporter system is going to be outlined here.  
 
The gene of Green Fluorescent Protein (GFP) and its variants such as enhanced GFP (eGFP) can also 
be used as reporter genes in screening the family of aaRS enzymes. In an example of this system 
(Santoro, Wang, Herberich, King, and Schultz, 2002), two termination codons are placed within a 
T7 RNA polymerase gene, which in turn, if translated, expresses a GFP gene (under control of the 
T7 promoter). A third termination codon is placed in a chloramphenicol resistance gene.  All these 
genes, along with an amber suppressor tRNA are encoded on the same plasmid. In this complex 
example, a double selection is also employed. The first step involves expressing the aaRS variants in 
the presence of UAA and chloramphenicol so that clones that can aminoacylate the suppressor tRNA 
with any amino acid will read through chloramphenicol resistance gene, survive antibiotic selection 
and go on to produce both T7 RNA polymerase and thus GFP. The screen is then repeated in a second 
step in the absence of both UAA (i.e. natural AAs only) and chloramphenicol, so those cells with 
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fluorescent signal include enzyme variants that recognise only natural AA, while those functional 
synthetases that aminoacylate tRNA suppressor with UAA were unable to read through T7 RNA 
polymerase and GFP genes and thus do not have fluorescent signal. The second step is coupled with 
FACS sorting and fluorescent cells are discarded. In this way, the cells with desired aaRS variants 
can be isolated and the sequence of mutant enzyme determined.  
 
1.7.2.1. Fluorescent protein– GFP and its variants 
GFP is the most well-known and established fluorescent protein with application across different 
fields of life sciences. It was originally isolated from a jellyfish Aequorea victoria and firstly 
published in 1962 (Shimomura, Johnson, and Saiga, 1962). GFP is made of 238 amino acids and its 
molecular weight is approximately 27 kDa. It has a β-barrel structure of eleven β-strands with a 
chromophore found in the centre of this structure as seen in Figure 1.17. (F. Yang, Moss, and Phillips, 
1996). The chromophore emits green fluorescence upon exposure to blue light and when oxidisation 
of α–β carbon bond of residue Tyr66 occurs (Heim, Prasher, and Tsien, 1994). Truncated GFP will 
not exhibit any fluorescence. Its most common application includes protein localisation, organelle 
labelling, gene regulation (Kaishima, Ishii, Matsuno, Fukuda, and Kondo, 2016). 
 
Currently, a variety of GFP homologous from different organisms are also available and often used 
instead of the original one as they offer enhanced properties in terms of signal intensity, stability, 
different excitation and emission spectra (better suitable for the application), length of emission and 
others. As an example enhanced GFP (eGFP) is based on wtGFP but with mutations around the 
chromophore region. Thus mutating residue Ser65 to Thr allowed for stabilisation of hydrogen-
bonding network and making it 5-fold brighter than wtGFP and faster to detect when using eGFP in 
living cells as a fluorescent marker (Heim, Cubitt, and Tsien, 1995). An additional mutation of Phe64 
to leucine improved maturation of protein at 37 °C. The disadvantage of using eGFP over wtGFP is 
its weak predisposition to dimerize and minor sensitivity to pH (Day and Davidson, 2009). To ensure 
that eGFP remains a monomer, one of the three point mutations, F223R, L221K, and most preferable 
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A206K, can be introduced to the gene (Nagai et al., 2002; Zacharias, Violin, Newton, and Tsien, 
2002). eGFP has a peak excitation wavelength at 488 nm and a peak excitation wavelength at 507 
nm. Considering that other fluorescent proteins were developed based on eGFP variant (with slightly 
different properties), eGFP remains a very reliable and well-used fluorescent market during library 






Figure 1.17. The β-barrel structure of A. victoria GFP. 
Drawing includes approximate dimensions of A. victoria GFP and it is based on Protein Data Bank ID: 1w7s 
(Day and Davidson, 2009). 
 
 
1.8. Current advances in introducing UAAs into proteins and expansion 
of genetic code 
The technologies to incorporate UAAs into proteins were developed for both in vivo and in vitro 
applications. The earliest research involved chemical aminoacylation of tRNAs as pre-charged 
tRNAs that were then used for in vitro translation (Hecht, Alford, Kuroda, and Kitano, 1978). A 
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different approach was largely developed by Schultz and co-workers and involved engineering aaRS 
and tRNA pairs. This approach had been extensively developed ever since also by other researchers, 
and currently, there are over 200 UAAs that can be incorporated into proteins in vivo or in vitro by 
different mutant pairs. 
 
1.8.1. Chemical aminoacylation 
Chemical aminoacylation was first developed by Hecht and colleagues (Hecht et al., 1978). At that 
time, it was assumed that aaRSs are not efficient in aminoacylating tRNAs with UAAs and an 
alternative method was sought. Therefore, chemical aminoacylation was developed for the purpose 
of using pre-charged tRNAs with UAAs during proteins synthesis. In the process, tRNA with deleted 
3’-terminal cytidine and adenosine is ligated with 2’(3’)-O-acylated pCpA derivatives by T4 RNA 
ligase (Robertson, Ellman, and Schultz, 1991). The reaction has been developed further for the 
number of years, but it is generally considered as technically challenging.  
 
1.8.2. Flexizyme system  
Suga and co-workers began the research on synthetic ribosomes that can aminoacylate tRNAs in the 
early 2000s (Lee, Bessho, Wei, Szostak, and Suga, 2000). He later developed Flexizyme system that 
is well-known for charging UAAs onto tRNAs (Murakami, Ohta, Ashigai, and Suga, 2006; Ohuchi, 
Murakami, and Suga, 2007a). It comprises of a synthetic ribosome that demonstrates the aaRSs-like 
function of aminoacylation various tRNAs. The flexizyme distinguishes tRNA by its 3’-end RCCA-
3’ (R=A/G) and its discriminator base is at position 73. It also recognises benzylic moiety on the 
leaving group (Murakami et al., 2006). The system is widely used in in vitro translation system for 
incorporation of UAAs into proteins. Flexizyme can charge amino acids onto tRNA in a high-
throughput manner and it is far more advantageous to conventional chemical aminoacylation. 
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1.8.3. Engineering cognate aaRS and tRNA pairs 
The most commonly aaRS and tRNA pairs used for genetic code expansion are Methanocaldococcus 
jannaschii Tyrosyl-tRNA synthetase-tRNATyr pair (MjTyrRS-tRNATyr) or the Methanosarcina 
barkeri Pyrrolysyl-tRNA synthetase-tRNAPyl pair (MbPylRS-tRNAPyl) as wild-type or engineered 
(Vargas-Rodriguez, Sevostyanova, Söll, and Crnković, 2018). The first methods of incorporation 
UAAs into proteins involved using amber suppression codon, as this is a rare codon in E. coli, and it 
can be used to encode UAA of choice. However, both pairs allow for anticodon mutation of tRNA 
without losing the enzyme’s specificity. MjTyrRS-tRNATyr can only be used in prokaryotic systems 
such as E. coli because in vivo it can cross-connect with the endogenous system of eukaryotic TyrRS 
and tRNATyr (Vargas-Rodriguez et al., 2018). Conversely, unique properties of PylRS and its cognate 
tRNAPyl (known also as tRNACUA) make the pair an interesting tool for incorporation of UAAs via 
amber suppression. The pair is known to be orthogonal in bacterial and eukaryotic cells and therefore, 
it can be used alongside endogenous tRNAs and aaRSs (Wan, Tharp, and Liu, 2014).  
 
The cognate pair PylRS-tRNACUA (including the active site engineered PylRS) was used in several 
studies by Chin and colleagues (Elliott, Bianco, and Chin, 2014) as well as Schultz and co-workers 
(Vargas-Rodriguez et al., 2018). For example, it was employed to incorporate lysine with post-
translational modification like methylation, acetylation or ubiquitination into the proteins (Elliott et 
al., 2014). Other UAAs included biophysical probes such as photo-crosslinkers. Also, the site-
specific labelling of proteins for fluorescence resonance energy transfer (FRET) studies was 
developed. Another technology by Chin and colleagues used this pair in parallel with his orthogonal 
ribosome ribo-Q1 which recognises quadruplet codons for the incorporation of UAAs (Neumann, 
Wang, Davis, Garcia-Alai, and Chin, 2010).  
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1.9. The aims and objectives of the project 
This project aimed to provide the foundations for the development of a novel in vitro translation 
system to introduce multiple UAAs via in vitro translation of proteins to expand the genetic code, 
ultimately from 20 to 32 codons. The system would work in parallel with ProxiMAX randomisation 
and synthetic genes to be utilised during library generation and screening. Since ProxiMAX is a 
nondegenerate saturation mutagenesis procedure, it only uses 20 codons from the genetic code, 
‘leaving’ many spare codons that could be used in the novel system. 
 
To be able to develop an in vitro translation system, there is a requirement to engineer novel 
aminoacyl-tRNA synthetases which recognises UAAs (in particular D-AAs) and insert them in a 
protein during in vitro translation. Novel tRNA molecules are also essential so they form cognate 
pairs with novel enzymes.  
 
In this project, the development of new enzymes is based on E. coli AlaRS while new tRNAs are 
based on E. coli tRNAAla. The lack of anticodon recognition by AlaRS makes it an ideal target for 
mutagenesis since tRNA specificity is determined only by the acceptor arm. Thus, it is possible to 
mutate the anticodon of tRNAAla whilst leaving the acceptor arm unchanged. Meanwhile, the amino 
acid binding site of E. coli AlaRS will be mutated to promote binding with D-Ala and subsequently, 
other UAAs. This AlaRS already misacylates both smaller glycine and larger serine in its natural 
environment (Guo et al., 2009). Therefore, there is a possibility that by mutating residues within the 
amino acid binding site, new amino acids will be recognised by the enzyme. Obviously, since the 
acceptor arm of the tRNAAla remains unchanged, resulting tRNAs would be individually pre-charged, 
prior to being placed in the in vitro translation reactions, akin to the semi-synthetic approach of Suga 
and co-workers (Ramaswamy, Saito, Murakami, Shiba, and Suga, 2004; Murakami et al., 2006; 
Ohuchi, Murakami, and Suga, 2007b). Ultimately, to prevent recycling or editing of mutant tRNAs 
by native AlaRS, these pre-charged mutant tRNAs along with native pre-charged tRNAs (or possibly 
only pre-charged tRNAAla) would be used in an in vitro translation reaction of synthetic genes in 
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which only the normal 20 ProxiMAX codons are used to encode natural AAs and the remaining 12 
codons are used to encode UAAs in positions of saturation. 
 
The fundamental and central part of the project is to create a gene library based on E. coli AlaRS and 
mutating its amino acid binding site. The library will be generated using ProxiMAX randomisation 
because it is a nondegenerate, unbiased and achieving maximal diversity method of making gene 
variant libraries. Two libraries will be produced. The first library would be based on the N-terminal 
domain of E. coli AlaRS only. This domain can aminoacylate tRNAs on its own (Naganuma et al., 
2014) and excludes the editing function that is not desired for the application of this project. 
Meanwhile, the second library would be a full-length enzyme in which the editing function is 
eliminated by a C666A mutation. As a preparation for the library build, the genes that will be used 
in the generation of libraries have to be amplified from E. coli and cloned into vectors. Their 
expression and functionality in aminoacylation assays will also be undertaken. 
 
Once the gene libraries are produced, it is vital to screen them using a reliable assay. Previous aaRS 
mutagenesis has been developed using orthogonal systems such as the PylRS and cognate tRNACUA 
that are orthogonal to the cells in which they are produced (Blight et al., 2004). However, such 
systems are not suitable to translate with multiple UAAs in parallel, since they rely on the use of a 
single, amber termination codon for UAA incorporation. Therefore, the final objective of this project 
is to develop an assay for screening libraries of E. coli AlaRS variants, conducted in a different host 




Chapter 2: Materials and Methods 
Medium and buffers were prepared with distilled water (dH2O). Extra purified 18.2 MΩ water also 
called double distilled water (ddH2O) was used in all molecular procedures such as Polymerase Chain 
Reaction (PCR), DNA elution in DNA extraction and others. To any work related to RNA DEPC-
Treated Water was used. 
 
2.1. Materials 
2.1.1. Risk Assessments 
The appropriate risk assessments were undertaken and stored in the laboratory. 
 
2.1.2. Cell lines 
Table 2.1. Cell lines for E. coli and S. cerevisiae. 
Organism Strain Genotype  
E. coli Tuner™(DE3) F– ompT hsdSB (rB– mB–) gal dcm lacY1(DE3) 
E. coli DH5α F– φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
S. cerevisiae BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 




2.1.3. Vectors  
Table 2.2. List of vectors used in the study. 
Vector  Source  Comments  




Thermo Fisher Scientific 
(formerly Fermentas) 
Purchased from Thermo Fisher Scientific 
pET45b(+) Novagen™ Already present in Prof Anna V Hine’s lab stock 
pYES2 Invitrogen™ A gift from Prof Roslyn Bill’s lab stock 
pXRH3 Addgene A gift from Prof Marc Gartenberg  
(Addgene plasmid #63145; http://n2t.net/addgene:63145; 




2.1.4.1. DNA ladders 
2.1.4.1.1. HyperLadder™ 1 kb (Bioline) 
2.1.4.1.2. HyperLadder™ 25 bp (Bioline) 
2.1.4.1.3. 1 kb DNA ladder (NEB) 
2.1.4.1.4. GeneRuler™ 1 kb DNA Ladder (Fermentas) 
2.1.4.1.5. GeneRuler™ 1 kb Plus DNA Ladder (Thermo Scientific) 
2.1.4.1.6. Low Molecular Weight Marker, 10-100 nt (Affymetrix) 
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2.1.4.2. Protein Ladders 
2.1.4.2.1. PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
2.1.4.2.2. Prestained Protein MW Marker (Thermo Scientific) 
2.1.4.2.3. PageRuler Prestained Protein Ladder (Thermo Scientific) 
 
2.1.5. Media recipes 
2.1.5.1. Solid medium 
The medium was prepared according to the recipe and substituted with 1.5 % (w/v) Difco™ Agar, 
Granulated (BD Biosciences). The solution was autoclaved at 121 °C for 20 min and left to cool to 
approximately 55 °C. To prepare solid medium plates, 25-30 mL of agar-media solution was added 
in a sterile manner onto a petri dish. The plates were then left to set at the room temperature overnight 
and stored at 4 °C on the following day. 
 
2.1.5.2. LB broth medium 
Tryptone 1 % (w/v) 
Yeast extract (YE) 0.5 % (w/v) 
Sodium chloride (NaCl) 1 % (w/v) 
 
To prepare 2 % (w/v) medium solution, LB broth powder (Fisher Bioreagents) was dissolved in 
distilled H2O. The solution was autoclaved at 121 °C for 20 min. LB was supplemented with 100 
µg/mL sterile ampicillin solution (when cooled down) or 1.5 % (w/v) agar for solid medium (prior 
to autoclaving), as required. 
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2.1.5.3. 2X YT medium (at Isogenica) 
Tryptone 1.6 % (w/v) 
Yeast extract (YE) 1 % (w/v) 
Sodium chloride (NaCl) 0.5 % (w/v) 
 
2.1.5.4. SOC medium (Super Optimal Broth with Catabolite repression) 
Tryptone 2 % (w/v) 
Yeast extract (YE) 0.5 % (w/v) 
Sodium chloride (NaCl) 0.01 M 
Potassium chloride (KCl) 0.0025 M  
Magnesium chloride (MgCl2) 0.01 M  
Magnesium sulfate (MgSO4) 0.01 M  
Glucose 0.02 M  
 
2.1.5.5. YPD medium (Rich Medium) 
Yeast extract (YE) 1 % (w/v) 
Peptone 2 % (w/v) 
Dextrose 2 % (w/v) 
 
To prepare YPD medium, yeast extract and peptone were mixed in 90 % of the final volume of 
distilled H2O and autoclaved at 121 °C for 20 min. Once it cooled down to approximately 55 °C, 
filter sterilised 20 % (w/v) dextrose was added. YPD was supplemented with 1.5 % (w/v) agar for 
solid medium (prior to autoclaving), as required. 
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2.1.5.6. Synthetic Defined (SD) (Selective/Minimal) Medium 
Complete Supplement Mixture (CSM) Single or Double Drop-Out (Formedium) and Yeast Nitrogen 
Base (YNB) without amino acids (Formedium) were mixed according to the manufacturer’s 
instructions. The solution was autoclaved at 121 °C for 20 min. Once it cooled down to 
approximately 55 °C, filter sterilised 20 % (w/v) dextrose or 20 % (w/v) galactose was added. SD 
was supplemented with 1.5 % (w/v) agar for solid medium (prior to autoclaving), as required. 
 
2.1.6. Buffer recipes 
2.1.6.1. 1X Tris-Acetate-EDTA (TAE) Buffer (50X) (Fisher Scientific)  
Tris 0.04 M 
Acetic acid 0.02 M 
EDTA 0.001 M 
 
2.1.6.2. 1X Tris-Borate-EDTA (TBE) Buffer (10X) (Gibco™ by Life Technologies)  
Tris 0.1 M 
Boric acid 0.09 M 
EDTA 0.001 M 
 
2.1.6.3. 1X Standard Taq DNA Polymerase Reaction Buffer (10X) (NEB)  
Tris-HCl 0.01 M 
Potassium chloride (KCl) 0.05 M 
Magnesium chloride (MgCl2) 0.0015 M 
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2.1.6.4. 1X Q5® High-Fidelity DNA Polymerase Reaction Buffer (5X) (NEB)  
 
2.1.6.5. 1X Phusion HF Buffer (5X) (Thermo Scientific) 
 
2.1.6.6. 1X AMV Reverse Transcriptase Reaction Buffer (10X) (NEB) 
Tris-Acetate 0.05 M 
Potassium acetate 0.075 M 
Magnesium acetate 0.008 M 
Dithiothreitol (DTT) 0.01 M 
 
2.1.6.7. DNA Gel Loading Dye (6X) (Thermo Fisher Scientific) 
Tris-HCl (pH 7.6) 0.00167 M 
Bromophenol blue   0.005 % 
Xylene cyanol FF 0.005 %  
Glycerol 10 % 
EDTA 0.010 M 
 
2.1.6.8. GelPilot Loading Dye (5X) (QIAGEN) 
 
2.1.6.9. Gel Loading Dye Purple (6X) (NEB) 
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2.1.6.10. Blue Gel Loading Dye (6X) (NEB)  
Ficoll®-400 2.5 %  
EDTA   0.011 M 
Tris-HCl 0.0033 M  
SDS 0.017 % 
Bromophenol blue 0.015 % 
 
2.1.6.11. 1X T4 DNA Ligase Reaction Buffer (10X) (NEB) 
Tris-HCl  0.05 M  
Magnesium chloride (MgCl2) 0.01 M 
ATP 0.001 M 
Dithiothreitol (DTT)  0.01 M 
 
2.1.6.12. 1X T4 DNA Ligase Buffer (10X) (Thermo Scientific)  
Tris-HCl  0.04 M  
Magnesium chloride (MgCl2) 0.01 M 
ATP 0.0005 M 




2.1.6.13. 1X CutSmart Restriction Digest Buffer (10X) (NEB) 
Tris-Acetate  0.02 M  
Magnesium acetate  0.01 M 
Potassium acetate 0.05 M 
BSA 100 µg/mL 
 
2.1.6.14. 1X FastDigest Buffer (10X) (Thermo Scientific™) 
 
2.1.6.15. 1X SYBR® Gold Nucleic Acid Gel Stain (10,000X) (Invitrogen™ by Life 
Technologies) 
 
2.1.6.16. 1X SYBR® Safe DNA Gel Stain (10,000X) (Invitrogen™ by Life Technologies) 
 
2.1.6.17. SDS-PAGE, PAGE, acid-urea PAGE and Protein purification buffers 
 
At Isogenica: 
2.1.6.17.1. Binding buffer (A)  
Sodium phosphate buffer (pH 7.5) 0.05 M  
Sodium chloride (NaCl) 0.5 M 
Imidazole  0.02 M 
 
To obtain pH 7.5 of sodium phosphate buffer, 84% of Na2HPO4 was mixed with 16% of 
NaH2PO4.The buffer was filter sterilised using the Corning units with 0.22 μm pore filter. 
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2.1.6.17.2. Elution buffer (B)  
Sodium phosphate buffer (pH 7.5) 0.05 M  
Sodium chloride (NaCl) 0.5 M 
Imidazole  0.25 M 
 
To obtain pH 7.5 of sodium phosphate buffer refer to 2.1.6.17.1.  
 
2.1.6.17.3. 1X NuPAGE™ MOPS SDS Running Buffer (20X) (Novex™ by Life 
Technologies) 
3-(N-morpholino)propanesulfonic acid (MOPS) 0.05 M  
Tris 0.05 M 
SDS 0.1 % 
EDTA 0.01 M 
pH 7.7 
 
2.1.6.17.4. 1X NuPAGE™ LDS Sample Buffer (4X) (Novex™ by Life Technologies) 
2.1.6.17.5. 1X Bolt® Sample Reducing Agent (10X) (Novex™ by Life Technologies) 
 
At Aston: 
2.1.6.17.6. Lysis buffer (pH 8.0) 
Sodium phosphate buffer 0.05 M  
Sodium chloride (NaCl) 0.3 M 
Imidazole  0.01 M 
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2.1.6.17.7. Native column wash buffer (pH 8.0) 
Sodium phosphate buffer 0.05 M  
Sodium chloride (NaCl) 0.3 M 
Imidazole  0.02 M 
 
2.1.6.17.8. Native column elution buffer (pH 8.0) 
Sodium phosphate buffer 0.05 M  
Sodium chloride (NaCl) 0.3 M 
Imidazole  0.25 M 
 
2.1.6.17.9. 1X SDS-PAGE sample buffer 
Tris-HCl (pH 6.8) 0.05 M  
Dithiothreitol (DTT) 0.1 M 
SDS  2 % (w/v) 
Glycerol 8 % (v/v) 
Bromophenol blue 0.1 % (w/v) 
 
2.1.6.17.10. 1X Tris-Glycine-SDS PAGE Buffer (10X) (National Diagnostics) 
Tris  0.025 M  
Glycine 0.192 M 
SDS  0.1 % (w/v) 
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2.1.6.17.11. 1X Acid-Urea PAGE running buffer 
Sodium acetate (pH 5.0) 0.1 M 
 
2.1.6.17.12. 1X Acid-Urea PAGE sample buffer 
Urea 7 M  
Sodium acetate (pH 5.0) 0.1 M 
Bromophenol blue 0.05 % (w/v) 
 
2.1.6.17.13. 1X Acid-Urea PAGE staining solution 
Sodium acetate (pH 5.0) 0.1 M 
SYBR® Gold Nucleic Acid Gel Stain (Invitrogen) 1X 
 
2.1.6.18. 1X Transfer buffer for Western Blot 
Tris 0.025 M 
Glycine 0.192 M 
pH 8.3 
 
2.1.6.19. 1X Aminoacylation buffer 
HEPES 0.1 M 
Magnesium chloride (MgCl2) 0.02 M 
Dithiothreitol (DTT) 0.01 M 
ATP 0.01 M 
Potassium chloride (KCl) 0.01 M 
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2.1.7. Other solutions 
2.1.7.1. Ammonium Persulfate  
Ammonium Persulfate (Sigma-Aldrich) 20 % (w/v) 
 
2.1.7.2. Ampicillin (Amp) 
The stock solution of ampicillin (100 mg/mL) was prepared by dissolving 4.5 g ampicillin powder 
(Sigma) in 45 mL ddH2O. Solution was sterilised using 0.22 µm syringe filter. Stocks of 1.5 mL were 
stored at -20 °C. 
 
2.1.7.3. 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) 
To prepare 2 % (w/v) X-gal, 0.2 g powder X-Gal was dissolved in 10 mL DMF. The solution was 
sterilised using 0.22 µm syringe filter. Stocks of 1 mL aliquots were stored at -20 °C. 
 
2.1.7.4. dNTPs 
To prepare dNTP solutions from 100 mM stock solution (NEB, Promega), ddH2O was used to dilute 
the stock to required concentration. 
 
2.1.7.5. Ethanol 
Ethanol 70 % (v/v) 
 
2.1.7.6. EZ-ECL (Biological Industries) 




Dextrose [D-(+) Glucose] (Sigma-Aldrich) 20 % (w/v) 
The solution was filter sterilised. 
 
2.1.7.8. Glucose 
Dextrose [D-(+) Glucose] (Sigma-Aldrich) 20 % (w/v) 
The solution was filter sterilised. 
 
2.1.7.9. InstantBlue™ Protein Stain (Expedeon) 
 
2.1.7.10. Isopropanol 
Isopropanol 70 % (v/v) 
 
2.1.7.11. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
To prepare 1 M IPTG, 2.38 g powder IPTG was dissolved in 10 mL ddH2O. Solution was sterilised 
using 0.22 µm syringe filter. Stocks of 1.5 mL were stored at -20 °C. 
 
2.1.7.12. Lithium Acetate 
To prepare 1 M Lithium Acetate (LiAc), 0.102 g was mixed in 10 mL distilled water. The solution 




2.1.7.13. Poly(ethylene glycol) (PEG) 
Poly(ethylene glycol) average MW (3015-3685) 
(Aldrich Chemistry)  
50 % (w/v) 
 
2.1.7.14. Sodium Dodecyl Sulfate (SDS) 
Sodium Dodecyl Sulfate (Sigma-Aldrich)  10 % (w/v) 
 
2.1.7.15. Salmon Sperm Single-Stranded DNA 
It was a gift from Dr. Michelle Clare. 
 
2.2. Methods  
2.2.1. Molecular procedures 
2.2.1.1. Polymerase Chain Reaction (PCR) 
PCR reactions were carried out in 1X reaction buffer (2.1.6.3., 2.1.6.4., 2.1.6.5), 200 μM dNTPs 
(2.1.7.4.), 100-500 nM forward and reverse primers (Eurofins Genomics or Sigma) and 1 pg – 1 μg 
of DNA. Enzyme concentrations varied depending on the manufacturer's recommendations (Taq 
Polymerase vs High-Fidelity Polymerase). PCR conditions, temperature and time were based on the 
manufactures instructions, but generally the conditions for High-Fidelity Polymerase (Phusion or 
Q5) were: 98 °C for 30 sec followed by 30 cycles of: 98 °C for 10 sec, primers dependent temperature 
for 30 sec and 72 °C for 20-30 sec/kb, with a final step at 72°C for 2 min. While the conditions for 
Taq Polymerase were: 95 °C for 30 sec followed by 30 cycles of: 95 °C for 30 s, primers dependent 
temperature for 30 sec, and 68 °C for 1 min/kb, with a final step at 68 °C for 5 min. Every set of 
reaction included negative control without DNA present.  
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2.2.1.1.1. Gradient PCR 
Gradient PCR reactions were set up based on 2.2.1.1. The conditions of cycling were determined by 
testing a gradient temperature for primers annealing. The volume per reactions was usually 10-25 
μL. 
 
2.2.1.1.2. Colony PCR 
Colony PCR reactions were set up based on 2.2.1.1. A colony was picked with a sterile pipette tip 
from a solid media plate and inoculated in an individual PCR reaction tube. PCR was performed with 
Taq Polymerase. The volume per reactions was usually 10-25 μL. The colonies were saved by 
inoculating in liquid media or by streaking on solid media plates. 
 
2.2.1.2. RT-PCR 
RT-PCR used in this study was two-step RT-PCR using AMV Reverse Transcriptase (10 U/µL) 
(NEB). Every RT-PCR reaction included negative control without AMV Reverse Transcriptase 
present. The difference was made up with RNA DEPC-Treated Water.  
 
Step one: 20 ng of total extracted RNA (2.2.1.8.4), 1 µM gene-specific forward and reverse primer, 
10 mM dNTPs and RNA DEPC-Treated Water was mixed in a total volume of 10 µL. The reaction 
mixture was incubated at 65 °C for 5 min, followed by a brief spin and placed on ice. To 10 µL of 
RNA/primer mixture were added 1X AMV buffer (2.1.6.6.), 10 U AMV Reverse Transcriptase, up 
to 10 U RNase Inhibitor and RNA DEPC-Treated Water. The total reaction volume was 20 µL. The 
reaction mixture was incubated at 25 °C for 5 min, followed by 42 °C for 60 min and AMV enzyme 
was inactivated 80 °C for 5 min.  
 
Step two: cDNA generated in step one served as a template for amplification in step two RT-PCR. 
Step two RT-PCR was carried out in 1X Taq buffer (2.1.6.3.), 200 μM dNTPs (2.1.7.4.), 200 nM 
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gene-specific forward and reverse primers (Eurofins Genomics) and 2 µL of cDNA template (step 
one reaction) in a total volume of 50 µL. The total volume was made up with RNA DEPC-Treated 
Water. The reaction was incubated at following conditions: 95 °C for 30 sec, followed by 30 cycles 
of: 95 °C for 30 sec, 55 °C for 30 sec, and 68 °C for 1 min/kb, with a final step at 68 °C for 5 min. 
Every step two reactions included a negative control without cDNA present. 
 
2.2.1.3. Addition of phosphate group to the 5’-ends of DNA (phosphorylation) 
Up to 20 pmol DNA were incubated in 1X ligase buffer (2.1.6.11. or 2.1.6.12.), 1 mM ATP and 10 
U T4 Polynucleotide Kinase (NEB or Thermo Scientific) in a total volume of 20 µL at 37 °C for 30 
min. The enzyme was heat-inactivated at 65 °C for 20 min. 
 
2.2.1.4. Removal of a phosphate group from the 5’-ends of DNA (dephosphorylation) 
Up to 1 pmol DNA were incubated in 1X Antarctic Phosphatase Reaction Buffer (10X) and 5 U 
Antarctic Phosphatase (NEB) in a total volume of 20 µL at 37 °C for 30 min. The enzyme was heat-
inactivated at 80 °C for 2 min. If required, the reaction was scaled up.  
 
2.2.1.5. Ligation 
The ligation was performed in the molar ratio of 1:3 vector to insert with up to 100 ng of insert DNA. 
The reaction was set up in 1X ligase buffer (2.1.6.11. or 2.1.6.12.) and 400 U T4 DNA Ligase (NEB 
or Thermo Scientific) in a total volume up to 50 µL. The ligation was incubated at 16 °C overnight 
or at 22 °C for 2 h with inactivation at 65 °C for 10 min.  
 
2.2.1.6. Restriction digest 
The restriction digestion was performed using up to 1 µg of DNA, 1X digestion buffer (2.1.6.13. or 
2.1.6.14.), 10 U of restriction enzyme in a reaction volume up to 100 µL. Incubation and inactivation 
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parameters varied depending on the enzyme used. 
 
2.2.1.7. Mutagenesis 
2.2.1.7.1. ProxiMAX randomisation 
Colibra™ (Isogenica) was employed for ProxiMAX randomisation (Ashraf et al., 2013; Frigotto et 
al., 2015; Poole, 2015). 
 
2.2.1.7.2. Via PCR 
In order to introduce mutation in DNA using PCR, appropriate primers were designed with one 
carrying a mutation to use in PCR reaction (2.2.1.1.). 
 
2.2.1.8. Nucleic acid purification 
2.2.1.8.1. DNA purification including PCR products, enzyme digestions, and other 
DNA containing samples  
Samples were purified using different purification spin columns kits: QIAquick® PCR Purification 
Kit (QIAGEN), MinElute® PCR Purification Kit (QIAGEN), Wizard® SV Gel and PCR Clean-Up 
System (Promega) or GENECLEAN® Turbo Kit (MP Biomedicals) according to the manufacturer’s 
instructions. NanoDrop was used to quantify purified DNA (2.2.1.9.). 
 
2.2.1.8.2. DNA plasmids  
To extract plasmid DNA from the bacterial culture grown in LB broth (2.1.5.2.), QIAprep® Spin 
Miniprep Kit (QIAGEN) was used according to the manufacturer’s instructions.  
 
To isolate plasmid DNA from yeast cells grown in Selective Medium (2.1.5.6.), a protocol “Isolation 
of plasmid DNA from yeast using the QIAprep® Spin Miniprep Kit” was followed. It was found on 
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QIAGEN® website as a User-Developed Protocol by Michael Jones, Chugai Institute for Molecular 
Medicine, Ibaraki, Japan. The following changes were applied to the methodology. In step 2, 500 μL 
instead of 250 μL of Buffer P1 were used. In step 3, 600 μL of acid-washed glass beads (425-600 
μm) (Sigma-Aldrich) were used to mix with the sample and lyse in TissueLyser LT (QIAGEN), for 
5-10 min at 50 Hz. The TissueLyser LT insert adapter for the samples was pre-cooled for 30 min at 
-80 °C. NanoDrop was used to quantify extracted plasmid DNA (2.2.1.9.). 
 
2.2.1.8.3. Gel extraction 
DNA was extracted from the agarose gel using QIAquick® Gel Extraction Kit (QIAGEN) or Wizard® 
SV Gel and PCR Clean-Up System (Promega) according to the manufacturer’s instructions. 
NanoDrop was used to quantify gel extracted DNA (2.2.1.9.). 
 
2.2.1.8.4. RNA extraction 
RNA was isolated from S. cerevisiae using RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instructions. Prior to extraction, cells had to be lysed following 2.2.7.3. Once cells 
were lysed, DNase digestion was performed using RNase-Free DNase Set (QIAGEN) with 
incubation at 22 °C for up to 30 min before adding lysed supernatant onto a column. Instead of 70 % 
(v/v) ethanol, 70 % (v/v) isopropanol was used. RNA was eluted with RNase-free water provided in 
the kit. If required, RNA was re-purified with another DNase treatment before column purification. 
NanoDrop was used to quantify purified RNA (2.2.1.9.). 
 
2.2.1.9. Nucleic acid quantification 
NanoDrop 2000c (at Aston) or NanoDrop 8000 (at Isogenica) (Thermo Scientific) was used to 
measure the concentration and quality of DNA and RNA. A blank solution, for example, 1 μL of 
ddH2O or Buffer EB (QIAGEN) was used to calibrate the spectrophotometer. Measurements were 
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taken by pipetting 1 μL of sample onto the pedestal of NanoDrop. After calibration or measurement, 
the pedestal was cleaned with a tissue. 
 
2.2.2. Electrophoresis  
2.2.2.1. Agarose gel electrophoresis of DNA 
Dependent on the size of analysed DNA, gels of different concentrations were prepared by dissolving 
Hi-Res Standard Agarose powder (AGTC Bioproducts) in 1X TAE (2.1.6.1.) (at Aston) or Molecular 
Grade Agarose powder (Melford) in 1X TBE (2.1.6.2.) (at Isogenica). The mixture was heated in a 
microwave until fully dissolved. When the solution cooled down, 1X SYBR® Safe DNA Gel Stain 
(10,000X) (2.1.6.15.) or 1X SYBR® Gold Nucleic Acid Gel Stain (10,000X) (2.1.6.16.) 
(Invitrogen™ by Life Technologies) was added for nucleic acid detection. The mixture was purred 
into a gel form with a comb attached to form well, and it was left to set.  
 
The analysed samples were pre-mixed with 1X sample loading buffer (2.1.6.7.-2.1.6.10.) before 
being loaded to the wells. DNA markers/ladders (2.1.4.1) were used as a reference. Electrophoresis 
was performed in 1X TAE (Aston) or 1X TBE (Isogenica) at 10 V/cm. The gel was visualised by 
SYBR® Safe DNA or SYBR® Gold Nucleic Acid staining under UV light in the transilluminator. 
GeneSnap software was used to see the photo on the computer. 
 
2.2.2.2. Agarose gel electrophoresis of RNA 
Prior to the start, any equipment used for the experiment was sterilised with DNA zap (Ambion). 
Any used plasticware or sample tubes were RNase free. Water used was double distilled water (for 
buffers), DEPC-treated or RNase water. Samples were prepared by mixing with purple 6X gel 
loading dye (New England Biolabs) and heated for 3 min at 70 °C, followed by a snap cool on ice 
for 1 min. A 1 % (w/v) agarose gel was prepared with 0.5X TAE. Electrophoresis was performed at 
80 V for 30 min ensuring that the running buffer, 0.5X TAE did not overheat. A DNA ladder was 
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loaded in a parallel with the samples to confirm the correct procedure of electrophoresis, not as a size 
reference. 
 
2.2.2.3. Polyacrylamide gel electrophoresis 
2.2.2.3.1. SDS-PAGE (at Isogenica) 
Electrophoresis was performed using pre-casted gels NuPAGE 4-12 %, 1.0 mm (Novex™ by Life 
Technologies), XCell SureLock™ Mini-Cell Electrophoresis System (Thermo Fisher Scientific) and 
PowerEase® 500 Power Supply (Thermo Fisher Scientific). 
 
Sample preparation: Lysed and purified samples were prepared by mixing with 1X LDS Sample 
Buffer NuPAGE (4X) and 1X Bolt™ Sample Reducing Agent (10X). Unpurified samples (whole 
cell lysate) were prepared by mixing 0.5X sample with 1X NuPAGE LDS Sample Buffer (4X), 1X 
Bolt™ Sample Reducing Agent (10X) and 0.5X ddH2O. Sample mixtures were incubated at 95 °C 
for 5 min and cooled down before loaded to the gel.  
 
Samples were loaded to the wells alongside the marker (2.1.4.2.). The electrophoresis was performed 
in 1X NuPAGE MOPS SDS Running Buffer at 200 V for 50 min. The gel was removed from the 
plates and incubated in InstantBlue™ (Expedeon) at the rocking platform from 15 min to 1 hour. The 
image of the gel was captured using a digital camera or UV transilluminator. 
 
2.2.2.3.2. SDS-PAGE (at Aston) 
Electrophoresis was performed using handcast gels and Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell (BioRad) and PowerPac™ HC High-Current Power Supply (BioRad). If gels 
could not be handcasted, 4–15% Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad) were used. 
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Gel preparation: Firstly, 12 % resolving gel was prepared according to the recipe in Table 2.3. The 
components were added sequentially, well mixed and purred between 0.7 mm glass plates to set. The 
gel was covered with 70% ethanol to obtain a uniform set. After polymerisation, the ethanol was 
washed off with dH2O three times. Secondly, a 4 % stacking gel was prepared according to the recipe 
in Table 2.3. The components were mixed and added onto set resolving gel. The comb was applied 
and the gel was left to set.  
 
Table 2.3. Components in resolving and stacking SDS-PAGE gels. 
1 ProtoGel 30% (w/v), 37.5:1 Acrylamide to Bisacrylamide Solution (National Diagnostics) 
2 Tetramethylethylenediamine (National Diagnostics) 
 
 
Sample preparation: Lysed and purified samples were prepared by mixing with 1X SDS-PAGE 
Sample Buffer (2.1.6.17.9.). Unpurified samples (whole cell lysate) were combined with equal 
volumes of 4X SDS-PAGE Sample Buffer (2.1.6.17.9.). Samples mixed with buffer were incubated 
at 95 °C for 5 min and cooled down before loaded to the gel.  
 
Samples were loaded to the wells alongside the appropriate standard (2.1.4.2.). The electrophoresis 
was performed in 1X Tris-Glycine-SDS PAGE Buffer (2.1.6.17.10.) at a constant voltage of 150 V 
until the dye migrated until the bottom of the gel. It was then removed from the plates and incubated 
in InstantBlue™ (2.1.7.9.) at the rocking platform for 15 min to 1 hour. The image of the gel was 
captured using a digital camera or UV transilluminator.  
Component Resolving gel Stacking gel 
Polyacrylamide1 12 % 4 % 
Tris-HCl *(pH 6.8 and 8.8) 0.4 M *(pH 8.8) 0.3 M *(pH 6.8) 
SDS 0.1 % 0.1 % 
Ammonium persulfate 0.07 % 0.08 % 
TEMED2 0.08 % 0.1 % 
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2.2.2.3.3. Acid-urea PAGE (Aston) 
Electrophoresis was performed using handcast gels and the same system as in 2.2.2.3.2.  
Gel preparation: components and their final concentrations for this type of gel can be found in Table 
2.4. Urea was weighed out and mixed with acrylamide solution and sodium acetate (pH 5.0). The 
mixture was left on the magnetic stirrer until urea was fully dissolved. The solution was prepared 
with UltraPure™ DEPC-Treated Water (Thermo Fisher Scientific) until 20 mL. Freshly prepared 
ammonium persulfate and TEMED were added to the concentration given in Table 2.4. Well mixed 
solution was purred between 0.7 mm glass plates to set. Acid-urea PAGE gels were uniform and no 
stacking gels were prepared. 
 










1 Accugel 40% (w/v), 19:1 Acrylamide to Bis-acrylamide solution (National Diagnostics) 
 
Sample preparation: samples were prepared by mixing in 1:1 ratio with 1X acid-urea PAGE Sample 
Buffer (2.1.6.17.12.). When analysed tRNA on its own, samples were incubated at 95 °C for 5 min 
and cooled down before loaded to the gel.  
 
The gel was pre-run at 4 °C for 30 min. Prior to sample loading, the wells were extensively washed 
using 1000 µL pipette tip to wash off residual urea in the well. Samples were loaded to the wells 
alongside the appropriate standard (2.1.4.2.). The electrophoresis was performed in 1X acid-urea 
Component  Final concentration  
Polyacrylamide1 12-25 % 
Urea 7 M 
Sodium acetate (pH 5.0) 0.1 M 
Ammonium persulfate 0.12 % 
TEMED 0.06 % 
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PAGE Running Buffer (2.1.6.17.11.) at a constant voltage of 100 V to do not exceed 10 V/cm until 
the dye migrated 3/4th of the gel. It was then removed from the plates and incubated in 1X acid-urea 
PAGE Staining Solution (2.1.6.17.13.) at the rocking platform for 15-30 min. The image of the gel 
was captured using UV transilluminator. 
 
2.2.3. Transformation  
2.2.3.1. Into E. coli  
The competent cells were thawed on ice. DNA to be transformed was added to competent cells (Table 
2.1. DH5α or Tuner™(DE3) cells) and incubated on ice for 10 min. The tube was placed in a water 
bath or heat block at 42 °C for 30 sec and then placed on ice for 2 min. Following that, 250 µL SOC 
medium (2.1.5.4.) was added and the mixture was incubated in a shaker (220-250 rpm) at 37 °C for 
up to 60 min. If white/blue screening was performed, 50-200 µL of transformed cells was first added 
to 50 µL 2 % X-gal (2.1.7.3.) and 10 µL 1M IPTG (2.1.7.11.). Otherwise, the mixture was plated out 
directly on LB agar (amp) plates which were incubated at 37 °C overnight. 
 
2.2.3.2. Into S. cerevisiae  
In order to introduce plasmids into S. cerevisiae, lithium acetate method was chosen for yeast 
transformation (Schiestl and Gietz, 1989). Five ml of liquid YPD was inoculated with a freshly 
streaked single colony of desired S. cerevisiae strain and grown overnight at 30 °C with shaking at 
200 rpm. This starting culture was then used the next day to inoculate 50 mL YPD to OD600 of 0.2. 
The culture was grown at 30 °C until OD 0.7 followed by centrifugation at 3,000 rpm for 3 min at 
room temperature to pellet the cells. The pellets were washed twice with 1 mL distilled water and 
centrifuged at 7,000 rpm for 30 sec after each wash. Finally, the pellet was resuspended in 300 µL 
of 100 mM LiAc to achieve competent cells. Once the cells were ready, the following components 
were mixed for each sample in the given order: 
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- 50% (w/v) PEG  240 µL 
- competent cells 50 µL 
- plasmid 800 – 1000 µg 
- Salmon Sperm ssDNA 10 µL 
 
The tube was briefly vortexed and at the end 32 µL 1 M LiAc was added. The content of the tube 
was again briefly vortexed and incubated for 20 min (one-plasmid transformation) or 30 min (two-
plasmid transformation) at 30 °C and followed by heat shock for 15 min (one-plasmid 
transformation) or 20 min (two-plasmid transformation) at 42 °C. After temperature incubations, the 
samples were centrifuged at 7,000 rpm for 30 sec, then the pellets were washed twice with 1 mL 
distilled water to ensure complete pellet resuspension. Finally, the cells were resuspended in 1 mL 
distilled water and 200 µL was plated on selective media plates and grown for 2 to 3 days at 30 °C. 
 
2.2.4. Sequencing 
2.2.4.1. Sanger sequencing  
The service of Eurofins Genomics was used for sequencing purified plasmid DNA. To sequence 
samples, the cycle sequencing technology (dideoxy chain termination/cycle sequencing) on ABI 
3730XL sequencing machine was used. This method is a modification of the traditional Sanger 
sequencing method. It uses personally designed primers that are offered to be synthesized by Eurofins 
Genomics. The sample that was sent for sequencing was purified plasmid DNA (2.2.1.8.2.) of 
concentration 50-100 ng/µL. 
 
2.2.4.2. Next-Generation Sequencing (NGS) 
NGS libraries for analysis with MiSeq platform were prepared according to the manufactures’ 
instructions and SOP at Isogenica Ltd. Data analysis was also performed at Isogenica Ltd.   
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2.2.5. Aminoacylation 
The aminoacylation reaction was performed using the aminoacylation buffer (2.1.6.18.), 19 µM 
tRNA, 500 nM enzyme and 100 µM amino acid. The reaction was incubated at 37 °C for 30-40 min 
and the tubes were placed on ice immediately after until analysis. 
 
2.2.6. Protein expression 
2.2.6.1.  In E. coli  
Transformed Tuner™(DE3) cells (E. coli) were expressed in LB broth medium (2.1.5.2.) substituted 
with 100 μg/mL ampicillin. Starting culture was inoculated with a single colony from the agar plate 
and incubated overnight at 37 °C. The overnight culture was added in 1:100 or 1:50 ratio to pre-
warmed LB in the culture flasks. The flasks were incubated at 37 °C in the shaking incubator at 220-
250 rpm until the achieved growth was at least 0.4 and did not exceed 0.9 at OD600. The growth was 
monitored by measuring 1 mL of culture at OD600 using a spectrophotometer. Once the appropriate 
growth was achieved, the expression was induced with IPTG if required, and the culture was 
incubated at a specified temperature and time. Post-expression cells were pelleted by centrifugation 
at 5,000 x g and the resulting pellets stored at -20°C. 
 
2.2.6.2.  In S. cerevisiae 
Cells were freshly transformed using method 2.2.3.2. A single colony from the freshly transformed 
plate was inoculated in required SD Drop-Out media (2.1.5.6.) and grown at 30 °C at 200 rpm for 
the required amount of time. 
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2.2.7. Lysate production 
2.2.7.1. Using sonication  
Bacterial cell pellets were resuspended in 0.1 original culture volume of native cell lysis buffer 
(2.1.6.17.6.) and incubated on ice for 10 minutes. Post-incubation the cells were sonicated 10 times 
at 90% power for 20 sec with 2 min cooling period in between cycles using sonicator IKA®-
Labortechnik ULTRA-TURRAX™ T25 (JANKE & KUNKEL). The insoluble fraction was pelleted 
by centrifugation at 16,000 x g for 20 min at 4 °C. The pellet was discarded and the supernatant with 
soluble fraction was transferred to a fresh tube and stored at -20 °C until required.  
 
2.2.7.2. Using BugBuster® 
Bacterial cell pellets were resuspended in BugBuster® MasterMix (Merck Millipore, previously 
Novagen®) at 5 mL per 1 g cell pellet. If required, BugBuster® could be supplemented with protease 
inhibitors such as cOmplete™, Mini Protease Inhibitor Cocktail (Roche). The mixture was incubated 
on the rocking platform for up to 20 min at room temperature. The insoluble fraction was pelleted 
by centrifugation at 16,000 x g for 20 min at 4 °C. The pellet was discarded and the supernatant with 
soluble fraction was transferred to a fresh tube and stored at -20 °C until required.  
 
2.2.7.3. Using glass beads 
Normally, 5 – 10 mL yeast culture was used to collect cells at 3,000 rpm for 5 min. To lyse the cells, 
pellets were resuspended in 600 μL buffer RLT supplemented with reducing agent, 14.3 M 2-
Mercaptoethanol and then mixed with 500 μL acid-washed glass beads (425-600 μm) (Sigma-
Aldrich). The mixture was lysed in TissueLyser LT (QIAGEN), for 5-10 min at 50 Hz. 
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2.2.8. Protein purification  
2.2.8.1. Using Ni-NTA resins and chromatography column (at Aston) 
Cell lysate (2.2.7.1. or 2.2.7.2.) was mixed with up to 1 mL Ni-NTA His•Bind® Resin (Merck 
Millipore previously Novagen®) and incubated on a rocking platform or roller mixer for 1 hour at 
the room temperature. The mixture was loaded onto Poly-prep® Chromatography Column (BioRad) 
and the cap was removed to allow flow-through, followed by two washes of the column with 4 mL 
wash buffer (2.1.6.17.7.). The protein was eluted 4 times using 0.5 mL elution buffer (2.1.6.17.8.). 
All fractions were collected in separate tubes and 20 μL was removed for analysis in SDS-PAGE 
gel. 
 
2.2.8.2. Using Ni2+ column in ÄKTA Start (at Isogenica) 
Bacterial cell lysate (2.2.7.2) was purified according to the manufacturer’s protocol. Protein 
purification was performed on HisTrap™ HP 1 mL column (GE Healthcare Life Sciences) using 
ÄKTA start system (GE Healthcare Life Sciences). Prepared Binding and Washing buffer 
(2.1.6.17.1) were used. The protein was eluted over 30 ml in 30 fractions using Elution buffer 
(2.1.6.17.2.). Flow-through, washes and elutions were collected in separate tubes for analysis in SDS-
PAGE gel. Software UNICORN Start was used to monitor the process of purification. 
 
2.2.9. Fluorescence microscopy 
For analysis of protein expression (eGFP) under fluorescence microscopy, 1 mL of yeast culture was 
removed and cells were collected at 7,000 rpm for 3 min. After removing 900 μL supernatant, the 
pellet was resuspended in the remaining volume. Fifteen μL was pipetted onto a glass plate and 
covered with a coverslip before using nail varnish to seal around the edges. To view the sample under 
the microscope, a drop of oil was added on the top of a lens and the inverted glass plate was placed 
under Leica DMI4000 B inverted microscope (Leica Microsystems) connected to Leica DFC360 FX 
camera with objective HCX PL FLUOTAR 63.0x1.25 OIL. Green fluorescence emission (508 nm) 
87 
images of cells were taken after excitation with 488 nm laser. The images were taken and processed 
in LAS AF software. 
 
2.2.10. Western Blot 
2.2.10.1. Semi-dry method 
To allow the analysis in Western Blot, firstly, protein samples were resolved on SDS-PAGE gel 
(2.2.2.3.2.). To prepare for transfer of proteins from the gel to the membrane, PVDF membrane was 
pre-wetted in 100% methanol and then washed for 10 min in 1X transfer buffer (2.1.6.18.) with filter 
paper. The sandwich was assembled on a semi-dry blotter (Thermo Scientific) according to the 
manufacturer’s protocol and transferred at 25 V for 35 min.  
 
2.2.10.2. Protein detection 
The membrane was blocked using 5% (w/v) skimmed milk solution in PBS-T (PBS with 0.1% 
Tween-20) at room temperature for 30 min. After, the membrane was incubated in 5% (w/v) 
skimmed milk solution in PBS-T with the primary HRP-conjugated antibody (at given concentration) 
at 4 °C overnight. The next day, the membrane was washed three times for 5 minutes in PBS-T. The 
membrane was then equilibrated for 2 min with earlier prepared EZ-ECL Enhanced 
Chemiluminescence Detection Kit for HRP. C-DiGit® Blot Scanner (LI-COR Biosciences) was used 
to capture the image of the blot using Image Studio Digits program (LI-COR). 
 
2.2.11. Flow Cytometry 
Flow cytometry was performed using FC500 (Beckman Coulter). For each sample, 100,000 events 
were acquired under a medium flow rate, and samples were collected in triplicates. The fluorescence 
emission for eGFP (508 nm) was measured after excitation at 488 nm. While for DRAQ5 Fluorescent 
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Probe Solution (Thermo Scientific™) subsequent excitation was at 647 nm followed by emission at 
681 nm. The results were analysed using FlowJo program.  
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Chapter 3: Cloning of native and mutant alaS genes 
3.1. Cloning of the wild type E. coli AlaRS gene 
The E. coli alanyl-tRNA synthetase gene is called alaS and is 2631 base pairs (bp) long. This gene 
was amplified from E. coli by PCR (2.2.1.1.) and its size was confirmed in agarose gel 
electrophoresis (2.2.2.1.). The resulting product (Figure 3.1.) was phosphorylated (2.2.1.3.) and 
ligated (2.2.1.5.) into pET45b(+) that had been digested (2.2.1.1.) with PmlI, which generates blunt 
ends. The resulting ligated plasmids were transformed into E. coli and plated onto LB (amp) plates 
(2.2.3.1.). Resulting colonies were screened by colony PCR (2.2.1.1.2.) using a T7 promoter forward 
primer and an alaS-specific reverse primer, to generate a product of the expected size of 2742 bp. 
Two positive colonies were identified (Figure 3.2.). The correct sequence of native alaS in clone 




Figure 3.1. Amplification of alaS gene from E. coli Tuner™(DE3) cells. 
1 % agarose gel stained with SYBR Safe dye shows results of PCR with an expected size of 2631 bp, amplified 








Figure 3.2. Colony screening of clones pET45b(+):alaS. 
1 % agarose gels stained with SYBR Safe dye shows results of colony screening with a. colony PCR and b. 
enzyme digestion. a. Colony PCR for clone 1 and 2 with an expected size of 2742 bp amplified using T7 
promoter forward primer and an alaS-specific reverse primer. b. Linearised clone 2 confirms the expected size 
of 7891 bp as a total plasmid length. L: GeneRuler 1 kb Plus DNA ladder. NTC: a non-template control. 
 
 
3.2. Cloning of truncated gene enzyme N461_AlaRS  
3.2.1. Gene amplification 
The N-terminal domain of AlaRS is also called the aminoacylation domain and hence its name; this 
domain alone is sufficient to catalyse an aminoacylation reaction. As such, this domain can itself be 
used as a truncated enzyme, with the advantage of removal of editing domain function that is native 
to intact AlaRS. To clone the aminoacylation domain, the existing clone of native alaS described in 





Figure 3.3. The workflow of cloning truncated enzyme N461_AlaRS. 
a. Template clonal plasmid pET45b(+):alaS was amplified whilst concomitantly introducing two STOP codons 
via one of the PCR. b. The PCR product was phosphorylated by T4 Polynucleotide Kinase to aid ligation. c. 
The phosphorylated PCR product was ligated. d. Final product of the ligation, the truncated N461 AlaRS 
enzyme as a new clone pET45b(+):N461.  
 
 
Appropriate primers were designed to amplify the vector and N-terminal domain only (first 461 
amino acids) from clone pET45b(+):alaS. In addition, two termination codons were introduced in 
the primer annealing to the 3’-end of N461 domain. The PCR reaction using Phusion Polymerase 
amplified a product of 6649 bp with annealing temperature at 55 °C (2.2.1.1.). The product was 
analysed in 1 % TBE agarose gel by electrophoresis (Figure 3.4.). PCR reactions were purified using 




Figure 3.4. Amplification of pET45b(+):alaS for generation of truncated gene N461_AlaRS in pET45b(+) 
vector. 
0.8 % agarose gels stained with SYBR Safe dye shows results of PCR with an expected size of 6649 bp. PCR 
product was amplified using Phusion Polymerase. HpL I: HyperLadder™ 1kb (Bioline). NTC: non-template 
control. 
 
3.2.2. Self-ligation  
Prior to ligation, phosphate groups were attached to the 5’-end of amplicons by the T4 Polynucleotide 
Kinase, following manufacturer’s instructions, to permit subsequent intramolecular ligation of the 
PCR product. Self-ligation reactions were performed with varying quantities of the phosphorylated 
PCR product (65, 78, 98 ng) with 5 units of T4 DNA Ligase (5 U/μL) in a total volume of 30 μL for 
1 h incubation at 22 °C, followed by heat inactivation at 72 °C for 5 min (2.2.1.5.).  
 
The self-ligation reaction was assessed by PCR, using two primers: T7 terminal primer which 
sequence is found within pET45b(+) and a sequencing primer, designed and used previously for 
sequencing of clone pET45b(+):alaS. If self-ligation was successful and 5’- and 3’-ends of linear 
PCR amplicon were joined, the polymerase would amplify the product passing through the point of 
ligation and generate a 1090 bp PCR product. Figure 3.5. suggests that self-ligation had been 




Figure 3.5. Amplification from self-ligation of pET45b(+):N461. 
1 % agarose gels stained with SYBR Safe dye shows results of PCR of ligation sample with an expected size of 




Ligations products of pET45b(+):N461 were transformed into OneShot Chemically Competent Cells 
(E. coli DH5α strain) (2.2.3.1.). The results are shown Table 3.1. Although the transformation 
efficiency for the manufacturer’s test plasmid was lower than expected (>1x109), the number of 
colonies achieved from the self-ligations was substantial. 
 
 
Table 3.1. Transformation of self-ligated samples for pET45b(+):N461. 
ligation 
quantity of self-






300 6.38 x 105 
800 3.42 x 105 
L2 78 
160 2.86 x 105 
592 2.11 x 105 
L3 95 
328 4.62 x 105 
960 2.72 x 105 
pUC19 (control) 0.01 51 1.41 x 106 
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3.2.4. Colony PCR  
Colony PCR was set up using the same primers as when verifying the success of ligation, T7 terminal 
primer, sequencing primer, and Taq Polymerase in 30 μL reactions (2.2.1.1.2.). QIAxcel Advanced 






Figure 3.6. Colony screening for pET45b(+):N461 by colony PCR. 
The results of colony PCR were analysed using QIAxcel Advanced – a capillary electrophoresis system. 




Four clones were selected and used to set up a 3 mL starting culture (2X YT (2.1.5.3.) with 100 
μg/mL Amp). These cultures were used for plasmid DNA purifications (2.2.1.8.2.) that were then 
sent for Sanger sequencing. Results showed that three clones had 100 % correct sequence while one 
lacked the two STOP codons that were supposed to have been introduced by the C-terminal primer.  
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3.3. Cloning of a full-length alaS gene with a mutation to knock out the 
native editing function  
It has previously been demonstrated that a Cys to Ala mutation at position 666 in the ORF of the 
full-length of AlaRS is sufficient to prevent editing (Guo et al., 2009). This approach was employed 
in the current study to knock out the editing function in AlaRS from the existing clone 
pET45b(+):alaS. Primers were designed to amplify the full-length of pET45b(+):alaS with one 
primer introducing Ala instead of Cys at residue 666 (Figure 3.7.). 
 
Figure 3.7. The workflow of introducing a point mutation into pET45b(+):alaS. 
a. Template clone pET45b(+):alaS was amplified with primers while forward primer carried a C666A 
mutation to pET45b(+):alaS. b. The resulting PCR product with C666A point mutation was phosphorylated by 
T4 Polynucleotide Kinase to aid ligation. c. Phosphorylated PCR product was self-ligated. d. The final product 
of the ligation, a full-length enzyme with knock out of the native editing function C666A_AlaRS as a new clone 
pET45b(+):C666A_875.  
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3.3.1. Gene amplification 
A gradient PCR with annealing temperatures from 58 °C to 70 °C was set up for 9 reactions of 50 
μL each, using Phusion Polymerase (2.2.1.7.2., 2.2.1.1.1.). The results showed that at an annealing 
temperature of 65.2 °C and below, there was a secondary product of about 2500 bp, likely due to 
nonspecific annealing of the primer(s) (Figure 3.8.). The expected PCR product is 7891 bp and it 
corresponds to the top band in Figure 3.8. A single product is observed for the temperature 66.9 °C 
and above. Therefore, to amplify and mutate pET45b(+):alaS as required, a PCR with amplification 
temperature at 67 °C was set up in the total volume of 100 μL. Amplicons were purified (2.2.1.8.1.) 
and 50 ng and 100 ng of DNA were visualised on the gel (Figure 3.9.). The results from 





Figure 3.8. Gradient PCR for amplification of pET45b(+):alaS for generation of pET45b(+):C666A_875. 
0.5 % agarose gels stained with SYBR Safe dye shows results of gradient PCR with an expected size of 7891 
bp. Gradient PCR with annealing temperatures 58-70 °C was set for the amplification with Phusion 
Polymerase of pET45b(+):alaS to introduce the C666A mutation. The unspecific amplification is found for 







Figure 3.9. Amplification of pET45b(+):alaS for generation of pET45b(+):C666A_875. 
0.5 % agarose gels stained with SYBR Safe dye shows results of PCR with an expected size of 7891 bp. PCR 
products of 50 ng and 100 ng were analysed in the gel. The product of this PCR, pET45b(+):C666A_875, is a 
full-length AlaRS gene with a point mutation to knock out the native editing function of the enzyme that is 
inserted in pET45b(+) vector. HpL I: HyperLadder™ 1kb (Bioline). NTC: non-template control. 
 
 
Linearised PCR product pET45b(+):C666A_875 was then self-ligated (2.2.1.5.). The ligation 
reaction was preceded with the attachment of phosphate groups to the 5’-end of amplicons (2.2.1.3.). 
Ligation reactions were set up using a different amount of purified DNA pET45b(+):C666A_875 
and they were catalysed with 5 units of T4 DNA Ligase, in the total volume of 40 μL. Incubation for 
2 h 15 min at 22 °C was followed by enzyme heat deactivation for 5 min at 72 °C. Ligations were 
transformed into E. coli DH5α cells. Six colonies were selected for growing in liquid culture, and 
plasmids then extracted, as previously described. Purified plasmids were sent for DNA Sanger 
sequencing. Five out of 6 clones had 100% correct sequence and they were ready for subsequent use. 
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Chapter 4: Expression 
4.1. Optimisation of expression 
Initially, both the full sequence wtAlaRS and the truncated enzyme (N461_AlaRS) were expressed 
in E. coli Tuner™(DE3) cells under various conditions, in order to find out the optimal growth 
temperatures, time of induction and IPTG concentration for maximal expression of proteins 
(2.2.6.1.). Protein expression was examined in electrophoresis using SDS-PAGE gels (2.2.2.3.). Cell 
lysates were prepared with sonication or BugBuster® (2.2.7.). 
 
4.1.1. IPTG concentration 
Initially, different IPTG concentrations were examined to determine the optimal concentration for 
induction of expression (Figure 4.1.). Predicted sizes for enzyme wtAlaRS and N461_AlaRS 
(including a His tag of 1 kDa) are 97 and 53 kDa, respectively. These sizes were approximately 
confirmed in Figure 4.1a. and b. (predominant bands are indicated by red arrows), albeit that the 
PageRuler Plus 100 kDa marker migrates slightly faster in SDS-PAGE gel than the full-length AlaRS 
enzyme. Figure 4.1a. demonstrates that whilst there is slightly higher production of wtAlaRS in 
response to the highest (1.0 mM) concentration of IPTG, the expression of the truncated enzyme is 
similar across all IPTG concentrations tested.  
 
4.1.2. Temperature  
Post-induction growth temperature can affect both the quality (soluble or insoluble) and quantity of 
recombinant protein yield. Therefore, the effect of different temperatures was examined in the 
overnight expression of both full sequence and truncated enzyme. Both supernatant and cell debris, 
obtained after cell lysis, were analysed. Figure 4.2. shows that for wt875_AlaRS expression was 
observed at 25 °C as well as 30 °C but the protein is found in the insoluble fraction of cell debris 
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after cell lysis. Conversely, Figure 4.2. demonstrates a very good expression of soluble N461_AlaRS 





Figure 4.1. Expression of a. wild type full-length AlaRS (wt875_AlaRS) and b. truncated enzyme 
(N461_AlaRS) using different IPTG concentrations. 
Polyacrylamide gel electrophoresis using 4-12% gradient SDS-PAGE shows a. wt875_AlaRS and b. 
N461_AlaRS expression induced with 1.0, 0.8 and 0.6 mM IPTG for 3 h at 30 °C with shaking (220 rpm). Both 
gels show whole cell lysate samples with overexpression of full sequence (MW=97 kDa) and truncated 








Figure 4.2. Expression of wild type full-length AlaRS (wt875_AlaRS) and truncated enzyme (N461_AlaRS) 
at different temperatures in cell debris and supernatant. 
Polyacrylamide gel electrophoresis using 4-12% gradient SDS-PAGE shows samples from the overnight 
uninduced expression of full-length and truncated enzyme at different temperatures, in cell debris (labelled D) 
and supernatant (labelled S) after cell lysis. Red arrows indicate expressed wt875_AlaRS (to the left) and 
N461_AlaRS (to the right). The gel was stained with InstantBlue. 
 
 
4.1.3. Reiteration of IPTG concentration  
Having selected optimal expression temperatures of 25 and 30 °C, further IPTG induction 
concentrations were examined to compare production levels of both the full sequence and truncated 
enzymes (Figure 4.3.).  
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Figure 4.3. Expression of a. wild type full-length AlaRS (wt875_AlaRS) and b. truncated enzyme 
(N461_AlaRS) samples using different temperatures and IPTG concentrations. 
Polyacrylamide gel electrophoresis using a 4-12% gradient SDS-PAGE of samples from overnight expression 
at 25 and 30 °C in the absence or presence of 0.25 and 0.5 mM IPTG, for a. the full-length and b. truncated 
enzymes. D: cell debris. S: supernatant. The predominant bands show the expression of the desired enzyme. 





The determined conditions were then used to express C666A_AlaRS, which showed similar 
expression characteristics to those observed for wtAlaRS as shown in Figure 4.4. where the protein 







Figure 4.4. Expression of wtAlaRS, C666A_AlaRS and N461_AlaRS in E. coli. 
Polyacrylamide gel electrophoresis using a 4-12% gradient SDS-PAGE shows sample of expression wtAlaRS 
at Aston for (A) and Isogenica for (I), as well as N461_AlaRS at Isogenica, and C666A_AlaRS at Aston. 
Samples were analysed after lysis but before purification. Conditions for expression of the proteins were as 
followed: wtAlaRS (Aston): 1 mM IPTG, 3h at 37 °C; wtAlaRS (Isogenica): 0.6 mM IPTG, 4h at 30 °C; 
C666A_AlaRS (Aston): 1mM IPTG, 4h at 37 °C; N461_AlaRS (Isogenica): 0.6 mM,4h at 30 °C. Each 
expressed protein compares soluble (S) fractions (supernatant), versus insoluble (D) fractions (cell debris). 
Predominant bands show the expression of the desired enzyme with the expected size of: 97 kDa for wtAlaRS 




4.2. AlaRS purification  
4.2.1. AKTA purification 
Since the yield of the truncated protein N461_AlaRS was much greater, this protein was purified 
using the AKTA system (2.2.8.2.), which is a liquid chromatography system using columns in protein 
purification and allows precise analysis of eluted fractions. Analysis of the starting material (whole 
cell lysate - WCL), flow-through, wash and eluted fractions by PAGE confirmed a very good level 
of expression of the truncated protein (1 mM IPTG at 30 °C for 3 h) (Figure 4.5.). The maximal yield 
of soluble, recombinant protein was observed in elution fractions 9-11, whilst the final fraction (lane 
14) shows that the vast majority of the protein had been eluted by this point. The purified samples 
show a major band around 55 kDa marker band corresponding to N461_AlaRS and a low level of 
co-purified protein below the size of N461_AlaRS. The results show that the protein could be isolated 







Figure 4.5. Expression and purification of truncated enzyme N461_AlaRS using AKTA start. 
Polyacrylamide gel electrophoresis using a 4-12% gradient SDS-PAGE to examine the samples of expression 
of the truncated enzyme when induced with 1 mM IPTG and incubated at 30 °C for 3 h, followed by AKTA 
purification of the soluble enzyme. The size of the protein is expected to be 53 kDa (with His tag). The gel was 




4.2.2. Laboratory-scale, affinity purification and activity of wtAlaRS, 
C666A_AlaRS and N461_AlaRS. 
Using the determined conditions, each of the proteins was expressed in 50 ml cultures and purified 
using bench-scale affinity chromatography (2.2.8.1.). As illustrated in Figure 4.6., the truncated 





 a.           b.   
 c.  
 
 
Figure 4.6. Purification of a. wtAlaRS, b. C666A_AlaRS and c. N461_AlaRS expressed in E. coli. 
Polyacrylamide gel electrophoresis using a 4-12% gradient SDS-PAGE shows samples of expression and 
purification also shown in Figure 4.4. with details about induction of expression. The purification was an 
affinity column chromatography. The expected size of the protein is 97 kDa (wtAlaRS and C666A_AlaRS and 




4.3. Aminoacylation activity 
Interestingly, with a few exceptions, most publications in the field do not demonstrate 
aminoacylation of tRNA by purified enzymes per se, but rather tend to show the incorporation of 
UAAa (following aminoacylation) into proteins and/or peptides. To determine whether it was 
possible to detect aminoacylation reliably, both mass spectrometry of commercial, pre-acylated 
tRNA and acid-urea PAGE gel (2.2.2.3.3.) analysis of native tRNA, commercial, pre-acylated tRNA 
and tRNA aminoacylated with one or more of the purified enzymes was attempted (Figure 4.7.). 
Figure 4.8. shows the result of electrophoresis pre-charged and uncharged tRNAPhe in acid-urea 
PAGE gel with a difference in migration distance between the samples. Uncharged tRNAs are 
expected to migrate faster because their mass is lower than those of charged tRNAs. The results of 
aminoacylation (2.2.5.) of tRNAAla, the tRNAAla microhelix (Musier-Forsyth and Schimmel, 1999) 
and the tRNAAla tetraloop (Musier-Forsyth and Schimmel, 1999) are shown in Figure 4.9. 
 
Unfortunately, none of the methodologies were able to clearly distinguish the difference between 
acylated and nonacylated tRNAs (Figure 4.8. and Figure 4.9.) and the activities of the purified 
enzymes could not, therefore, be determined with certainty. As an example, Figure 4.9. shows 
aminoacylation of tRNAAla microhelix with L-Ala by truncated enzyme. The difference between lane 
5 and 9 that only have unacylated microhelixAla and lane 6 that should have acylated microhelixAla as 
it is a sample of aminoacylation shows somehow slower migration for lane 6, at least partially. The 
band in lane 6 appears thicker what would indicate that there are two populations of microhelixAla, 
acylated with L-Ala and unacylated and/or deacylated.  
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                  a.    
 




Figure 4.7. Expression and purification of a. N461_AlaRS and b. C666A_AlaRS for aminoacylation studies. 
Polyacrylamide gel electrophoresis using a 4-12% gradient SDS-PAGE to show expressed a. N461_AlaRS and 
b. C666A_AlaRS. The expression was when induced with 1 mM IPTG and incubated at 30 °C for 4 h, followed 





Figure 4.8. Comparison of commercial unacylated and acylated control samples of tRNAPhe. 
12 % acid-urea PAGE gel stained with 1X SYBR® Gold Nucleic Acid Gel Stain shows electrophoresis of 
unacylated and acylated controls tRNAPhe. Samples were commercially acquired. Electrophoresis was at 
constant 7 W for 2 h. Lanes: 1: DNA ladder; 2: unacylated tRNAPhe 0.1 unit (A260); 3: uncharged tRNAPhe 
0.005 unit (A260); 4: uncharged tRNAPhe 0.0025 unit (A260); 5: acylated tRNAPhe 22.5 pmol; 6: DNA ladder. 
Note: DNA ladder used was not to reference the size of tRNAPhe but to confirm the electrophoresis experiment 





Figure 4.9. Aminoacylation reactions with controls and microhelixAla. 
20 % acid-urea PAGE gel stained with 1X SYBR® Gold Nucleic Acid Gel Stain shows electrophoresis of 
aminoacylation reaction which involved truncated enzyme, microhelixAla and L-Ala. The electrophoresis was 
at 100 V, 4 °C until bromophenol blue reached the bottom of the gel. Lanes: 1: Low Molecular Weight Marker, 
10-100 nt (Affymetrix); 2: unprocessed 100 pmol microhelixAla; 3: boiled 100 pmol microhelixAla; 5: folded 
and ethanol precipitated microhelixAla; 6: ethanol precipitated aminoacylation reaction 1 (5 µL); 9: ethanol 
precipitated aminoacylation reaction 2 without L-Ala (5 µL), 10: Low Molecular Weight Marker, 10-100 nt 
(Affymetrix). “x” indicates wells where samples were not loaded. Pink braces indicate the presence of bands. 
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4.4. Discussion 
Both truncated and full-length AlaRS enzymes with removed editing function were effectively 
expressed in E. coli Tuner™(DE3) cells. The optimisation included changing IPTG concentration 
and temperature. Different IPTG concentration of 0.6 mM, 0.8 mM and 1.0 mM used for induction 
of expression wt875_AlaRS and N461_AlaRS did not change the expression levels. However, during 
temperature optimisation, it was demonstrated that protein was expressed at 25 °C and 30 °C but did 
not express at 20 °C for both, wt875_AlaRS and N461_AlaRS. During expression of wt875_AlaRS, 
it was shown that a large proportion of protein goes into the insoluble fraction (debris). This was not 
observed with the truncated protein suggesting that perhaps the full-length protein is harder for E. 
coli to fold when overexpressed.  
 
Despite multiple approaches, methods used to detect acylated tRNAs were unable to show the 
difference between acylated and nonacylated tRNAs convincingly (Figure 4.8. and Figure 4.9.). In 
order to achieve better resolution on acid-urea PAGE gels, shorter species of tRNAAla, microhelixAla 
and even tetrahelixAla (data not shown) were used in aminoacylation reactions. Unfortunately, even 
these failed to show a clear difference. Inability to distinguish between acylated and nonacylated 
tRNAs also applied to commercial, pre-acylated tRNA, thus, suggesting that the problem was not 
with aminoacylation reaction but with detection methods. Having said that, the aminoacylation 
reaction could not be evaluated and therefore, its outcome remains unknown. Nevertheless, 
aminoacylation reactions are generally not shown in the studies of incorporating UAAs in the protein 
but instead, the protein is directly used in vivo or in vitro experiment and the enzyme’s function is 
assessed in different methods, for example, by generation of a fluorescent product. 
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Chapter 5: Library generation 
5.1. Library design: Modelling of the E. coli AlaRS amino acid binding 
site 
Library generation was a key component of this study which determined the direction of engineering 
novel enzymes aaRSs. The fundamental component was the choice of enzymes and their site of 
mutagenesis. The first library was based on the truncated enzyme – aminoacylation domain that 
fulfils the requirements of tRNA acylation and works on its own without other domains (Section 
3.2.). The second library was constructed on the full-length gene with a knock out of the native 
editing function via C666A point-mutation (Section 3.3.). In both libraries, the target for mutations 
was the amino acid binding pocket found in the N-terminal domain for which the crystal structure 
had been previously resolved for E. coli and is available in Protein Bank Database: reference 3HXU. 
This structure also exists with bound alanyl-AMP analogue (Ala-SA) which allowed for a close 
examination of residues found in close proximity to aminoacyl moiety. Upon assessment of the 
crystal structure, those amino acids whose functional groups interact directly with L-Ala or lie in 
close proximity were carefully chosen for mutations. Codon saturation was introduced by ProxiMAX 
randomisation (2.2.1.7.1; controlled saturation mutagenesis, Ashraf et al., 2013). In total, six 
positions from the amino acid binding site were targeted in an effort to promote binding of selected 
UAA and expand the scope of the site (Figure 5.1.). These positions were: alanine 41 (A41), 
methionine 43 (M43), tryptophan 170 (W170), asparagine 212 (N212), valine 214 (V214), and 
methionine 216 (M216). In order to produce the most variable library possible (facilitated by 
ProxiMAX), each position was targeted with 18 amino acids (excluding methionine and cysteine 
which are prone to oxidation and often excluded from libraries by ProxiMAX). Consequently, each 
library size was 186, equal to 34,012,224 different genes and it remains within maximal capacity in 
terms of variant numbers of many screening methods. 
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This specific randomisation of six positions is unique in the production of aaRS library for 
engineering purposes. If the aims of this engineering studies were to be met, the diverted selectivity 
of E. coli AlaRS towards UAA would be paired with tRNAAla that has mutated anticodon to 
accommodate new amino acid in ProxiMAX randomisation platform.  
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a.        b.    
 
                               c.    
 
    d.   
 
Figure 5.1. Randomisation position in the amino acid binding pocket of AlaRS.  
Program RCSB - Ligand Explorer Viewer was used to view PBD entry 3HXU. Six positions in the amino acid 
binding site were chosen for randomisation and they are: a. alanine 41 (A41) and methionine 43 (M43); b. 
tryptophan 170 (W170); c. asparagine 212 (N212), valine 214 (V214), and methionine 216 (M216). Each of 
these six positions was mutated with 18 amino acids (excluding methionine and cysteine) what generated a 
library of 34,012,224 genetic variants. Two libraries were generated based on this randomisation: first 
including truncated enzyme with aminoacylation domain only, while second had a full-length enzyme but with 
a knock out of the native editing function.  
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5.2. Library construction 
Two variants of the AlaRS enzyme were used for library generation: the full-length AlaRS containing 
the C666A point mutation to knock out the editing function (C666A_AlaRS) (Guo et al., 2009) and 
the N-terminal aminoacylation domain only of AlaRS, comprising amino acids 1-461 
(N461_AlaRS). The genes were divided into segments of ‘framework’ (FW – conserved regions of 
the gene) and ‘library’ (Lib – sections of the genes that would incorporate codon randomisation, 
Figure 5.2.). Codon saturation was introduced by ProxiMAX randomisation (controlled saturation 
mutagenesis; Ashraf et al., 2013) at residues 41 and 43 (Lib1) and 212, 214 and 216 (Lib2), whilst 
residue 170 was instead saturated simply by employing multiple PCR primers (2.2.1.7.2.). To 
distinguish its method of construction, this section was named Framework 3 (FW3). All fragments 
but the last framework, FW4, were the same for both libraries. All residues were randomised with an 
equal mix of 18 amino acids, excluding methionine and cysteine, since these residues are prone to 




Figure 5.2. The strategy of mutagenesis for libraries Lib_C666A_AlaRS and Lib_N461_AlaRS. 
The figure shows a breakdown of libraries as a mixture of framework and library fragments with the location 
of randomised positions 41, 43, 170, 212, 214 and 216. FW: framework, a fragment without randomisation. 
Lib: library, a fragment with randomisation by ProxiMAX. Note: FW3* is a framework fragment with a 
randomisation position that was introduced by PCR primers.  
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5.3. Library assembly design 
The libraries were then assembled by step-wise ligation of BsaI-treated fragments with compatible 
overhangs as demonstrated in Figure 5.3. a. and b.  
              
 
 
Figure 5.3. The workflow of assembly for a. Lib_N461_AlaRS and b. Lib_C666A_AlaRS. 
Ligation of library fragments was performed in the particular order and stages as illustrated: Ligation 1, 




BsaI is a type IIS restriction endonuclease that recognises asymmetric DNA sequence outside of their 
recognition sequence and the cleavage produces a 5‘-sticky-ended overhang of a variable sequence 
as shown in Figure 5.4. When producing FW and Lib fragments the primers were used to attach BsaI 
recognition site. Using BsaI enzyme allowed for flexibility in choosing the cleavage site and the 
fragment size. The sticky-ends of all fragments had to be carefully designed in order to discourage 




Figure 5.4. BsaI restriction enzyme cleavage site demonstrating 5’-overhang. 
 
5.4. Generation of library fragments  
The conserved library fragments FW1, 2, and FW4_N461 were amplified from clone 
pET45b(+):N461. PCRs were performed with Phusion Polymerase in 100 μL reactions (2.2.1.1.) and 
an annealing temperature of 60 °C. PCR products were purified (2.2.1.8.1.) and digested with BsaI 
enzyme (2.2.1.6.). The resulting digested fragments were gel-purified (2.2.1.8.3.) and examined by 
agarose gel electrophoresis (2.2.2.1.; Figure 5.5.). The difference in size between digested and 
undigested samples is observed for FW1 and FW2. However, the difference between undigested and 
digested FW4_N461 was only 10 bp and with a fragment size of about 700 bp it was impossible to 
discern. 
 
As already described, the saturation of codon 170 in FW3 (Figure 5.2.) was introduced by PCR using 
multiple primers. In fact, it was a mixture of 18 forward primers in equimolar quantities, each 
encoding one of the desired 18 amino acids (all amino acids excluding methionine and cysteine). A 
PCR was set up using pooled forward primers and a reverse primer, Phusion Polymerase and clone 
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pET45b(+):alaS as a template in 100 μL reactions. The annealing temperature was 60 °C. The 
product of this reaction is shown in Figure 5.6. Once FW3 was amplified it was purified using column 
(2.2.1.8.1.), digested with BsaI and gel purified. Fragment FW4_C666A_875 was prepared in the 
same manner, using pET45b(+):C666A_875 as a template and 60 °C for the annealing temperature 
in the PCR reaction. 
 
Generation of library fragments was performed as described previously via ProxiMAX 
randomisation (2.2.1.7.1.; Ashraf et al., 2013). When the fragments were randomised, the samples 
were purified, followed by digestion with BsaI and gel extraction of digests. Figure 5.7. confirms 






Figure 5.5. Enzyme digestion of fragments FW1, FW2 and FW4_N461. 
2 % agarose gel stained with SYBR Safe dye show results of enzyme digestion for fragments FW1, FW2 and 
FW4_N461. The digestion was performed with BsaI and the gel shows fragments before and after digestion 






Figure 5.6. Amplification of fragment FW3. 
2 % agarose gel stained with SYBR Safe dye shows results of PCR product for fragment FW3 with an expected 






Figure 5.7. Enzyme digestion of fragments Lib1 and Lib2. 
2 % agarose gel stained with SYBR Safe dye show results of enzyme digestion for Lib1 and Lib2. The digestion 
was performed with BsaI and the gel shows fragments before and after digestion with an indication of expected 
sizes below the gel. HpL V: HyperLadder II (Bioline). 
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5.5. The library assembly  
As illustrated in Figure 5.3., the library assembly was performed in stages. Figure 5.8. shows the 
final product of the assembly for Lib_N461_AlaRS and Lib_C666C_AlaRS. The major product in 
the “ligation” lanes correspond to the final assemblies, which are expected to be 1389 bp for 
Lib_N461_AlaRS and 2631 bp for Lib_C666C_AlaRS. The bands below correspond to the partial 
ligation of the fragments used in that reaction or unused components. The “pre-lig” lanes show the 
input material (no ligase was added to these samples), while the last lanes, “ctrl”, show the size 
control samples of FW4_N461 and FW4_875. All expected sizes are indicated below the figure and 




Figure 5.8. Final assembly of fragments for Lib_N461_AlaRS and Lib_C666A_AlaRS. 
2 % agarose gel stained with SYBR Safe dye show results of the final library assembly for Lib_N461_AlaRS 
and Lib_C666A_AlaRS. The sizes of the fragments used in the assembly are given below the gel image. Above 
the gel, ‘ligation’ indicates the resulted product of fragments’ ligation (full and partial ligation), whilst ‘pre-




To confirm that the major bands visible on the gel in the ligation lanes in Figure 5.8. were indeed the 
expected products, PCRs were performed using the forward primer used for the generation of FW1 
and the reverse primer used for the generation of either FW4_N461 or FW4_C666A_875, with 
Phusion Polymerase in 100 μL total reaction volumes. As shown in Figure 5.9., products of expected 
sizes were generated in both libraries. The PCR reactions were then purified and sent for Sanger 
sequencing which confirmed the presence of randomised sites at the expected locations in the gene, 






Figure 5.9. Amplification of the final assembly ligation product for Lib_N461_AlaRS and 
Lib_C666A_AlaRS. 
1 % agarose gel stained with SYBR Safe dye show results of final PCR of ligations for libraries 
Lib_N461_AlaRS and Lib_C666A_AlaRS with an expected size of 1389 bp and 2631 bp, respectively. NTC: 
non-template control. HpL I: HyperLadder I (Bioline). 
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5.6. Next-generation sequencing 
Residues chosen for randomisation were substituted with 18 amino acids, excluding cysteine and 
methionine. Amino acids were evenly randomised, therefore each amino acid substitute should 
account for 5.56 % of the total sequences (100 % /18 = 5.56 %).  
 
In order to confirm even distribution at randomisation sites, library fragments were analysed by next-
generation sequencing using the Illumina MiSeq Sequencing System (2.2.4.2.). The results presented 
in Figure 5.10. and Figure 5.11. are based on sequencing of the libraries of truncated structure enzyme 
(Lib_N461_AlaRS) and full-length enzyme (Lib_C666A_AlaRS), respectively. Since the fragments 
of the libraries used in the assembly came from the same sample (apart from diverse FW4s), it is 
expected that the sequencing results will demonstrate a nearly identical distribution of amino acids 
among the two libraries. As shown in Figure 5.10. and Figure 5.11, there are insignificant differences 
that might be down to wrong base recall during sequencing. Observed and expected distribution of 
amino acids in randomised positions for fragments Lib1, Lib3 and FW3 are illustrated in Figure 5.10. 
and Figure 5.11. Observed frequencies matched very closely the expected values for most of the 
amino acids at all six randomised positions. It was also found that certain amino acids such as tyrosine 
(Y) or glutamate (E) were under-represented across all substitutions, whereas other amino acids, such 
as leucine (L) or valine (V), demonstrated over-representation. The mechanism of these under- and 
over-representations is unknown but it could be related to T4 DNA Ligase specificity in blunt-end 











Figure 5.10. Observed vs expected distribution of amino acids in randomised positions of the truncated 
enzyme library (Lib_N461_AlaRS). 
Letters in the legend correspond to universal amino acids abbreviations in the genetic code: P: proline; C: 
cysteine; K: lysine; R: arginine; H: histidine; W: tryptophan; Y: tyrosine; F: phenylalanine; G: glycine; A: 
alanine; V: valine; I: isoleucine; L: leucine; M: methionine; S: serine; T: threonine; Q: glutamine; N: 
asparagine; E: glutamic acid; D: aspartic acid; *: stop codon.  
















Figure 5.11. Observed vs expected distribution of amino acids in randomised positions of the full-length 
enzyme library (Lib_C666A_AlaRS). 
Letters in the legend correspond to universal amino acids abbreviations in the genetic code: P: proline; C: 
cysteine; K: lysine; R: arginine; H: histidine; W: tryptophan; Y: tyrosine; F: phenylalanine; G: glycine; A: 
alanine; V: valine; I: isoleucine; L: leucine; M: methionine; S: serine; T: threonine; Q: glutamine; N: 
asparagine; E: glutamic acid; D: aspartic acid; *: stop codon.  







ProxiMAX is marketed as Colibra™ and it is an automated and proprietary version commercialised 
at Isogenica Ltd. Although the name ProxiMAX was used throughout, the libraries of AlaRS were 
actually produced using the Colibra™ platform. Due to the license agreement, the full methodology 
of generating particular fragments of the library could not be disclosed and comprehensive data from 
library production could not be displayed here. 
 
There were two randomisation methods used in the construction of libraries: ProxiMAX and via 
primers in PCR. When comparing the frequency of observed vs expected amino acids using these 
methods, the randomisation introduced with primers shows a closer match to expected values than 
with ProxiMAX. It had proved that careful combining and mixing of primers can be used for single 
randomisation because it shows an excellent result in terms of amino acids distribution (Figure 5.10. 
and Figure 5.11.). However, for the purpose of randomisation of contiguous codons or even three 
near-contiguous such as positions 212, 214 and 216 in this study, using ProxiMAX codon saturation 
was required. ProxiMAX randomisation offers controlled codon saturation of multiple contiguous 
codons with the choice on amino acid ratio in each of mutated position. Moreover, ProxiMAX uses 
one codon per amino acid what gives a substantial advantage in terms of control of the library content. 
It also eliminates bias in the produced library, with each gene variant being unique what eliminates 
over-representation and under-representation of an amino acid in the mutated position. This 
decreases the total size of the library generated what increases the chances for a suitable screening 
method.  
 
The results herein prove that ProxiMAX randomisation was a suitable choice for library production. 
The results of even representation of codons in the randomised positions correlate well with other 
studies using the same method ensuring maximal diversity of the variants (Frigotto et al., 2015; 
Poole, 2015). Regardless of how close the match of observed to expected proportion of codon per 
position was, some amino acids were under-represented or over-represented. This could have been 
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the result of not equimolar mix of ProxiMAX oligonucleotides which was later strengthened and 
reinforced in amplifications. Another explanation is that T4 DNA ligase used during library 
generation has sequence specificity during blunt end ligation of two DNA sequences. The 
consequence of these deviations to even representation could be the introduction of bias into the 




Chapter 6: Initial development of a screening system for 
mutant AlaRS genes  
After library generation, library screening and selection are the next two crucial steps in protein 
engineering. They respectively allow for evaluation of the library and elimination of nonfunctional 
variants (Xiao et al., 2015). Thus the aim of screening and selection is to find a new, optimal, 
engineered protein from within a pool of variants as a successful hit in the well-designed assay. 
Library screening and selection can be challenging and often requires optimisation or even a change 
of methodology. In the end, a successful library screening process will work only if it has carefully-
selected controls, if it is to lead to the discovery of a novel protein with required activity.  
 
The library generated in Chapter 5 has over 34 million variants and as such, in terms of numbers, is 
not a challenging library to work with. It can be analysed in vivo since transformation efficiency is 
able to cover the numbers of clones. The size of the library does however impose a high-throughput 
method for screening phenotypes. The library contains variants for E. coli alanyl-tRNA synthetase 
for engineering a change in substrate specificity and as being an enzyme library, the screening has to 
be based on the phenotypic properties (Ferreira Amaral et al., 2017). 
 
AlaRS variant libraries have not previously been created and since this project will ultimately require 
mutation of the tRNA anticodon as well as the AlaRS charging enzyme, it was necessary to develop 
a new assay. As an adaptation of the assay described by Kuhn, Rubini, Fuhrmann, Theobald, and 
Skerra (2010) employed for selecting amber suppression mutants, Fluorescence-Activated Cell 
Sorting (FACS) was selected as a screening method. The AlaRS activity was coupled with expression 
levels of eGFP which serves as a reporter. Since eGFP has a weak tendency for dimerisation (Day 
and Davidson, 2009), a point mutation A206K was introduced to ensure that the protein remains in 
the monomer form (Nagai et al., 2002) (refer to Section 1.7.2.1.). As described previously (Kuhn et 
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al., 2010), to select for the functional synthetases, the assay was designed to contain both negative 
and positive selections. 
 
6.1. Screening design 
The aim of the screening was to select for functional E. coli AlaRS synthetases that are able to 
aminoacylate E. coli tRNAAla with an UAA, for ultimate use in an in vitro translation system. 
Consequently, since both the enzyme and tRNA originate from E. coli, the library of enzymes could 
not be screened in E. coli because of cross-reaction between synthetic and native bacterial tRNAs. 
Similarly, E. coli tRNA that was used in the assay would interact with bacterial synthetases. To 
overcome this challenge, the assay had to be developed in a different host to exclude interaction 
between native and orthogonal enzymes and tRNAs. The organism S. cerevisiae has been employed 
in previous amber suppression studies to develop orthogonal yeast tRNAs and was therefore selected 
for use in the current study. 
  
For the purpose of screening assay development, a novel amber suppression system employing the 
E. coli tRNAAla gene was chosen, so that subsequent mutation of the tRNAAla anticodon to multiple 
alternatives would be possible. 
 
The core components of this in vivo fluorescence screening assay are:  
1) an E. coli tRNAAla suppressor gene in which the anticodon is mutated to bind the amber (5’-TAG-
3’) termination codon,  
2) an eGFP gene (eGFPamber39) containing the amber codon introduced at the permissive position 39 
(this position can be mutated without affecting the fluorescence of eGFP (Kuhn et al., 2010), 
3) an AlaRS gene that is capable of aminoacylating the mutant tRNAAla with an amino acid (either 
native or unnatural). 
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Ultimately, as described previously by Kuhn et al. (2010), the screening process should be divided 
into two parts: a positive and negative selection. In the current study, the positive selection would 
involve co-expression of the AlaRS gene (or gene library), the suppressor tRNAAla and the mutated 
eGFPamber39 in the presence of both natural AAs and the required UAA, followed by FACS selection. 
This step selects for the functional synthetases and so reduces library size by “weeding out” 
nonfunctional AlaRS enzymes. The population of cells with functional synthetases is then a subject 
for negative selection to further differentiate enzyme variants. The negative selection process repeats 
the co-expression, but in the absence of the required UAA. Providing that these cells express only 
functional enzymes, mutants that can incorporate only the required UAA can no longer read through 
the amber termination codon and as such, these mutants can no longer fluoresce. Thus, following 
FACS selection, the pool with cells expressing fluorescent eGFP contains variants that aminoacylate 
natural AAs, while the pool that expresses nonfluorescent truncated eGFP has variants of an enzyme 





Figure 6.1. Positive and negative selection process of library screening. 
The positive (+) selection (in green) selects for synthetases that recognise both AAs and UAAs and yields a 
pool of functional synthetases. Negative (–) selection (in red) selects for synthetases that recognise only AAs 
and yields a pool with nonfluorescent cells with a mutant enzyme that aminoacylates only UAAss (in blue). 
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Co-expression of three separate recombinant genes is challenging and previous studies have involved 
both, one and two-plasmid systems. Firstly, herein, a design involving a one-plasmid system using 
pYES2 with uracil selection was attempted (Figure 6.2.). pYES2 is a shuttle vector that can be 






Figure 6.2. Plasmid map of pYES2, uracil yeast selection plasmid. 
Among other features, the plasmid includes: URA3 gene for selection of yeast transformants in uracil-deficient 
medium, Gal1 promoter for inducible expression of cloned genes, pUC origin and 2μ origin for high copy 
replication in E. coli and yeast organisms, respectively. pYES2 also contains multiple cloning site (MCS) with 
a range of unique restriction sites to aid gene cloning. All maps were prepared using SnapGene software. 
(Biotech, SnapGene software) 
 
 
6.2. The controls for the library selection assay 
To evaluate the concept of the assay in terms of functionality, it would be essential that 
C666A_AlaRS and/or N461_AlaRS could aminoacylate the tRNAAla suppressor with Ala and that S. 
cerevisiae could then use the resulting orthogonal, charged tRNA to read through the amber 
termination codon of eGFPamber39. Failure to achieve any of these steps would lead to production of 
only truncated (nonfluorescent) eGFP and would thus render FACS incapable of separating 
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functional from nonfunctional synthetases. Accordingly, several controls were designed, as detailed 
in Table 6.1. There were also other checkpoints (Table 6.2.) that were purposely designed to confirm 
that the expressed components are truly orthogonal and do not cross-react with yeast’s translation 
machinery, a scenario outlined above (Section 6.1.). Hence, the work for the library screening began 
with the preparation of all constructs.  
 
 
Table 6.1. Negative and positive controls for library screening assay. 




Table 6.2. The constructs details and the purpose of their design. 
 
Construct / components Check point Expected colour 
eGFP Is eGFP expressed correctly under short Gal promoter? green 
tRNAsup, enzyme, eGFPamber39 Does the screening assay work? green 
tRNAsup, eGFPamber39 Does yeast aminoacylate the suppressor tRNAAla? no fluorescence 
eGFPamber39 Does yeast read through the stop codon? no fluorescence 
tRNAsup, enzyme Do the cells have any native/auto fluorescence? no fluorescence 






















eGFP - - - green 














- eGFPamber39 - C666A_AlaRS green 
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6.2.1. Construction of control plasmids  
6.2.1.1. Construct 1 – tRNAAla suppressor and eGFP 
Synthetic genes encoding the tRNAAla suppressor under the control of the Gal1 promoter and eGFP, 
codon-optimized for expression in S. cerevisiae (Kaishima et al., 2016) and under control of the short 
Gal promoter (Redden and Alper, 2015) were obtained from Eurofins Genomics (Ebersberg, 





Figure 6.3. The plasmid map of construct 1 with tRNAAla suppressor and eGFP gene. 
 
 
6.2.1.2. Construct 2 – eGFP only 
This control aimed to check both that the synthetic eGFP gene was functional and that it was 
expressed as expected under control of the short Gal promoter. Accordingly, the tRNAAla suppressor 
gene and proceeding Gal1 promoter were removed from construct 1. Firstly, primers were designed 
to cut out tRNAAla suppressor and Gal1 promoter by amplifying around the plasmid, leaving eGFP 
and associated components in the amplified region. To determine optimal annealing temperature, a 
gradient PCR was performed (2.2.1.1.1). As seen in Figure 6.5. a. the expected product of size 6195 
bp can be found in most samples. However, reaction 4 with the annealing temperature of 47.5 °C has 
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only one single band at the expected size and therefore, a temperature 48 °C was used to amplify the 
product in a new, scaled-up PCR (2.2.1.1.; Figure 6.5. b). Following amplification, the PCR reactions 
were pooled to be purified (2.2.1.8.1.), quantified (2.2.1.9.), phosphorylated (2.2.1.3.) and self-
ligated (2.2.1.5.). The ligations were transformed into E. coli (2.2.3.1.) and transformants plated on 
LB Amp plates for incubation overnight at 37 °C. The following day, three colonies were selected 
and grown in LB (Amp) overnight. Plasmids were then extracted using QIAGEN® QIAprep Spin 
Miniprep Kit (2.2.1.8.2.) and upon purification, 3 clones were sent for sequencing to Eurofins 
Genomics. The results received later showed correct sequences for all three clones. This workflow 































Figure 6.5. Amplification of plasmid backbone for construct 2. 
0.8 % agarose gels stained with SYBR Safe dye show results of PCRs with an expected size of 6195 bp. a. 
Gradient PCR amplifying plasmid backbone for construct 2. Lanes number 1 to 12 represent reactions for 
temperature gradient 45-60 °C amplified with Q5® High-Fidelity DNA Polymerase (NEB). 1 kb DNA ladder 
(NEB) is present on both sides of the gel. The marker on the far right side is HyperLadder 1kb (Bioline). MM: 
a non-template control. b. Scaled-up PCR with amplification at 48 °C representing lanes 1 to 10 as ten samples 
of 100 μL reactions. HpLI: HyperLadder 1kb. NTC: a non-template control. Construct 2: eGFP only (refer to 
Figure 6.4.).  
47.5ºC 
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6.2.1.3. Construct 3 – tRNAAla suppressor and eGFPamber39 
This control was constructed as a preparation for subsequent analysis and to ensure that yeast cannot 
aminoacylate the tRNAAla suppressor and so suppress eGFPamber39 in the absence of an orthogonal 
AlaRS gene. To prepare construct 3, a mutation with a TAG stop codon was introduced to the eGFP 
gene at codon 39 of construct 1. The mutation was introduced with PCR amplification (2.2.1.7.2.) 
by employing a reverse primer containing the appropriate mutation with a workflow as described in 
Figure 6.6. The results of the gradient PCR and scaled-up PCR are found in Figure 6.7. Three clones 









             
            
 
 













Figure 6.7. Amplification of plasmid backbone for construct 3. 
0.8 % agarose gels stained with SYBR Safe dye show results of PCRs with an expected size of 6868 bp. a. 
Gradient PCR amplifying plasmid backbone for construct 3. Lanes number 1 to 12 represent reactions for 
temperature gradient 40-54 °C amplified with Q5® High-Fidelity DNA Polymerase (NEB). 1 kb DNA ladder 
(NEB) is present on both sides of the gel. The marker on the far right side is HyperLadder 1kb (Bioline). MM: 
a non-template control. b. Scaled-up PCR with amplification at 44 °C representing lanes 1 to 10 as ten samples 
of 100 μL reactions. HpLI: HyperLadder 1kb. NTC: a non-template control. Construct 3: eGFPamber39, tRNAAla 
suppressor (refer to Figure 6.6.). 
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6.2.1.4. Construct 4a and 4b – tRNAAla suppressor, eGFPamber39 and either truncated 
(construct 4a) or full-length (construct 4b) AlaRS 
Constructs 4a and 4b were created to perform the aminoacylation assay with the truncated and full-
length E. coli AlaRS genes respectively and as such, serve as aminoacylation controls for each form 
of the enzyme. To prepare constructs 4a and 4b, genes of a truncated and full-length enzyme 
(Sections 3.2. and 3.3.) were added to construct 3, to be expressed as an operon under the control of 
the short Gal promoter which is located upstream of the eGFPamber39 gene. Firstly, restriction sites 
had to be introduced at the end of the genes to be able to ligate them with the vector backbone. As 
illustrated in Figure 6.8., a forward primer introduced both a NotI restriction site and Kozak sequence 
while the reverse primer added an SphI restriction site to both genes. Also, each primer had seven 
additional nucleotides at 5’-end to enable restriction digestion of PCR amplicons. The primers were 
used to amplify native genes from constructs in pET45b(+) vector (Sections 3.2. and 3.3.) 
 
A gradient PCR was set up for the truncated and full-length genes (N461_AlaRS and C666A_AlaRS) 
with results in Figure 6.9. a. and Figure 6.10. a., followed by scaled-up PCR (Figure 6.9. b. and 
Figure 6.10. b.) and purification of PCR products (2.2.1.8.1.). After purification, double digestion 
with SphI and NotI was set up for construct 3 (vector backbone) and the gene inserts, N461_AlaRS 
and C666A_AlaRS (2.2.1.6.). The reactions were incubated overnight at 37 °C. Additionally, 
construct 3 was dephosphorylated (2.2.1.4.). Subsequently, all digests were electrophoresed in low-
melt agarose and the fragments of the correct size were gel extracted (2.2.1.8.3.). Once the purified 
fragments were quantified, they were ligated (2.2.1.5.) and transformed into E. coli (2.2.6.1.). A 
number of colonies of construct 4a were screened in colony PCR with an example illustrated in 
Figure 6.11. where clones 3, 6, 7, 8, 10, 12, 13 had the correct size of PCR product. Chosen clones 
were then further assessed by digestion with an enzyme of a unique site to linearise the plasmid and 
analyse its total size in gel electrophoresis. After successfully passing both colony screening 
methods, several clones were sent for sequencing. For construct 4b, clones 2, 3, 4, 8, 11 showed a 
correct PCR product size in colony PCR (Figure 6.12. a.). These plasmids were later digested with 
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SphI to linearise and since all showed a correct size of 9510 bp were sent for sequencing. The results 
of sequencing for construct 4a and 4b confirmed correct sequencing in clones 10 and 15 for construct 
4a and clones 3 and 4 for construct 4b.  
 
 
    






    






















Figure 6.9. Amplification of gene insert N461_AlaRS for construct 4a. 
1 % agarose gels stained with SYBR Safe dye show results of PCR with an expected size of 1429 bp. a. Gradient 
PCR amplifying insert gene for a truncated enzyme for construct 4a. Lanes number 1 to 12 represent reactions 
for temperature gradient 45-65 °C amplified with Q5® High-Fidelity DNA Polymerase (NEB). b. Scaled-up 
PCR with amplification at 50 °C representing lanes 1 to 10 as ten samples of 100 μL reactions. HpLI: 
HyperLadder 1kb. NTC: a non-template control. Construct 4a: eGFPamber39, tRNAAla suppressor, N461_AlaRS 













Figure 6.10. Amplification of gene insert C666A_AlaRS for construct 4b. 
1 % agarose gels stained with SYBR Safe dye show results of PCR with an expected size of 2674 bp. a. Gradient 
PCR amplifying gene for truncated enzyme as an insert for construct 4b. Lanes number 1 to 12 represent 
reactions for temperature gradient 45-65 °C amplified with Q5® High-Fidelity DNA Polymerase (NEB). b. 
Scaled-up PCR with amplification at 57 °C representing lanes 1 to 10 as ten samples of 100 μL reactions. 
HpLI: HyperLadder 1kb. MM: a non-template control. Construct 4b: eGFPamber39, tRNAAla suppressor, 











Figure 6.11. Colony screening for construct 4a. 
0.8 % agarose gels stained with SYBR Safe dye show results of colony screening a. by colony PCR and b. 
enzyme digestion. a. An example of colony screening by colony PCR for clones 1 to 14 with an expected size 
of 2040 bp. b. Diagnostic enzyme digestion for colonies with correct size amplicons in colony PCR. SphI is the 
unique restriction site in the plasmid and the expected size of the linearised plasmid is 8265 bp. Colony 
screened are 10, 34, 38, 15, 24, 52. Undig: undigested plasmids. SphI: plasmid linearised with SphI. L: 
GeneRuler 1kb DNA ladder (Thermo Fisher). Construct 4a: eGFPamber39, tRNAAla suppressor, N461_AlaRS 











Figure 6.12. Colony screening for construct 4b. 
0.8 % agarose gels stained with SYBR Safe dye show results of colony screening a. by colony PCR and b. 
enzyme digestion. a. An example of colony screening by colony PCR for clones 1 to 15 with an expected size 
of 3265 bp. The correct size was found for clones 2, 3, 4, 8, 11. NTC – non-template control. L – GeneRuler 
1kb DNA ladder (Thermo Fisher). b. Diagnostic enzyme digestion for colonies with correct size amplicons in 
colony PCR. SphI is the unique restriction site in the plasmid and the expected size of the linearised plasmid 
is 9510 bp. Undig: undigested plasmids. SphI: plasmid linearised with SphI. L: GeneRuler 1kb plus DNA 
ladder (Thermo Fisher). Construct 4b: eGFPamber39, tRNAAla suppressor, C666A_AlaRS (refer to Figure 6.8.). 
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6.3. The functionality of the selection assay 
Having confirmed the DNA sequences in each of the constructs, the control constructs were then 
assessed by both inverted fluorescence microscopy and then FACS. 
 
6.3.1. Analysis of expression under fluorescence microscope 
All constructs were transformed into S. cerevisiae strain BY4741 (2.2.6.2.). Individual colonies were 
selected and grown and induced in selection media containing galactose, overnight at 30˚C. Slides 
were prepared and the cells examined by fluorescence microscopy (2.2.9.; Figure 6.13.). 
 
As illustrated in Figure 6.13., the native gene of eGFP is effectively expressed under the short Gal 
Promoter in both constructs 1 and 2. In both pictures, it is clear that expression under Short Gal 
Promoter is effective in SD-U media with supplementation of 2% (w/v) Galactose. The eGFP is 
bright and clearly visible in yeast cells. Similarly, construct 3 (tRNAAla suppressor and eGFPamber39) 
shows no fluorescence, as expected. However, constructs 4a and 4b also showed little/no 
fluorescence. The green colour indicating expression of eGFP is limited and found in only few cells, 
especially for construct 4b. When compared with intensity for construct 1 and 2, the successful 
suppression of the amber termination codon at position 39 is very poor. Expression of full-length 
eGFP from the eGFPamber39 gene in constructs 4a and 4b relies on both productions of functional 
tRNAAla suppressor and the enzyme alanyl-tRNA synthetase. The enzyme is expected to 
aminoacylate tRNAAla suppressor with Ala so that the yeast’s ribosomes can then add Ala in 
translation of eGFPamber39 at position 39, so suppressing the stop codon. Even though fluorescence 
from construct 4a and 4b was never expected to have intensity as high as that of construct 1 or 2, the 
level observed was insufficient to be of use for library screening assays. Conversely, there is no 
autofluorescence at all from the negative control, untransformed S. cerevisiae BY4741 cells, 




Figure 6.13. Expression of construct 1, 2, 3, 4a and 4b in S. cerevisiae BY4741.       
The fluorescence microscopy images of yeast cells expressing eGFP induced overnight in SD-U 2% Gal medium. Negative control: BY4741 cells only and construct 3. Parameters: eGFP: Exposure 
time: 100 ms; Gain: 5.9; Intensity: 5. Grey: Exposure time: 179 ms; Gain: 2; Intensity: 87. Expression of BY4741 cells only: Parameters: eGFP: Exposure time: 60 ms; Gain: 5.9; Intensity: 5. Grey: 
Exposure time: 179 ms; Gain: 2; Intensity: 56.  
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6.4. Introduction of SNR52 promoter and removal of CCA-3’  
The controls of construct 4a and 4b were designed to determine if expressed enzyme (N461_AlaRS 
or C666A_AlaRS) was able to aminoacylate tRNAAla suppressor to start expressing full-length GFP 
from eGFPamber39. The lack of clear green fluorescence in these constructs resulted from the 
unsuccessful suppression of the termination codon in eGFPamber39 and as such, changes in the assay 
design were essential.  
 
A manuscript “New Methods Enabling Efficient Incorporation of Unnatural Amino Acids in Yeast” 
by Wang and Wang (2008) outlined how to efficiently produce E. coli tRNA in S. cerevisiae. The 
authors suggested that in order to produce functional E. coli tRNA in S. cerevisiae, it was mandatory 
to follow and mimic yeast system of tRNA production. First, the triplet of nucleotides on 3’-end of 
tRNA that is present in E. coli is not found in yeast tRNA genes because it is added enzymatically in 
post-translational modifications. Therefore, for this study, CCA-3’ had to be removed from all 
tRNAAla suppressor constructs. Second, the manuscript explained the role of promoter elements A- 
and B-box sequences that are found within yeast’s tRNA gene but are absent in most E. coli tRNAs. 
The solution for this problem was to place a promoter that contains A- and B-box sequences upstream 
of E. coli tRNA. Consequently, the existing promoter Gal1 ahead of E. coli tRNA had to be replaced 
with the SNR52 promoter, one of two promoters tested in that manuscript.  
 
In summary, in order to express functional E. coli tRNA in yeast, two sets of primers were designed: 
one to remove CCA-3’ from tRNA in all constructs and another to amplify the SNR52 promoter 
sequence from S. cerevisiae genome in order to clone in into amended constructs without CCA-3’ in 




6.4.1. Removal of CCA-3’ from E. coli tRNAAla suppressor genes 
To remove CCA-3’ from the tRNAAla suppressor gene, a set of inverse primers was designed to 
amplify the constructs. After PCR and self-ligation of the constructs, transformation into E. coli and 
colony screening, the results of amplification using construct 1 as a template are shown in Figure 
6.14. Phosphorylated primers were used in this PCR. Despite a lot of efforts to optimise the PCR 
reaction, only a small yield of the product was obtained (Figure 6.14). Nevertheless, several reactions 
were set up to achieve enough product post-purification. Purified PCR reactions were self-ligated. 
The same methodology was repeated to construct 3, 4a and 4b. The new version of these construct 







Figure 6.14. Amplification of construct 1 excluding CCA-3’ from tRNA gene. 
0.8 % agarose gel stained with SYBR Safe dye shows result of a PCR with an expected size of 6865 bp amplified 
with Q5® High-Fidelity DNA Polymerase (NEB). The amplification temperature was 44 °C. L: GeneRuler 1kb 




6.4.2. Change of promoters for tRNAAla suppressor gene 
To exchange promoters upstream of tRNAAla suppressor gene within version 2 constructs, the 
required SNR52 promoter sequence was amplified from the S. cerevisiae genome by yeast colony 
PCR which generated a product of the correct size of 288 bp (Figure 6.15. a). After PCR purification, 
the product was digested with BclI (Figure 6.15. b.).  
 
Meanwhile, the Gal1 promoter was removed and concurrently, a BclI restriction site was introduced 
into constructs 4a and 4b by PCR as described previously (Figure 6.16.). The gradient PCR showed 
the correct product for annealing temperatures of 61.8 – 66.0 °C (2.2.1.1.1). For both constructs, 66 
°C was used for annealing in the scale-up PCR (2.2.1.1.). After PCR purification, the enzyme 
digestion with BclI was completed (2.2.1.8.1.; 2.2.1.6.). Having digested both insert and vector, the 
two were ligated as shown in Figure 6.17. (2.2.1.5.), transformed and resulting colonies screened by 
PCR (2.2.3.1.; 2.2.1.1.2.; Figure 6.18.). Several colonies were sent for sequencing (2.2.4.1.) and the 
correct sequences were found in colony 25 for construct 4bv3 and colonies 1, 5, 32 and 35 for 
construct 4av3. A suffix ‘v3’ for ‘version 3’ of controls was added to indicate an exchange of Gal1 
promoter for SNR52 promoter for expression of tRNA. The plasmid maps for construct 4av3 and 





                 
 
Figure 6.15. Amplification and enzyme digestion of SNR52 promoter. 
3 % agarose gels stained with SYBR Safe dye show results of amplification and enzyme digestion. a. 
Amplification of SNR52 promoter from S. cerevisiae genome with an expected size of 288 bp with Q5® High-
Fidelity DNA Polymerase (NEB). 1, 2: PCR reactions. NTC: non-template control. b. Enzyme digestion of PCR 
amplicons with BclI with the expected size of 274 bp upon digestion (lane BclI). Undig: undigested PCR. L: 













Figure 6.16. Amplification of construct 4a and 4b vector backbone. 
0.8 % agarose gels stained with SYBR Safe dye show results of PCR. a. Gradient PCR amplifying the vector 
backbone of construct 4a with an expected size of 7751 bp. b. Gradient PCR amplifying the vector backbone 
of construct 4b with an expected size of 8996 bp. Lanes number 1 to 12 represent reactions for temperature 
gradient 50-66 °C amplified with Q5® High-Fidelity DNA Polymerase (NEB). On the far right of both gels 
lane PCR represent scaled-up PCR with amplification at 66 °C. L: GeneRuler 1kb DNA ladder (Thermo 








Figure 6.17. Design of colony PCR screening for clones. 
Primers (green arrows) were designed to amplify through ligation site. Forward primer anneals to the SNR52 
promoter sequence, while reverse primer to vector backbone. Suffix ‘v3’ indicate 3rd generation of constructs 





Figure 6.18. Colony PCR for constructs 4av3 and 4bv3. 
2 % agarose gels stained with SYBR Safe dye show results of colony screening. for construct 4av3 (colonies 1-
10 and 31-38) and for construct 4bv3 (colonies 11-30). The product of colony PCR with an expected size of 
355 bp was detected in colonies 1, 2, 5, 25, 27, 32, and 35. NTC: non-template control. L: HyperLadder™ 







Figure 6.19. The plasmid maps of construct 4av3 and 4bv3. 
 
 
6.4.3. Analysis of expression under a fluorescence microscope  
To verify if the changes to the gene elements of tRNAAla suppressor improved its expression and in 
the resulting expression of full-length eGFP from eGFPamber39, the yeast cells with appropriate 
constructs were analysed under the fluorescence microscope (2.2.9.). With these changes, it was 
anticipated that the tRNAAla suppressor should now be produced efficiently when the constructs were 
transformed into yeast strain BY4741 (2.2.6.2.). As shown in Figure 6.20., construct 2, the positive 
control for expression of eGFP, gave a bright and fluorescent green colour. However, the cells for 
both constructs, 4av3 and 4bv3, remained of the same weak intensity green colour, just as with 
constructs 4a and 4b prior to removal of the CCA-3’ sequence and addition of the recommended 
promoter (Figure 6.13.). As part of the experiment, constructs 4av3 and 4bv3 without tRNA promoter 
serving as negative controls for 4av3 and 4bv3 were expressed alongside. In theory, these controls 
should not express any eGFPamber39 because tRNA suppressor is not expressed due to lack of 
promoter. From the images in Figure 6.20., it can be observed that fluorescence levels between both 





Figure 6.20. Expression of construct 2, 4av3 and 4bv3 in S. cerevisiae BY4741.  
The fluorescence microscopy images of yeast cells expressing eGFP induced overnight and 24h in SD-U 2% Gal medium. Parameters: eGFP: Exposure time: 120 ms; Gain: 5; 
Intensity: 5. Grey: Exposure time: 60 ms; Gain: 5; Intensity: 120.
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To determine whether the nonsense-mediated decay pathway was interfering with expression, an 
alternative strain of yeast was used. The strain BY4741 NMD2Δ has a deletion of protein NMD2 
which has a critical role in the Nonsense-Mediated mRNA Decay (NMD) pathway. The same 
controls were expressed in BY4741 NMD2Δ like in Figure 6.20. From the analysis of images under 
the fluorescence microscope (Figure 6.21.), it was observed that the expression of full-length eGFP 
was improved in this new strain, that even the exposure in the fluorescent/GFP channel had to be 
reduced from 120 ms to 20 ms. In order to keep the relative exposure of other controls within the 
same experiments as close as possible, the exposure in the fluorescent/GFP channel was reduced 
from 120 ms to 60 ms, when comparing to images in Figure 6.20. Yeast cells with pYES2 vector 
only as a negative control remained not fluorescent with only a few false-positive cells. When 
comparing assay controls (eGFPamber39, tRNA suppressor, enzyme), even at this lower exposure, the 
fluorescence levels for controls 4av3 and 4bv3 was higher in BY4741 NMD2Δ strain (Figure 6.21.) 
than for the same controls in BY4741 (Figure 6.20.). This indicates that using strain BY4741 
NMD2Δ for expression of constructs improved reading through termination codon in eGFPamber39. 
 
As part of the experiment, constructs 4av3 and 4bv3 without tRNA promoter serving as negative 
controls for 4av3 and 4bv3 were expressed alongside. In theory, these controls should not express 
any eGFPamber39 because tRNA suppressor is not expressed due to lack of promoter. When analysing 
the images obtained in Figure 6.21. and comparing 4av3/4bv3 with and without promoter for tRNA, 
there is more fluorescence in full constructs 4av3 and 4bv3 with the promoter for tRNA. To be 
accurate, there is some background fluorescence that is very similar to the one in control with pYES2 
vector only. 
 
Although the levels of eGFPamber39 expression in constructs 4av3 and 4bv3 had improved when 
compared with constructs 4a and 4b (Figure 6.20.), this level of fluorescence still remained 





Figure 6.21. Expression of construct 2, 4av3, 4bv3 and vector pYES2 in S. cerevisiae BY4741 NMD2Δ.  
The fluorescence microscopy images of yeast cells expressing eGFP induced overnight and 24h in SD-U 2% Gal medium.  Parameters: eGFP: Exposure time: 60 ms (20 ms for 
construct 2); Gain: 5 (3 for construct 2); Intensity: 5 (3 for construct 2). Grey: Exposure time: 60 ms; Gain: 5; Intensity: 120. 
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6.5. Two-plasmid system – transfer of the eGFP gene to a different 
vector 
The next rational step was to turn into the optimisation of the AlaRS enzyme expression. In previous 
constructs 4a/4av3 and 4b/4bv3, the AlaRS gene was part of an operon with the eGFPamber39 gene. If 
expression of either was adversely affected, poor expression of full-length GFP would result. 
Consequently, a two-plasmid system was tested, in which the eGFP amber39 gene was transferred to 
vector pXRH3 (Figure 6.22. a.), which is compatible with both pYES2 and S. cerevisiae BY4741 
NMD2∆.  
 
6.5.1. Preparation of new constructs for the two-plasmid system 
In the new constructs (v4), the short Gal promoter and the eGFP gene were moved to plasmid pXRH3 
(Figure 6.22. b.). In this design, each gene had its own promoter and terminator: in pYES2 vector 
there was SNR52 promoter for tRNA and the short Gal promoter for the AlaRS enzyme, while in 
pXRH3 vector, the short Gal promoter was also used for eGFP. This promoter was used again, since 
it had already proved to be effective in eGFP expression from construct 2 (eGFP only). Vector 
pXRH3 is selected by histidine and can be used for simultaneous transformation into BY4741 strains 














6.5.1.1. Preparation of construct 4av4 and 4bv4 
To prepare construct 4av4 and 4bv4, the eGFPamber39 gene had to be removed from the existing 
construct 4av3 and 4bv3. Firstly, primers were designed to remove this gene and amplify around the 
plasmid to achieve a pYES2 vector without eGFPamber39 gene, as shown in Figure 6.23 (2.2.1.1.). 
Despite efforts to optimise PCR reaction, for both constructs, there were some additional unspecific 
bands other than the band of interest (7294 bp for 4av3 and 8539 bp for 4bv3). Instead of PCR 
optimisation to achieve a single band, the bands of interest were gel extracted (2.2.1.8.3.; Figure 
6.24.) and used in a subsequent self-ligation (2.2.1.5.). Once transformed into E. coli (2.2.3.1.), 
colonies were screened in colony PCR (2.2.1.1.2.) with the expected size of 299 bp for both, construct 
4av4 (colonies 21-27) and 4bv4 (colony 28). All colonies showed the correct size of colony PCR as 
shown in Figure 6.25. Colonies 21, 22, 28 were sent for sequencing and all had correct sequence of 
eGFPamber39. However, clone 28 had some additional sequence after eGFPamber39 gene, hence the 
additional bands in colony PCR. The additional diagnostic enzyme digestion with SphI as a unique 
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restriction site for colonies 21, 22 and 28 aimed to linearise the plasmids to analyse their total size. 









Figure 6.23. The workflow for generation new constructs a. 4av4 and b. 4bv4.  
The plasmid maps of construct 4av3 (a.) and 4bv3 (b.) with annealed primers to remove eGFPamber39 gene by 
amplification and self-ligation of PCR reaction to generate construct 4av4 (a.) and 4bv4 (b.). New constructs 















Figure 6.24. Amplification of plasmid backbone 4av3 and 4bv3 for construct 4av4 and 4bv4. 
0.8 % agarose gel stained with SYBR Safe dye shows results of PCRs with an expected size of 7294 bp for 4av3 
backbone and 8539 bp for 4bv3 backbone. The reactions were amplified using Q5® High-Fidelity DNA 
Polymerase (NEB). For both lanes, there are visible additional unspecific amplification fragments of shorter 
lengths than an expected product of PCR. L: GeneRuler 1kb DNA ladder (Thermo Fisher). Construct 4av3/bv3 









Figure 6.25. Colony PCR for construct pXRH3_eGFPamber39, pXRH3_eGFP, 4av4 and 4bv4. 
2 % agarose gels stained with SYBR Safe dye show results of colony screening. for construct 
pXRH3_eGFPamber39 (colonies 1-20), pXRH3_eGFP (colonies 29-38), 4av4 (colonies 21-27) and for construct 
4bv3 (colony 28). The product of colony PCR for colonies 1-20 with an expected size of 1099 bp was detected 
in all 20 colonies. The same product was detected in colonies 30-33 and 35-38 for construct pXRH3_eGFP. 
The product of colony PCR for colonies 21-28 with an expected size of 299 bp was also detected in all colonies. 
Lane 28 showed other two unspecific bands corresponding to longer DNA than desired PCR product. Other 
colonies had a single band product in the experiment. NTC: non-template control. L: HyperLadder™ 50bp 
(Bioline). Construct pXRH3_eGFPamber39: GFPamber39 (refer to Figure 6.22). Construct 4av4/bv4: tRNAAla 






Figure 6.26. Plasmid screening by enzyme digestion. 
0.8 % agarose gel stained with SYBR Safe dye shows results of enzyme digestion for colonies of construct 
pXRH3_eGFPamber39, 4av4 and 4bv4. Enzyme EcoRI was used for pXRH3_eGFPamber39 and SphI for 4av4 and 
4bv4. L1: GeneRuler 1kb DNA ladder (Thermo Fisher). L2: GeneRuler 1kb plus DNA ladder (Thermo Fisher). 
Construct pXRH3_eGFPamber39: eGFPamber39 (refer to Figure 6.22). Construct 4av4/bv4: tRNAAla suppressor, 




6.5.1.2. Preparation of construct pXRH3_eGFPamber39 and pXRH3_eGFP 
To prepare a new vector with eGFPamber39 and another with eGFP under control of the short Gal 
promoter, the relevant sequences were digested from construct 4bv3 with SacI and EcoRI as shown 
in Figure 6.27. (2.2.1.6.). Resulting fragments were gel extracted and ligated into pXRH3 that had 
been similarly digested and transformed into E. coli (2.2.1.8.3., 2.2.1.5., 2.2.3.1.). The colonies were 
screened in colony PCR using M13 primers and the results of screening colonies 1 to 20 are shown 
in Figure 6.25. (2.2.1.1.2.). All 20 samples showed the correct size of PCR at 1099 bp. Colonies 1, 2 
and 3 were sent for sequencing and the results showed correct insertion of eGFPamber39 into pXRH3. 
The vector was called pXRH3_eGFPamber39. As a control to determine the expression of eGFP in the 
new vector, the same new vector was similarly-prepared, but with the wt gene of eGFP, from 
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construct 2 (Figure 6.28.). This vector was called pXRH3_eGFP. The colony screening was done 
using colony PCR and colonies 30-33 and 35-38 showed correct product in Figure 6.25. Colonies 






                                    
                                     
 
 
Figure 6.27. The workflow for generation new plasmid, pXRH3 with eGFPamber39. 
A new vector pXRH3 was cloned with the insert, the eGFPamber39 gene under short Gal promoter, from construct 
4bv3. 











                                          
                                            
 
 
Figure 6.28. The workflow for generation new plasmid, pXRH3 with eGFP. 
A new vector pXRH3 was cloned with the insert, the eGFP gene under short Gal promoter, from construct 2. 
  





6.5.2. Analysis of expression under a fluorescence microscope for two-
plasmid system. 
As it had been performed previously in Sections 6.3.1. and 6.4.3., the dual constructs were 
transformed into S. cerevisiae BY4741 NMD2Δ strain (2.2.3.2.) and were analysed by fluorescence 
microscopy (2.2.9.). 
 
Upon analysis of the fluorescence microscopy images, it was confirmed that eGFP gene that was 
moved to vector pXRH3 to form pXRH3_eGFP, expressed the protein and yeast cells exhibited green 
phenotype. A negative control shown in Figure 6.30., sample with only cells remains without 
fluorescence Two-plasmid system was analysed. Cells expressing construct 4av4 and 
pXRH3_eGFPamber39 as well as construct 4bv4 and pXRH3_eGFPamber39 were analysed. Nevertheless, 
changing from one-plasmid to two-plasmid system did not elicit changes in the fluorescence levels. 
Additionally, cells with eGFPamber39 only show comparable fluorescence. Clearly, the limited 
fluorescence is dependent on the presence of the eGFPamber39 gene, since no fluorescence at all is 
visible for cells lacking this gene. Interestingly, there is still some fluorescence in the cells that 
contain only pXRH3_eGFPamber39, suggesting that the yeast cells may inherently be able to read 
through the termination codon at position 39 to a low level. However, close examination of Figure 
6.30. also suggests that fluorescence is a little brighter when the AlaRS and tRNAAla suppressor genes 
are present. Since the fluorescence is clearly dependent on the presence of the eGFPamber39 gene, it 




Figure 6.29. Expression of constructs 4av4 and 4bv4, and controls in S. cerevisiae BY4741 NMD2Δ. 
The fluorescence microscopy images of yeast cells expressing eGFP induced overnight and 24h in SD-U 2% Gal medium. Parameters: eGFP: Exposure time: 60 ms; Gain: 5; 






Figure 6.30. The fluorescence microscopy of yeast cells S. cerevisiae BY4741 NMD2Δ. 
The fluorescence microscopy images of yeast cells. Parameters: eGFP: Exposure time: 60 ms; Gain: 5; 
Intensity: 5. Grey: Exposure time: 60 ms; Gain: 5; Intensity: 120. 
 
 
6.5.3. Analysis of expression by Flow Cytometry for the two-plasmid 
system. 
Flow cytometry was employed to further quantify fluorescence in S. cerevisiae (2.2.11.). To measure 
fluorescence resulting from eGFP rather than other sources such as cell debris, dye DRAQ5 which 
is a cell-permeable far-red fluorescent dye that intercalates in DNA was used in conjunction with 
GFP fluorescence, to detect nucleated cells that are also expressing GFP protein. Gates were set to 
exclude fluorescence resulting from untransformed cells. Cells containing the various combinations 
of constructs were then examined using this gating, as illustrated in Figure 6.31. 
 
The negative sample containing cells only was used to set the gate and so has 0% events in the gated 
region. Conversely, as expected in the positive sample with eGFP only, there are 83.7 % events in 
the gated region. While controls with tRNA, enzyme, eGFPamber39, have only 0.55 % (with 
N461_AlaRS) and 0.32 % (with C666A_AlaRS) of cell population exhibiting fluorescence. At the 
same time, negative control with eGFPamber39 only (no suppressor tRNA or AlaRS) has 1.61 % events 
with fluorescence. This latter result indicates that even though other components (like tRNAAla 
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suppressor and enzyme) are not present to aid expression of eGFPamber39, the expression, although 
minimal, still occurs. These findings support results from the fluorescence microscopy and suggest 
that the yeast cells are inherently able to suppress the termination codon at position 39 of eGFPamber39, 
without the help of orthogonal tRNA or AlaRS. Moreover, the flow cytometry results further 
determine that these orthogonal genes do not, as was previously suggested by fluorescence 










Figure 6.31. Flow cytometry of control samples for eGFP and DRAQ5. 
negative control – cells only                             positive control – eGFP                              tRNAAla suppressor, N461_AlaRS                   tRNAAla suppressor, C666A_AlaRS 
                    
 
tRNAAla suppressor, N461, eGFPamber39          tRNA




Since the orthogonal tRNA and AlaRS genes do not appear to enhance expression of full-length GFP, 
the obvious question is therefore whether or not these genes are being expressed at all. To determine 
whether the respective genes eGFPamber39, tRNAAla suppressor and either full-length or truncated 
AlaRS were all being transcribed by the S. cerevisiae cells in constructs 4av4 and 4bv4, reverse-
transcriptase PCR (RT-PCR) analysis was employed (2.2.1.2.). 
 
This experiment was particularly important to exclude uncertainties about expressing the AlaRS 
enzymes under control of short Gal promoter downstream of eGFPamber39 as an operon. Although it 
had been confirmed that this promoter works efficiently in expressing eGFP, up to this point it was 
still unclear whether downstream placed gene of enzyme also get an efficient transcription and 
translation in constructs 4a and 4b (all versions).  
 
For an effective RT-PCR experiments, a reliable RNA extraction and purification is critical. The 
RNA extraction is the most determinant process for RT-PCR. RNA extracted has to be of the highest 
quality, free of carry-over DNA and RNases. DNA can interfere with subsequent amplification step 
and serve as a template while RNases present will have a damaging effect on the RNA template. The 
easiest way to extract RNA is using commercial RNA extraction kits. However, in order to use the 
kit, the sample has to be lysed. The chosen method of lysis was using glass beads to break the yeast 
cells in a bead mill TissueLyser LT (QIAGEN) (2.2.7.3.). Essential when working with these samples 
was to purify RNA twice, with DNase treatments during each purification. This was critical for 





6.5.4.1. Assessment of RNA integrity 
The integrity and intactness of high quality purified RNA samples should follow a pattern of: 60 % 
28S rRNA, 30 % 18S rRNA, 10 % tRNA/snRNA (Park et al., 1996). Once the RNA was purified 
and quantified (2.2.1.8.4.), it was assessed in agarose gel electrophoresis, which also demonstrated 
the importance of heat treating RNA samples to prevent aggregation by base pairing, as is reflected 
in sharp and clear bands for heat-treated RNA fractions in Figure 6.32. Moreover, the ratio of 28S to 
18S is 2:1 as expected (Figure 6.32.), confirming that the quality of the prepared RNA was suitable 








Figure 6.32. Analysis of RNA integrity post-purification. 
1 % agarose gel stained with SYBR Safe dye shows results of electrophoresis of RNA samples that were 
extracted using RNeasy column (QIAGEN) including DNase treatment. The experiment compares heat-treated 
samples vs untreated, loaded in two amounts, 200 ng and 400 ng. Ladder was run to confirm correct 
electrophoresis procedure and not for the size reference. RNA was extracted from S. cerevisiae transformed 





6.5.4.2. Analysis of RT-PCR results 
To find out if genes in construct 4av4 and 4bv4 are expressed under the control of their promoters, 
two-step RT-PCR was employed. One-step RT-PCR was also employed earlier (data not shown) but 
it was quickly changed to two-step process since reaction without reverse transcriptase (noRT) 
repeatedly gave a product in one-step RT-PCR, and optimisation did not improve the results. Two-
step RT-PCR worked well and all noRT controls were free of product as shown in Figure 6.33. 
Similarly, non-template controls for step two, which was amplification of cDNA, were also free of 
product, as expected. Most importantly, expression of all genes present in constructs 4av4 and 4bv4 
was successful in RT-PCR. eGFPamber39 expression gave the strongest signal when analysed in 
agarose electrophoresis confirming that expression of this gene. The same was observed for tRNA 
and enzymes genes. Particularly reassuring was expression of the enzyme genes, here already 
separated from eGFPamber39 unlike in previous versions of constructs 4a and 4b. Weaker signal was 
observed for C666A_AlaRS (Figure 6.33c.) most likely do to not completely optimised conditions 
for cDNA amplification of the longest of gene fragments in this experiment. Expression of tRNA 
gene in both constructs was also demonstrated, although not a strong signal was recorded on the gel 
as shorter fragments of DNA can appear blurred in electrophoresis. This is normal for tRNA gene 
with PCR reaction at 70 bp and the same can be observed for the lowest two bands of the ladder at 




















Figure 6.33. RT-PCR of 4av4 and 4bv4 samples in the context of gene expressions of eGFPamber39, AlaRS 
and tRNAAla suppressor. 
3 % (a.) and 1.5 % (b., c.) agarose gels stained with SYBR Safe dye show results of electrophoresis of two- 
step RT-PCR reaction samples of 4av4 and 4bv4. The gene expressions that were analysed included a. tRNAAla 
suppressor for 4av4 and 4bv4; b. eGFPamber39 and N461_AlaRS for 4av4; c. eGFPamber39 and C666A_AlaRS for 
4bv4. noRT – negative control without reverse transcriptase enzyme. The expected RT-PCR sizes are 70 bp for 
tRNA, 720 bp for eGFPamber39, 1386 bp for N461_AlaRS, and 2631 bp for C666A_AlaRS.  NTC: non-template 
control. L: for a. HyperLadder™ 50 bp (Bioline); b. GeneRuler 1kb DNA ladder (Thermo Fisher); c. left: 





6.5.5. Western blot 
Since the RT-PCR had determined that all genes were being transcribed successfully, similar samples 
were examined by Western blot (2.2.10.) for translation of eGFP (Figure 6.34.). No eGFP was 
detectable in protein samples from cells containing the eGFPamber39 gene, regardless of other 
combinations of proteins. This result is consistent with the very low levels of fluorescence seen by 
both the fluorescence microscopy and flow cytometry analyses, where protein levels would likely be 






Figure 6.34. eGFP expression in S. cerevisiae BY4741 NMD2Δ. 
Western blot showing whole cell lysate expression levels of eGFP in samples 1: tRNAAla suppressor, 
N461_AlaRS, eGFPamber39; 2: tRNAAla suppressor, C666A_AlaRS, eGFPamber39; 3: eGFP; 4: eGFPamber39. The 
protein was detected in sample 3 only, at the expected size of 27 kDa. An anti-GFP Polyclonal Antibody, HRP 







A suitable screening method had to be employed in order to find out subsequently if engineering 
studies resulted in the generation of novel aaRSs that accept and activate UAA (D-Ala) as well as 
aminoacylating the tRNA. The assay was designed to be conducted in a different system than E. coli, 
so selected E. coli AlaRS and tRNAAla would not interact with native enzymes and tRNAs from S. 
cerevisiae. Just like with previous screening methods (developed by Schultz), the assay was based 
on a phenotype of a reporter gene, eGFP, with a termination codon in the permissive position along 
with expression of E. coli AlaRS and a tRNAAla amber suppressor. As a proof of concept, both 
truncated and full-length with C666A mutation AlaRS were used, since both had been previously 
proved effective in aminoacylating tRNAAla with L-Ala (Swairjo et al., 2004; Guo et al., 2010). 
 
Unfortunately, the optimisation efforts brought little effect. For instance, after applying necessary 
changes recommended in the manuscript “New Methods Enabling Efficient Incorporation of 
Unnatural Amino Acids in Yeast” by Wang and Wang (2008) including removal of CCA-3’ in tRNA 
gene and exchange of promoter to achieve efficient expression of E. coli tRNA in yeast, there was 
nearly no difference in expressing eGFPamber39 found in constructs 4av3 and 4bv3. Moreover, a 
different yeast strain with deletion of protein NMD2 which plays a critical role in Nonsense-mediated 
mRNA decay (NMD) pathway had little effect. Similarly, the expression of proteins in a new deletion 
strain, BY4741 NMD2Δ, did not meet the expected results of an efficient eGFPamber39 expression.  
 
Taken together, the results presented in this chapter demonstrate that the anticipated assay, developed 
herein, is not suitable to analyse variant AlaRS libraries since the expression of full-length eGFP 
from the eGFPamber39 gene as a result of orthogonal tRNAAla and AlaRS expression was not achieved. 
Since both genes were transcribed successfully (as shown in RT-PCR experiments), this is not a 
result of the constructs or their promoters, but rather must, therefore, result from lack of orthogonal 
functionality within the yeast cells. Moreover, the fluorescence microscopy experiments 
demonstrated that the low level of eGFPamber39 expression without other components (AlaRS or 
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tRNA) present was achieved. Although it had not been proved, it appears that yeast was reading-






Chapter 7: Discussion 
7.1. Summary of results 
The initial aim of this project was to clone genes of AlaRS that will be used during library generation. 
The gene alaS was successfully amplified from E. coli Tuner™(DE3) strain and cloned into 
pET45b(+). From the existing construct, the two required genes were prepared. The first included 
the aminoacylation domain of AlaRS only (N461_AlaRS), whilst the second incorporated the full-
length AlaRS with mutation C666A to remove the editing function of the enzyme (C666A_AlaRS). 
Once all three constructs were successfully prepared and confirmed in Sanger sequencing, expression 
experiments were undertaken. Expression and purification of both N461_AlaRS and C666A_AlaRS 
in E. coli were successful. Better expression was achieved for the truncated enzyme (N461_AlaRS) 
while the full-length with mutation (C666A_AlaRS) was also expressed at sufficient levels. The 
expressed proteins were used in aminoacylation reactions but the difference between acylated and 
nonacylated tRNA could not be confirmed unequivocally.  
 
After cloning and expression studies, engineering studies commenced. They began with the analysis 
of the crystal structure of the AlaRS aminoacylation domain bound with Ala-SA and included 
analysis of the amino acid binding site. Those residues that were in the direct binding with the 
functional group of Ala were targeted for mutation. In total, six residues were randomised in two 
gene libraries of AlaRS using ProxiMAX randomisation. The first library involved truncated AlaRS 
of N-terminal domain only (N461_AlaRS) and the second library had full-length AlaRS with a knock 
out of editing function (C666A_AlaRS). Genes used as a template for the library build came from 
initial constructs in pET45b(+). The gene was divided into conserved regions and randomised regions 
called also library fragments. Each fragment was separately prepared in a series of amplification, 
digestion and ligation steps. The randomisation with 18 amino acids (excluding Met and Cys) at all 
six positions in three different fragments was successfully completed. The results of next-generation 
sequencing showed a close match of observed vs expected encoding of the required 18 amino acids 
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in an even distribution. Each library had over 34 million of unique gene variants of N461_AlaRS and 
C666A_AlaRS. 
 
Another aim of the project was to design a novel screen for use with the libraries of aaRSs, specific 
to the system being developed within this project. Design included positive and negative selection. 
Before the screening, various controls were designed to ensure that each component of the assay was 
working correctly. It was proved that the short Galactose promoter (Redden and Alper, 2015) ahead 
of the eGFP gene prompted effective eGFP expression. However, when co-expressing eGFPamber39, 
wt enzyme (truncated or full-length) and tRNAAla suppressor, the phenotype of eGFP was not as 
green as expected, indicating that the assay was not working properly. In the efforts to make it works, 
a number of things were changed including different promoters for tRNA; removal of CCA from the 
3’-end of tRNA; moving the gene for eGFPamber39 into a different plasmid so that eGFPamber39 and 
AlaRS genes were placed under two promoters rather than one (they were first expressed as an 
operon), which ultimately led to swapping of a one-plasmid system for a two-plasmid system, and 
finally, use of different yeast strains. Nevertheless, the applied changes did not produce desired 
results and the most that was achieved was low expression of eGFPamber39. Moreover, under 
fluorescence microscopy analysis it was observed that the level of expression was very similar when 
eGFPamber39 was expressed alone (i.e. without E. coli tRNAAla suppressor or E. coli AlaRS). 
Therefore, it could not be concluded that the low level of expression was due to the wt E. coli AlaRS 
aminoacylating the tRNAAla suppressor and adding amino acid in the stop codon inserted at 39th 
position of eGFPamber39. To confirm the observations from microscopy, the samples were analysed in 
the flow cytometer. The experiment revealed similar findings. To further investigate the low level of 
eGFPamber39 expression, RT-PCR confirmed that all genes, tRNA, eGFPamber39, enzyme were 





7.2. Future directions 
7.2.1. Towards a novel in vitro translation system 
The system for which this project anticipates to provide a fundamental background would be used in 
the expansion of genetic code to include multiple D-forms of amino acids. The main application of 
this novel system would be to encode multiple D-AAs or indeed other UAAs in preparation of gene 
libraries using nondegenerate saturation mutagenesis – specifically, via ProxiMAX randomisation, 
since the current method of ProxiMAX selects only 20 codons to cover 20 amino acids (Ashraf et 
al., 2013) and thus many codons could be used to encode UAAs simultaneously.  
 
As such, the core part of this project was to create a library of AlaRSs that could be screened 
repeatedly with different D-AAs and even other UAAs. Resulting in vitro translation would require 
engineering up to 19 aminoacyl-tRNA synthetases and cognate tRNAs based on E. coli AlaRS and 
E. coli tRNAAla native molecules. Ultimately, within a fully-synthetic system, any twelve of these 
could be used in translating a synthetic gene that used only 20 codons for the native amino acids in 
all positions. These numbers result from the rules governing wobble in the third position of the codon, 
further developed from Crick’s original rules by Murphy and Ramakrishnan (2004). When no base 
modifications are permitted (because the tRNA is transcribed in vitro), the codon-anticodon wobble 
rules allow base pairing between anticodon•codon: A•U/C/G, C•G, G•C/U and U•A/G/U in the first 
position of the anticodon and third position of the codon, respectively.  
 
While the library was constructed successfully, the developed screen was found wanting. Thus, 
although the ambition of the project was to set the foundation for a novel system, it may be more 
prudent to reduce future ambition and to use enzymes that have already been produced elsewhere. 
For example, Schultz has produced many variants of the PylRS that many incorporated UAAs 
(Young and Schultz, 2018). PylRS from M. barkeri, like E. coli AlaRS, also ignores the anticodon 
of the tRNA (Wan et al., 2014) and therefore potentially, the project could in future simply use these 
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already developed aaRSs to aminoacylate appropriately mutated tRNAs (mutated at the anticodon 
only) in vitro, as originally envisaged at the beginning of the project. Such a system could further 
allow the use of native E. coli aaRSs to re-charge native E. coli tRNAs if required since the mutant 
PylRSs and cognate tRNAs should be orthogonal to the E. coli system.  
 
7.2.1.1. Pyrrolysyl-tRNA synthetase and tRNACUA pair  
Pyrrolysine (Pyl) is found in nature as 22nd amino acid (selenocysteine, Sec being 21st) and is 
encoded by UAG codon, normally known as amber termination codon (Krzycki, 2005). Methanogens 
are archaeal microorganisms which utilise carbon dioxide and convert it into methane during 
anaerobic respiration in the process called methanogenesis. During formation of methane, genes 
associated with the process encode essential Pyl by conserved in-frame amber termination codon 
(Soares et al., 2005). These genes have been found in M. barkeri, Methanosarcina mazei, 
Methanosarcina acetivorans and Methanococcoides burtonii, and Pyl is present in 
Methanosarcinacea and Gram-positive Desulfitobacterium hafniense (Paul, Ferguson, and Krzycki, 
2000; Krzycki, 2005). While Sel cannot be found as free metabolite and instead is formed directly 
on tRNA, Pyl resembles other 20 amino acids with cognate aaRS and tRNA. It was confirmed in in 
vitro and in vivo studies that Pyl has its cognate archaeal class II Pyrrolysyl-tRNA synthetase (PylRS) 
and is aminoacylated onto tRNA.  
 
PylRS does not activate natural amino acids and does not aminoacylate tRNAs other than tRNACUA, 
making PylRS and tRNACUA an orthogonal pair in E. coli and other tested eukaryotic cells. Therefore, 
if there is a requirement to expand genetic code for pyrrolysine, an expression of only two genes, 
pylS and pylT for PylRS and tRNACUA, respectively, is needed (Blight et al., 2004). However, for 
further expansion of genetic code and incorporation of UAAs into the proteins, many studies 
investigated M. barkeri PylRS (MbPylRS) variants of the active site to use in different organisms, 
including common E. coli (Elliott et al., 2014). While amber termination codon can be used to encode 
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UAA, the enzyme also has little specificity for anticodon of tRNACUA, giving the possibility for 
expansion.  
 
7.2.2. In vitro transcription/translation  
The in vitro translation or transcription/translation system supports the production of the protein in a 
cell-free environment. This is an alternative and convenient way of protein production when 
overexpression of the product becomes toxic to the organism, or when it goes into insoluble fractions 
making it difficult to purify, or more importantly when the protein function is affected due to 
degradation via proteolytic lysis ("The Basics: In Vitro Translation.," no date). The extension of this 
in vitro system is far beyond being only an alternative to protein synthesis. It can be employed for 
using cognate aaRSs and tRNAs pairs during in vitro translation when the pair cannot be used in the 
eukaryotic or prokaryotic system due to interaction with the native system. Hence, and this is parallel 
with the interest of this project in terms of a long term goal, in vitro translation or 
transcription/translation system can be used to incorporate UAAs in proteins.  
 
7.2.3. In vitro translation in UAA incorporation 
Cell-free protein translation technologies are often chosen to introduce UAA in proteins. This was 
firstly described by Schultz and his co-workers in 1989 (Noren, Anthony-Cahill, Griffith, and 
Schultz, 1989). They used E. coli extracts to successfully introduce UAAs in beta-lactamase by 
replacing Phe66 with an amber stop codon within the gene and supplying chemically aminoacylated 
tRNA suppressor with UAA. The suppressor tRNA used in this study was S. cerevisiae tRNAPhe with 
anticodon mutation to recognise amber stop codon in the beta-lactamase gene. From the earlier 
studies, it was confirmed that S. cerevisiae tRNAPhe will not interact with endogenous E. coli PheRS 
found in E. coli extracts. Kwok and Wong (1980) proved that less than 1 % of S. cerevisiae tRNAPhe 
can be acylated by E. coli PheRS, hence Schultz’s choice. Incorporating UAA into proteins became 
even easier when the reconstituted cell-free technologies emerged. These systems enabled the users 
to pick and choose what components they require for in vitro translation. For example, the 
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reconstituted cell-free system allowed for the replacement of endogenous E. coli synthetases for 
engineered enzymes or enzymes from different species. It also enabled to manipulate with the set of 
tRNAs and to introduce orthogonal tRNA and aaRS pairs (Forster, Cornish, and Blacklow, 2004) or 
pre-charged tRNA (Forster et al., 2003). Using in vitro translation via cell-free methods for 
incorporation of UAA into proteins have been developing for decades and thanks to the progression, 
proteins and peptides with UAAs can now be produced for various purposes (Chong, 2014). 
 
In order to translate in vitro, extracts need to have all necessary components that participate in 
translation and these are: tRNAs, aaRSs, 70S or 80S ribosomes, initiation/elongation/termination 
factors. However, this component list is not exhausted and the user has to supply amino acids, ATP 
and/or GTP as the energy source, an energy regenerating system (different for prokaryotes – 
phosphoenol pyruvate and pyruvate kinase, and for eukaryotes – creatine phosphate and creatine 
phosphokinase), as well as other co-factors (for example K+, Mg2+). The difference between in vitro 
translation and transcription/translation system is used RNA and DNA template, respectively 
(Chong, 2014; "The Basics: In Vitro Translation.," no date). However, the system envisaged in this 
project would be much simplified. Because tRNAs will be pre-charged, neither aaRSs nor the energy 
system required to regenerate them are needed, leaving (in addition to the pre-charged tRNAs) just 
ribosomes and associated factors, GTP for ribosomal translocation and the required mRNA encoding 
the protein, or more likely, the peptide of interest. 
 
In vitro systems based on extracts from E. coli are more suitable for coupled in vitro 
transcription/translation. This is because exogenous mRNA is targeted by endogenous nucleases 
causing its degradation. The translation machinery from E. coli is also less complicated and complex 
to eukaryotic. The E. coli cell-free system is available as reconstituted purified E. coli system 




7.2.4. Comparison between the proposed system and current methods 
for incorporating multiple UAAs 
Current methods that aim to incorporate two UAAs in vivo or in vitro involve either using two 
termination codons, one termination (amber) and one quadruplet codon, or finally, two quadruplet 
codons. Quadruplet codons and amber codons are read from orthogonal mRNA by specially 
engineered orthogonal ribosome ribo-Q1 (Neumann et al., 2010). As an example, mutually 
orthogonal pairs were developed, MbPylRS-tRNACUA and AzPheRS-tRNAUCCU. AzPheRS was 
engineered based on well-known MjTyrRS and its cognate tRNACUA which was changed to 
accommodate quadruplet anticodon as tRNAUCCU. MbPylRS was found to be specific for its 
substrate, N6-[(2-propynyloxy)carbonyl]-L-lysine (CAK). These two pairs were designed to 
incorporate two different UAAs encoded by different codons and thanks to their orthogonality, the 
aminoacylation was specific. As a result, the protein GST-calmodulin included two UAAs, p-azido-
L-phenylalanine (AzPhe) (by AzPheRS-tRNAUCCU pair) and CAK (by MbPlyRS-tRNACUA). The 
protein was produced in E. coli (Neumann et al., 2010). 
 
The development of technology using quadruplet codons and ribosome ribo-Q1 is complex and 
requires engineering of different components. The advantage of this method is that, in theory, there 
can be up to 256 quadruplet codons available to encode UAAs (Neumann et al., 2010). Alternatively, 
a much simpler approach is to engineer variants of PylRS and tRNACUA pairs and to assign codons 
unused in ProxiMAX to UAAs of interest, what could be an extension of this project. Since PylRS 
has little specificity in recognition of anticodon, the native anticodon recognising amber suppression 
can be changed to accommodate others. This method would avoid a requirement for the development 
of a synthetic ribosome (Neumann et al., 2010). It would also focus on engineering only one of the 
aaRSs, preferably PylRS, rather than trying to find mutually orthogonal pairs (an example above). 
As a development of this project, multiple UAAs would be inserted in the synthetic peptide or protein 
via pre-charged tRNAs during in vitro translation. Aminoacylation of tRNAs with distinct anticodons 
would be isolated and independent of each other and therefore, mutually orthogonal aaRS-tRNA 
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pairs would not be needed. PylRS-tRNACUA pair was already successfully coupled with various 
codons (Wan et al., 2014) demonstrating a sought flexibility for future directions described.   
 
Commonly used amber termination codon for insertion of UAAs into proteins permits incorporation 
of only one UAA at a time without competition from natural AAs. Using one codon is considered 
here as a limitation since the project aimed to create a system that will allow for incorporation of 
multiple UAAs simultaneously. Only one UAA insertion is common when, for example, MbPylRS-
tRNACUA and MjTyrRS-tRNATyr are used (Vargas-Rodriguez et al., 2018). The advantage is that 
these tRNAs can have mutations in their anticodon, but when used in eukaryotes or prokaryotes, not 
much is possible in terms of codon reassignment unless the whole genome is synthetic. This is very 
challenging and time-consuming pointing out that cell-free protein synthesis and using pre-charged 
tRNAs is more realistic to achieve. Therefore, engineering MbPylRS or MjTyrRS for acceptance of 
D-AAs and then aminoacylating tRNAs (with mutated anticodons) is preferable in cell-free protein 
synthesis.  
 
Nevertheless, in vivo methods have their advantages over cell-free systems for the production of 
proteins with UAAs. For example, if it is necessary to produce a protein with UAA in large quantities, 
in vivo production would achieve far higher yields than cell-free systems which are not suitable for 
large scale production. In addition, while cell-free systems permit to use more chemically complex 
amino acids, in vivo methods are more comprehensive because they enable, for example, functional 
assessments of engineered protein in the natural biological environment (Passioura and Suga, 2014). 
Moreover, using in vivo approaches for incorporation of even only one UAA via orthogonal 
engineered aaRS-tRNA pair allows for recycling of tRNAs whereas when pre-charged tRNAs are 
employed, they are discarded once AA is delivered.  
 
In terms of methods engaging pre-charged tRNAs, chemical aminoacylation is challenging and 
others, more convenient methods are available. Flexizyme system offers high-throughput acylation 
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of tRNAs via engineered ribozymes. Prefix ‘flexi’ defines the flexible approach of the system 
towards various tRNAs and UAAs. This technology offers a lot of advantages including mutation of 
anticodon because flexizymes require only conserved CCA-3’ of tRNA in the reaction of 
aminoacylation (Passioura and Suga, 2014). There are three flexizymes available, with different 
specificity for UAAs. When comparing to the proposed system, Flexizyme technology has great 
flexibility towards different tRNAs and UAAs what is a substantial advantage, as such plasticity will 
never be achieved with a single engineered aaRS. Flexizyme is also capable of aminoacylating 
tRNAs with D-AAs (Katoh, Tajima, and Suga, 2017). 
 
The aim of introducing D-AAs into proteins in the cell-free system via pre-acylation of tRNA by 
engineered aaRSs and tRNAs must consider the translation machinery in such system. D-AAs are 
stereochemically different from L-AAs, and since the latter are naturally occurring, they will be 
favoured by the translational machinery. While favouring is not an issue because there is no 
competition when amino acids are codon-assigned, however, if the components such as ribosomes 
or factors associated with translation discriminate against tRNAs charged with non-natural AAs, this 
can become problematic for the whole process. It was reported before that while in the effort of 
introducing D-AAs via amber termination codon in vivo, D-AA-tRNAs were poorly accepted (less 
than 10 % when compared with canonical L-AAs) by elongation factors of the translation machinery. 
Subsequently, the newer investigation revealed that the efficiency of D-AAs incorporation varies and 
results demonstrated that eight D-AAs achieve over 40 % efficiency, four D-AAs between 10 and 40 
%, and the remaining seven D-AAs, indeed less than 10 % what is considered as poor efficiency 
(Passioura and Suga, 2014). Therefore, to create a technology for the incorporation of UAAs 
including D-AAs, it must be considered if they are compatible with the system and if they are not, 




Nevertheless, while incorporating D-AAs into the proteins still remains challenging with currently 
available in vivo, in vitro or cell-free systems, there is still space for discovery and development of 
novel technology that would include improved incorporation of D-AAs at multiple positions.  
 
7.3. Conclusion 
Two very high-quality libraries were produced each encoding over 34 million unique E. coli AlaRS 
variants as determined by NGS. However, the development of a library screening protocol remained 
challenging and served to identify more straightforward (albeit less commercially viable) alternatives 
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